[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TAR DNA-binding protein, which is involved in RNA metabolism and DNA repair. Mutations in TARDBP are associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the loss of motor neurons. The provided pathway includes multiple subunits of complex I of the mitochondrial electron transport chain, suggesting altered mitochondrial function may contribute to disease pathology. The interaction between TARDBP and mitochondrial complex I subunits implies a role for TARDBP in mitochondrial integrity and function, which, when disrupted, may lead to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TAR DNA-binding protein, which is involved in RNA processing and regulation of gene expression. Variants in TARDBP have been implicated in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The network definition provided suggests an interaction with components of complex I of the mitochondrial electron transport chain, indicating a possible link between mitochondrial dysfunction and the pathological effects of TARDBP mutations. This interaction may contribute to the neurodegenerative process seen in ALS by disrupting energy production in neurons.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TAR DNA-binding protein, which is involved in RNA processing and DNA repair. Mutations in TARDBP have been implicated in amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the loss of motor neurons. TARDBP is also associated with frontotemporal dementia (FTD), indicating a role in both neurological disorders. The pathway described includes genes related to complex I of the mitochondrial electron transport chain, suggesting that TARDBP may influence mitochondrial function, which is critical in neuronal health. Disruption in this pathway could contribute to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor gene located on chromosome 3. Mutations in VHL lead to the inactivation of the VHL protein, which is critical for the degradation of HIF1A under normoxic conditions. Without functional VHL, HIF1A accumulates, leading to the activation of downstream genes like VEGFA, PDGFB, and TGFA, promoting angiogenesis and cell proliferation. This pathway is central to the development of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. The provided pathway illustrates how the VHL complex (VHL, RBX1, ELOC, ELOB, CUL2) regulates HIF1A stability, and its dysfunction results in aberrant HIF1A/ARNT activity, driving tumorigenesis. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes a tumor suppressor protein that is part of an E3 ubiquitin ligase complex critical for targeting the HIF1A protein for degradation under normoxic conditions. When VHL is mutated or inactivated, HIF1A accumulates, leading to the activation of HIF1A/ARNT heterodimers. This results in the upregulation of downstream target genes such as VEGFA, PDGFB, and TGFA, which promote angiogenesis, cell proliferation, and survival. These effects are characteristic of clear cell renal cell carcinoma (ccRCC). Thus, the VHL allele's biological effect is primarily associated with the development of ccRCC.\n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes the von Hippel-Lindau tumor suppressor protein, which is a key component of an E3 ubiquitin ligase complex that targets the hypoxia-inducible factor (HIF) for degradation. When VHL is dysfunctional, HIF1A stabilizes and forms a complex with ARNT, leading to the activation of downstream genes such as VEGFA, PDGFB, TGFA, and others involved in angiogenesis, cell proliferation, and survival. This pathway is central to the development of hemangioblastomas and clear cell renal cell carcinoma. The dysregulation of HIF signaling due to VHL loss is a hallmark of VHL disease, a hereditary cancer syndrome. \n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that regulates the cell cycle by inhibiting cyclin-dependent kinases. In the provided pathway, CDKN2A is upstream of MDM2 and TP53, which are critical in the p53 signaling pathway. Mutations or loss of CDKN2A function can disrupt the regulation of the cell cycle, leading to uncontrolled cell proliferation. This dysregulation contributes to the development of several cancers, particularly melanoma and certain types of neuroendocrine tumors. The pathway shows that CDKN2A influences the activity of TP53, which in turn activates CDKN1A, a downstream effector that inhibits CDK4/6 and CCND, thereby controlling the G1/S checkpoint. Loss of CDKN2A function compromises this checkpoint, increasing the risk of tumorigenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that functions as a tumor suppressor by inhibiting cyclin-dependent kinases, which are essential for cell cycle progression. In the provided pathway, CDKN2A inhibits MDM2, which would otherwise promote the degradation of TP53. TP53 activates CDKN1A, which also inhibits cyclin-dependent kinases, and suppresses the activity of cyclin D and CDK4/6 complexes, which in turn inhibit RB1. Inhibition of RB1 releases E2F, which promotes cell cycle progression. Mutations in CDKN2A may disrupt this regulatory network, leading to uncontrolled cell proliferation. This dysregulation is commonly observed in melanoma and other cancers. Therefore, alterations in CDKN2A contribute to tumorigenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a key role in regulating the cell cycle and preventing uncontrolled cell growth. When mutated or inactivated, CDKN2A loses its ability to halt cell cycle progression, leading to unchecked cell proliferation. This is particularly significant in the context of the described pathway, where CDKN2A is upstream of TP53, which in turn activates CDKN1A to inhibit cyclin-dependent kinases and prevent cell cycle progression. Loss of CDKN2A function can lead to aberrant activation of E2F transcription factors, promoting cell division and contributing to the development of tumors. This pathway dysfunction is commonly observed in melanoma and certain types of neuroendocrine tumors.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described begins with the APP (amyloid beta precursor protein) gene, which is central to Alzheimer's disease pathology. APP is processed to generate amyloid beta (A\u03b2), a key player in the formation of amyloid plaques. These plaques, along with neurofibrillary tangles, are hallmark features of Alzheimer's disease. The pathway also involves muscarinic acetylcholine receptors (mAChR), which are involved in cholinergic signaling, and subsequent intracellular calcium signaling pathways that can lead to mitochondrial dysfunction and apoptosis. This sequence of events is closely associated with the neurodegenerative processes observed in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is involved in amyloid beta (A\u03b2) signaling, which is central to Alzheimer's disease pathology. The APP gene encodes the amyloid precursor protein, which is proteolytically processed to generate A\u03b2. A\u03b2 accumulation leads to the activation of muscarinic acetylcholine receptors (mAChR), triggering downstream signaling through GNAQ, PLCB, IP3, ITPR, and calcium release, which can culminate in mitochondrial dysfunction and apoptosis via MPTP and CYCS. This cascade is implicated in neuronal damage and cognitive decline. Therefore, the biological effect of the APP allele is most closely associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the amyloid precursor protein (APP) and its downstream signaling involving Abeta, muscarinic acetylcholine receptors (mAChR), and mitochondrial calcium dynamics. This sequence is strongly associated with Alzheimer's disease. Accumulation of Abeta peptides leads to neurotoxicity, impaired cholinergic function, and mitochondrial dysfunction, which are hallmark features of Alzheimer's disease. The involvement of IP3, calcium, and mitochondrial permeability transition pore (MPTP) further supports the role of calcium dysregulation and mitochondrial impairment in neurodegeneration. Therefore, this APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nKCNC3 encodes a voltage-gated potassium channel, specifically a member of the Shal subfamily, which is important for regulating neuronal excitability. Mutations in KCNC3 have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. These mutations may lead to dysfunctional potassium channels, altering neuronal firing patterns and contributing to the ataxic phenotype. \n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit involved in neuronal excitability. Mutations in KCNC3 are associated with spinocerebellar ataxia type 13 (SCA13), a rare neurodegenerative disorder characterized by progressive loss of motor coordination, ataxia, and other neurological symptoms. These mutations disrupt normal potassium channel function, leading to impaired neural signaling and degeneration of the cerebellum and related brain regions. The biological effect of the KCNC3 allele, therefore, is its contribution to the development of SCA13.\n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in regulating neuronal excitability. Mutations in KCNC3 have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. This disease results from dysfunctional potassium channels, leading to impaired neuronal signaling and degeneration in the cerebellum and brainstem. \n\n\\boxed{Spinocerebellar Ataxia Type 13}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta), a key player in the pathogenesis of Alzheimer's disease. The pathway proceeds through muscarinic acetylcholine receptors (mAChR), GNAQ, PLCB, IP3, IPR, and calcium signaling, leading to mitochondrial Ca\u00b2\u207a uptake via MCU and eventual mitochondrial permeability transition pore (MPTP) opening, which releases cytochrome c (CYCS), initiating apoptosis. These events are strongly associated with neurodegeneration and are hallmark features of Alzheimer's disease. Therefore, this APP allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway begins with the amyloid precursor protein (APP), which is cleaved to generate amyloid-beta (Abeta). Abeta activates muscarinic acetylcholine receptors (mAChR), triggering a cascade that involves GNAQ, PLCB, IP3, and ITPR, ultimately leading to increased intracellular Ca\u00b2\u207a. This Ca\u00b2\u207a enters mitochondria via MCU, potentially leading to mitochondrial permeability transition pore (MPTP) opening, which releases cytochrome c (CYCS) and initiates apoptosis. This pathway is strongly associated with Alzheimer's disease, where accumulation of Abeta contributes to neuronal dysfunction and death. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway begins with the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). Abeta activates muscarinic acetylcholine receptors (mAChRs), leading to G protein (GNAQ) activation and subsequent phospholipase C beta (PLCB) activity. This results in the production of inositol trisphosphate (IP3), which triggers calcium release from the endoplasmic reticulum via IP3 receptors (ITPR). Calcium then enters the mitochondria through the mitochondrial calcium uniporter (MCU), potentially leading to mitochondrial permeability transition pore (MPTP) activation. This can cause cytochrome c (CYCS) release, contributing to apoptosis. This pathway is strongly implicated in Alzheimer's disease due to the central role of Abeta in the disease's pathogenesis. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves glutamate signaling through GRM1 and downstream calcium regulation, with ATXN3 influencing the IP3 receptor complex. ATXN3 is a gene associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by CAG repeat expansions in the ATXN3 gene, leading to toxic gain-of-function of the ataxin-3 protein, which disrupts cellular processes and results in progressive motor dysfunction and other neurological symptoms. \n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system. In the given pathway, ATXN3 is associated with ITPR1, which is involved in calcium signaling. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in its misfolding and aggregation, which disrupts cellular function. This is the molecular basis for spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. It is a neurodegenerative disorder characterized by progressive ataxia, dystonia, and other neurological symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This is a neurodegenerative disorder characterized by progressive loss of coordination, muscle spasms, and other neurological symptoms. The pathway described involves calcium signaling, which is critical for neuronal function, and dysregulation of this pathway could contribute to neurodegeneration. ATXN3 is part of a complex that regulates calcium release and mitochondrial function, and its dysfunction may lead to the pathologies observed in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the unfolded protein response (UPR) in the endoplasmic reticulum (ER). SOD1, a copper-zinc containing superoxide dismutase, is part of a network that includes BIP (Binding Immunoglobulin Protein, also known as GRP78), which is a major ER chaperone. When ER stress is induced, BIP binds to EIF2AK3 (PERK), which phosphorylates EIF2S1, leading to the activation of ATF4. ATF4 then upregulates DDIT3 (CHOP), a pro-apoptotic transcription factor. Mutations in SOD1, particularly in the context of this pathway, are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the death of motor neurons. These mutations may lead to protein misfolding and aggregation, triggering ER stress and the UPR, ultimately leading to neuronal apoptosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, which is known to be associated with amyotrophic lateral sclerosis (ALS). SOD1 is a copper-zinc superoxide dismutase that normally detoxifies superoxide radicals. Mutations in the SOD1 gene lead to the production of toxic protein aggregates, which are implicated in the degeneration of motor neurons, a hallmark of ALS. The pathway includes elements of the unfolded protein response, such as BIP, EIF2AK3, EIF2S1, ATF4, and DDIT3, which are activated under conditions of endoplasmic reticulum stress. This suggests that the SOD1 allele in question may contribute to ALS by inducing ER stress and subsequent neurodegeneration.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves SOD1, which is a key player in oxidative stress response. SOD1 is linked to the unfolded protein response (UPR) through the PERK (EIF2AK3) pathway, which leads to ATF4 activation and upregulation of DDIT3 (CHOP), a pro-apoptotic gene. Dysfunctional SOD1 is primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. Mutations in SOD1 lead to misfolding and aggregation, triggering the UPR and subsequent neuronal death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloid pathway, which is implicated in Alzheimer's disease. APP is cleaved to produce Abeta peptides, which aggregate into plaques, a hallmark of Alzheimer's. The network includes proteasome subunits involved in protein degradation, suggesting impaired proteostasis may exacerbate Abeta accumulation. This contributes to neurodegeneration and cognitive decline.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloid pathway, where it is cleaved to produce the amyloid-beta peptide (Abeta). Accumulation of Abeta is a hallmark of Alzheimer's disease. The listed genes are components of the 26S proteasome, which is involved in protein degradation. Dysfunction in proteasome function may lead to impaired clearance of Abeta, contributing to its accumulation. This pathway is closely associated with the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, particularly in the context of the provided pathway involving the proteasome 20S and 26S subunits, is associated with the generation of Abeta peptides. These peptides are central to the pathogenesis of Alzheimer's disease, as they form amyloid plaques in the brain, leading to neurodegeneration. The proteasome system is critical for protein degradation, and dysregulation in this pathway may impair the clearance of Abeta, contributing to its accumulation. Therefore, the APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described involves activation of the Ras-MAPK signaling cascade, which is critical for cellular proliferation and differentiation. Mutations in FGFR3 that lead to constitutive activation of this pathway can result in uncontrolled cell growth. This aberrant signaling is implicated in various cancers, particularly in benign and malignant neoplasms of the bone and cartilage. The FGFR3 gene is known to be mutated in multiple myeloma, bladder cancer, and most notably, in a subset of osteosarcomas and bladder urothelial carcinomas. The persistent activation of downstream effectors like RAS, RAF, MEK, ERK, and ultimately MYC contributes to oncogenesis by promoting cell proliferation and survival. \n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 signaling pathway described involves a series of kinase activations leading to MYC upregulation, which promotes cell proliferation and survival. Mutations in FGFR3, especially those leading to constitutive activation, are known to cause aberrant signaling and are implicated in several diseases. In particular, activating mutations in FGFR3 are strongly associated with bladder cancer, where they contribute to uncontrolled cell growth and tumor progression. These mutations can also be found in other cancers such as multiple myeloma and some solid tumors.\n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described involves a series of kinase activations starting from FGFR3 and leading to the activation of MYC, a transcription factor involved in cell proliferation and survival. Mutations in FGFR3 are known to cause aberrant signaling, leading to uncontrolled cell growth. This pathway is implicated in various cancers, particularly those involving the RAS-ERK-MAPK signaling cascade. Given the components of the pathway and the role of FGFR3 in signal transduction, the biological effect of this FGFR3 allele is most strongly associated with bladder cancer.\n\n\\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway described. The pathway involves HTT interacting with STX1A, which in turn regulates the VGCC (N-type) calcium channel, leading to Ca\u00b2\u207a influx. Mutations in the HTT gene, particularly expansions of CAG trinucleotide repeats, result in dysfunctional huntingtin protein. This dysfunction disrupts calcium signaling and other cellular processes, leading to neurodegeneration. The disease associated with HTT mutations is Huntington's disease, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway described. This pathway involves HTT interacting with STX1A, which in turn regulates the N-type voltage-gated calcium channel (VGCC), leading to Ca\u00b2\u207a release. Mutations in the HTT gene, specifically expansions of CAG repeats, result in the production of a mutant huntingtin protein. This dysfunctional protein disrupts normal cellular processes, particularly in neurons, leading to progressive neurodegeneration. The most well-known consequence of such HTT mutations is Huntington's disease, an autosomal dominant neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, and mutations in this gene, specifically expansions of CAG trinucleotide repeats, lead to Huntington's disease. This neurodegenerative disorder is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The provided pathway involves HTT interacting with STX1A and VGCC(N-type), which are involved in calcium signaling. Disruption of this pathway due to mutant HTT may perturb calcium homeostasis, contributing to neuronal dysfunction and death. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are strongly associated with autosomal recessive juvenile Parkinson's disease (PD). Parkin's role in mitochondrial quality control and protein degradation is critical; loss-of-function mutations impair these processes, leading to neuronal degeneration, particularly in dopaminergic neurons. This results in the progressive motor and non-motor symptoms characteristic of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (ARJP), a form of early-onset Parkinson\u2019s disease. Given the presence of PRKN in this pathway along with ubiquitin-related enzymes (UBE2L3, UBE2L6) and CDCREL1, it suggests a role in protein degradation and cellular quality control. Pathogenic variants in PRKN disrupt its function, leading to impaired mitochondrial function and neuronal degeneration, particularly in the substantia nigra. This contributes to the progressive loss of motor function seen in Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system, which is crucial for targeting misfolded or damaged proteins for degradation. Mutations in PRKN are a major cause of early-onset autosomal-recessive Parkinson's disease (PD). This pathway includes components of the ubiquitin conjugation system, such as UBCH7/8 and UBE2L3/UBE2L6, and interacts with SEPTIN5, suggesting a role in protein degradation and cellular quality control. Dysfunctional parkin leads to the accumulation of toxic proteins, mitochondrial dysfunction, and neuronal loss, particularly in dopaminergic neurons, which are hallmarks of Parkinson's disease. Thus, the PRKN allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nAXIN1 is a key component of the WNT/\u03b2-catenin signaling pathway, which regulates cell proliferation, differentiation, and survival. In the given pathway, AXIN1 is involved in the negative regulation of \u03b2-catenin (CTNNB1) by forming a complex with GSK3B and APC, leading to \u03b2-catenin phosphorylation and degradation. A mutation or dysfunction in AXIN1 can lead to the stabilization and nuclear accumulation of \u03b2-catenin, resulting in the activation of TCF/LEF target genes such as MYC and CCND1, which promote cell proliferation. This dysregulation is commonly associated with the development of colorectal cancer. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is part of the WNT/\u03b2-catenin signaling cascade. AXIN1 is a negative regulator of this pathway, acting as a scaffold for the destruction complex that phosphorylates and targets CTNNB1 (\u03b2-catenin) for degradation. A mutant or loss-of-function AXIN1 allele would lead to stabilization and accumulation of \u03b2-catenin, which then translocates to the nucleus and binds to TCF/LEF transcription factors to activate target genes like MYC and CCND1, promoting cell proliferation and survival. This dysregulation is commonly observed in colorectal cancer, where mutations in WNT pathway components, including AXIN1, contribute to uncontrolled cell growth.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is part of the Wnt/\u03b2-catenin signaling cascade. AXIN1 is a negative regulator of this pathway, as it forms a complex with GSK3B and APC to promote the phosphorylation and degradation of CTNNB1 (\u03b2-catenin). If AXIN1 is dysfunctional, \u03b2-catenin accumulates, leading to the activation of TCF/LEF transcription factors, which in turn upregulate target genes such as MYC and CCND1, promoting cell proliferation. Aberrant activation of the Wnt pathway is associated with various cancers, particularly colorectal cancer. Therefore, a defective AXIN1 allele can contribute to the development of \\boxed{Colorectal Cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) gene is central to the androgen signaling pathway, which is crucial for male sexual development and function. The given pathway includes various ligands (T, DHT, E2, P4) and regulatory elements that modulate AR activity, leading to the expression of KLK3, a marker of prostate-specific activity. Mutations or aberrant regulation of the AR gene can lead to dysregulated androgen signaling. This pathway\u2019s malfunction is strongly associated with **prostate cancer**, where increased AR activity or resistance to androgen deprivation therapy can drive tumor progression. Thus, alterations in this AR allele contribute to the development and progression of **prostate cancer**.\n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR allele in this pathway, influenced by androgenic molecules such as Testosterone (T), Dihydrotestosterone (DHT), and others, modulates the expression of KLK3, which encodes prostate-specific antigen (PSA). Elevated AR activity and subsequent KLK3 expression are strongly associated with the progression of prostate cancer. This genomic pathway highlights the role of androgen receptor signaling in promoting the growth and survival of prostate cancer cells.\n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR gene encodes the androgen receptor, a ligand-activated transcription factor that plays a critical role in androgen signaling. The pathway described involves androgens (T, DHT), estrogens (E2), progesterone (P4), and other factors influencing the activation of AR, which in turn regulates the expression of KLK3, a gene associated with prostate-specific antigen (PSA). Dysregulation of this pathway, particularly through AR activation, is closely linked to the development and progression of prostate cancer. Variants in the AR gene can influence the sensitivity of prostate cancer cells to androgens, thereby affecting disease progression and response to androgen deprivation therapy. \n\n\\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). Aberrant processing of APP due to PSEN1 mutations leads to the accumulation of amyloid-beta (A\u03b2) peptides, which form toxic plaques in the brain. These plaques, along with neurofibrillary tangles, are hallmarks of Alzheimer's disease. The pathway described involves calcium signaling and mitochondrial dysfunction, which are implicated in neuronal death and the progression of Alzheimer's. Therefore, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). In this pathway, PSEN1 likely influences intracellular calcium signaling through its interaction with ITPR, which regulates Ca2+ release from the endoplasmic reticulum. Aberrant calcium signaling can disrupt mitochondrial function, leading to increased production of reactive oxygen species and activation of the mitochondrial permeability transition pore (MPTP), ultimately resulting in cytochrome c release and apoptosis. These events are implicated in neurodegeneration characteristic of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in amyloid precursor protein (APP) processing. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These mutations disrupt normal amyloid-beta (A\u03b2) cleavage, leading to increased production of A\u03b242, a toxic peptide that accumulates in the brain, forming plaques. This pathway, involving calcium signaling through ITPR and MCU, and ultimately triggering MPTP and CYCS release, suggests a role for mitochondrial dysfunction and apoptosis in the disease process. The dysregulation of calcium homeostasis and mitochondrial permeability transition may exacerbate neuronal damage in AD. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway, starting with SPTBN2 and involving multiple components related to calcium signaling (e.g., IP3, ITPR, Ca\u00b2\u207a), suggests a role in synaptic transmission and neuronal function. SPTBN2 encodes a brain-specific spectrin that is crucial for maintaining the structural integrity of neurons. Mutations in SPTBN2 have been linked to autosomal recessive spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive loss of coordination and motor skills. This is supported by the involvement of calcium signaling pathways, which are central to neuronal communication and survival. Disruption of these pathways can lead to neurodegeneration. \n\n\\boxed{Autosomal Recessive Spinocerebellar Ataxia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe genomic pathway involves SPTBN2, a gene encoding spectrin beta non-erythrocytic 2, which is part of a signaling cascade related to calcium mobilization. This pathway includes GRM1, an excitatory glutamate receptor, followed by GNAQ, PLCB, IP3, and ITPR, which collectively control intracellular calcium levels. Mutations in SPTBN2 may disrupt this pathway, leading to altered calcium signaling, which is crucial for neuronal function. Disruption in this pathway has been implicated in neurological disorders, specifically in autosomal dominant leukodystrophy, also known as SPTBN2-related leukodystrophy. This disease is characterized by progressive degeneration of the white matter in the brain, leading to cognitive and motor impairments. \n\n\\boxed{SPTBN2-related leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta, non-erythrocytic 2, a protein involved in maintaining the structure of the neuronal membrane. The provided pathway involves SPTBN2 interacting with GRM1, a glutamate receptor, initiating a signaling cascade that leads to Ca\u00b2\u207a release through IP3 and ITPR. Dysregulation in this pathway can disrupt neuronal function. Mutations in SPTBN2 have been associated with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by progressive difficulty in walking and loss of coordination. This suggests that the SPTBN2 allele contributes to the development of ARSACS by compromising the structural integrity and signaling processes in neurons.\n\n\\boxed{Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the L-type voltage-gated calcium channel, which plays a critical role in calcium ion influx into cells. Mutations in this gene have been implicated in various neurological disorders due to its involvement in neuronal excitability and synaptic transmission. Specifically, CACNA1A mutations are strongly associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disease characterized by progressive loss of coordination and motor function. These mutations lead to dysfunctional calcium channels, resulting in neuronal dysfunction and degeneration. \n\n\\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-dependent calcium channel, which is crucial for neurotransmitter release at synaptic terminals. Mutations in CACNA1A are associated with a range of neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type-6. These conditions are characterized by impaired calcium regulation in neurons, leading to abnormal neuronal firing and synaptic dysfunction. Specifically, the CACNA1A allele contributes to **spinocerebellar ataxia type 6 (SCA6)**, an autosomal dominant neurodegenerative disorder primarily affecting the cerebellum, resulting in progressive motor coordination deficits. \n\n\\boxed{Spinocerebellar ataxia type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCACNA1A encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which is crucial for neurotransmitter release at synaptic terminals. Mutations in this gene are associated with a range of neurological disorders. Specifically, CACNA1A mutations are implicated in spinocerebellar ataxia type 6 (SCA6), a neurodegenerative condition characterized by progressive loss of coordination and balance due to degeneration of the cerebellum. These mutations often result in dominant-negative effects, impairing calcium signaling and synaptic function, which are essential for proper neuronal communication and cerebellar function. \n\n\\boxed{Spinocerebellar Ataxia Type 6}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of lysosomal enzymes such as GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing the function of the associated enzymes. This contributes to the pathogenesis of a lysosomal storage disorder known as neuronal ceroid lipofuscinoses (NCL). Specifically, mutations in PSAP are linked to a rare form of NCL called saposin B deficiency, also referred to as late-infantile neuronal ceroid lipofuscinosis type 3 (CLN3). This condition is characterized by progressive neurological degeneration, visual loss, and seizures.\n\n\\boxed{Neuronal Ceroid Lipofuscinosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential cofactors for lysosomal enzymes such as GBA (glucosylceramidase beta) and GALC (galactosylceramidase). Mutations in PSAP can lead to a deficiency in saposins, impairing the activity of these enzymes. This results in the accumulation of undegraded substrates in lysosomes, leading to the progressive neurological disorder known as saposin deficiency. This condition encompasses a spectrum of lysosomal storage diseases, including metachromatic leukodystrophy (MLD) and some forms of Krabbe disease, depending on which saposin is affected. Since PSAP is part of the pathway involving GBA and GALC, it plays a critical role in the degradation of glycosphingolipids. Defects in this pathway can cause a variety of neurodegenerative disorders.\n\n\\boxed{Lysosomal Storage Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in saposins, impairing the function of these enzymes. This deficiency is associated with the accumulation of substrates that these enzymes normally break down, leading to cellular dysfunction primarily in the central nervous system. The resulting condition is known as saposin deficiency, which is a rare autosomal recessive lysosomal storage disease. It contributes to a broader group of disorders known as sphingolipidosis. \n\n\\boxed{Saposin Deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This is a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and brainstem, leading to ataxia, dystonia, and other neurological symptoms. ATXN3 encodes a protein involved in ubiquitin-proteasome system function and autophagy. The pathway defined includes components of the autophagy machinery, suggesting that ATXN3 may interact with or regulate key autophagy-related proteins. Mutations in ATXN3, particularly those leading to CAG trinucleotide repeat expansions, are the primary cause of SCA3. These expansions result in the production of expanded polyglutamine tracts in the ATXN3 protein, leading to its misfolding, aggregation, and toxicity. This contributes to neuronal dysfunction and death, specifically in the cerebellum and brainstem.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of an abnormal ataxin-3 protein. This protein accumulates in neurons, causing their degeneration, particularly in the cerebellum, brainstem, and spinal cord. Symptoms include ataxia, dystonia, and bulbar dysfunction. The pathway involving ATXN3 and autophagy-related genes (BECN1, PIK3C3, ATG14, PIK3R4, AMBRA1) may be related to the cellular mechanisms of protein degradation and quality control affected in the disease.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and in some cases, ophthalmoplegia and dystonia. ATXN3 is a member of the E3 ubiquitin ligase family and is involved in autophagy regulation, which is critical for cellular health. The provided genomic pathway highlights autophagy-related genes (BECN1, PIK3C3, ATG14, PIK3R4, AMBRA1), indicating a functional connection between ATXN3 and the autophagic machinery. Mutations in ATXN3 lead to the accumulation of toxic protein aggregates, impaired autophagy, and subsequent neuronal dysfunction. Therefore, ATXN3 contributes to the pathogenesis of spinocerebellar ataxia type 3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, particularly the mutant forms such as PRNP codon 178 (e.g., M129V and L105F), is associated with prion diseases, specifically Creutzfeldt-Jakob disease (CJD). The prion protein (PrP) is central to this pathway, where it initiates a cascade involving CAV, FYN, PI3K, PRKCD, NOX2, and ROS, which may lead to oxidative stress and neurodegeneration. This pathway suggests a mechanism by which prion protein misfolding and aggregation can disrupt cellular processes, contributing to the pathogenesis of CJD.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the mutant form of the prion protein gene, is associated with prion diseases. These are a group of rare, fatal neurodegenerative disorders characterized by the misfolding of the prion protein into a pathological form, leading to progressive brain damage. The pathway described involves signaling through CAV, FYN, PI3K, PRKCD, NOX2, and ROS, which may contribute to oxidative stress and neuronal dysfunction. This PRNP allele contributes to diseases such as Creutzfeldt-Jakob disease (CJD), including variant CJD (vCJD) and familial CJD. These diseases are transmissible through exposure to prion-contaminated tissues or genetic predisposition.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the pathogenic variants in the PRNP gene, is associated with prion diseases, a group of fatal, neurodegenerative disorders. These diseases involve the misfolding of the prion protein (PrP) into a pathogenic form, which leads to accumulation of PrPSc, resulting in neuronal damage and progressive neurological decline. The pathway described\u2014PRNP \u2192 CAV \u2192 FYN \u2192 PI3K \u2192 PRKCD \u2192 NOX2 \u2192 ROS\u2014suggests a mechanism involving oxidative stress and cellular signaling. This process may contribute to the neurotoxic effects observed in prion disease. The most well-known prion disease is Creutzfeldt-Jakob disease (CJD).\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS (NRAS and KRAS) proteins activating PI3K, leading to PIP3 production, which in turn activates AKT. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS, which can constitutively activate this pathway, disrupt normal cell cycle control and apoptosis. This leads to uncontrolled cell proliferation, a hallmark of cancer. Specifically, NRAS mutations are frequently found in melanoma, chronic myelomonocytic leukemia (CMML), and certain types of lymphomas. These mutations contribute to tumor development by promoting tumor cell survival and resistance to apoptosis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-MAPK and PI3K-AKT signaling cascades, which are critical for cell growth, proliferation, and survival. Activating mutations in NRAS, such as those leading to constitutive activation, can drive uncontrolled cell growth. This pathway is commonly dysregulated in cancers, particularly melanoma, where NRAS mutations are prevalent. These mutations lead to persistent signaling through PI3K and AKT, contributing to tumor initiation and progression. Therefore, the biological effect of this NRAS allele is to promote tumorigenesis, especially in melanoma. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a signaling cascade initiated by NRAS and KRAS, which activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS, particularly in this context, can lead to constitutive activation of the pathway, resulting in uncontrolled cell proliferation and resistance to apoptosis. Such alterations are commonly observed in certain cancers. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in the given pathway, specifically in the intracellular calcium signaling cascade. It is a known polyglutamine repeat disease gene, where expansion of the CAG repeat in ATXN3 leads to the production of a toxic protein. This malfunction contributes to the pathogenesis of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other neurological symptoms. The role of ATXN3 in calcium signaling and mitochondrial dysfunction likely contributes to neuronal dysfunction and cell death in SCA3.\n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes the ataxin-3 protein, which is involved in the ubiquitin-proteasome system. In the given pathway, ATXN3 is highlighted as a modifier of ITPR1 activity, potentially affecting calcium signaling through intracellular calcium release. Mutations in ATXN3 are primarily associated with Spinocerebellar Ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive degeneration of the cerebellum and brainstem, leading to ataxia, spasticity, and oculomotor dysfunction. The inclusion of ATXN3 in this pathway underscores its role in calcium homeostasis, which may contribute to the pathophysiology of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes a protein that is part of the ubiquitin-proteasome system, involved in the degradation of misfolded proteins. Pathogenic mutations in ATXN3 lead to the expansion of a CAG trinucleotide repeat, resulting in a toxic gain-of-function of the ataxin-3 protein. This protein accumulation damages neurons, particularly in the cerebellum and brainstem, leading to progressive neurodegeneration. The disease associated with this allele is **Spinocerebellar Ataxia type 3 (SCA3)**, also known as Machado-Joseph disease. It is an autosomal dominant neurodegenerative disorder characterized by ataxia, dystonia, ophthalmoplegia, and other motor symptoms.\n\n\\boxed{Spinocerebellar Ataxia type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. Loss of PTEN function leads to constitutive activation of AKT, promoting cell proliferation, survival, and resistance to apoptosis. This aberrant signaling is implicated in various cancers, most notably in phosphatase and tensin homolog (PTEN)-deficient cancers such as glioblastoma, endometrial cancer, and certain types of breast and prostate cancers. The PTEN allele in question, which is associated with the pathway PTEN* // PIP3 -> AKT, would therefore contribute to the development of cancer.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene is a tumor suppressor that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the provided pathway, PTEN* (a mutated or dysfunctional allele of PTEN) leads to increased PIP3 levels, which in turn activates AKT1, AKT2, and AKT3. This hyperactivation of the AKT pathway promotes cell survival, proliferation, and migration, contributing to uncontrolled cell growth. Loss of PTEN function is strongly associated with the development of various cancers, most notably Cowden syndrome and certain types of breast, endometrial, and prostate cancers. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, PTEN* (a mutated or nonfunctional allele of PTEN) leads to increased PIP3 levels, which in turn activates AKT1, AKT2, and AKT3. This hyperactivation of the AKT pathway promotes cell survival, growth, and proliferation, contributing to uncontrolled cell division and tumor formation. Loss of PTEN function is strongly associated with several cancers, most notably Cowden syndrome and certain types of breast, endometrial, and thyroid cancers.\n\n\\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in the autophagy pathway, specifically through its interaction with the BECN1 and other autophagy-related proteins. Mutations or abnormal expression of ATXN3 can disrupt autophagy, leading to the accumulation of damaged proteins and organelles. This malfunction contributes to the pathogenesis of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. SCA3 is a neurodegenerative disorder characterized by progressive loss of motor control, eye movement abnormalities, and other neurological symptoms. The ATXN3 allele, when expanded, leads to toxic protein aggregation and neuronal degeneration, particularly in the cerebellum and brainstem.\n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive damage to the cerebellum and other regions of the brain, leading to ataxia, muscle spasms, and other neurological symptoms. ATXN3 encodes the ataxin-3 protein, which is involved in the ubiquitin-proteasome system and autophagy. The pathway described, involving ATXN3 and components of the autophagy-related machinery, suggests a role for autophagy in the disease process. Dysfunctional ATXN3 may impair autophagy, contributing to the accumulation of toxic proteins and neuronal degeneration. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is implicated in the ubiquitin-proteasome system and autophagy pathways. It interacts with proteins involved in autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are all part of the Beclin 1-containing class III phosphatidylinositol 3-kinase complex. This complex is essential for autophagosome formation. Mutations in ATXN3, particularly expansion of a CAG trinucleotide repeat, lead to the production of a toxic protein that disrupts autophagy and causes neuronal degeneration. This genetic defect is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, a neurodegenerative disorder characterized by progressive ataxia, dystonia, and other neurological symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). The pathway outlined begins with PSEN1 activating EIF2AK3, which phosphorylates EIF2S1, leading to the activation of ATF4 and ultimately DDIT3. This pathway is associated with the unfolded protein response (UPR) in the endoplasmic reticulum (ER). Dysregulation of this pathway, particularly due to PSEN1 mutations, contributes to the accumulation of amyloid-beta peptides, a hallmark of Alzheimer\u2019s disease. These mutations can lead to early-onset familial Alzheimer\u2019s disease (FAD). The PSEN1 allele is therefore strongly linked to Alzheimer\u2019s disease, a neurodegenerative disorder characterized by progressive cognitive decline and memory loss.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex and plays a central role in the processing of amyloid precursor protein (APP), which generates amyloid-beta peptides. Accumulation of these peptides is a hallmark of Alzheimer's disease. In the provided pathway, PSEN1 activates EIF2AK3, which phosphorylates EIF2S1, leading to the activation of ATF4 and subsequently DDIT3. This pathway is involved in the unfolded protein response and stress-induced gene regulation. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease, suggesting that dysfunctional PSEN1 can disrupt normal amyloid processing and contribute to the neurodegenerative pathology of the disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 lead to the production of abnormal amyloid-beta peptides, which accumulate as plaques in the brain, a hallmark of Alzheimer's disease. The provided pathway highlights a stress response cascade initiated by PSEN1, involving EIF2AK3 (PERK), which phosphorylates EIF2S1, leading to activation of ATF4 and subsequently DDIT3, a gene involved in cellular stress responses. This pathway is linked to endoplasmic reticulum (ER) stress and apoptosis. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease, contributing to neurodegeneration through amyloid pathology and disrupted ER stress regulation.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). In the provided pathway, PSEN1 activates ERN1, which in turn activates XBP1, a transcription factor crucial for the unfolded protein response (UPR). Dysregulation of this pathway may contribute to endoplasmic reticulum (ER) stress, a hallmark of AD. Thus, PSEN1 mutations disrupt normal ER function and amyloid processing, leading to the accumulation of toxic amyloid-beta peptides and neurodegeneration. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is involved in the proteolytic cleavage of the amyloid precursor protein (APP). This pathway, involving PSEN1, ERN1, and XBP1, is associated with the unfolded protein response (UPR) in the endoplasmic reticulum. Mutations in PSEN1 are strongly linked to early-onset Alzheimer's disease, as they lead to altered processing of APP, resulting in increased production of amyloid-beta peptides, a hallmark of Alzheimer's pathology. These mutations disrupt normal function of the UPR, potentially contributing to neurodegeneration.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the proteolytic cleavage of amyloid precursor protein (APP). This pathway, involving PSEN1, ERN1, and XBP1, is linked to the unfolded protein response (UPR) in the endoplasmic reticulum. Mutations in PSEN1 are strongly associated with early-onset Alzheimer\u2019s disease, as they lead to abnormal processing of APP, resulting in increased production of amyloid-beta peptides, which accumulate and form plaques in the brain\u2014a hallmark of Alzheimer\u2019s disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene is involved in the autophagy pathway, specifically in the ubiquitin-proteasome system and autophagic degradation. It is part of a network that includes PINK1 and PRKN, which are central to mitophagy\u2014the selective autophagy of damaged mitochondria. Mutations in SQSTM1 are strongly associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). SQSTM1 encodes sequestosome 1, a protein that binds ubiquitinated proteins and targets them for autophagic degradation. Pathogenic variants in SQSTM1 can impair this process, leading to the accumulation of damaged proteins and organelles, especially in motor neurons. This disruption contributes to the progressive degeneration observed in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in the ubiquitin-proteasome system and autophagy. It is part of a mitochondrial quality control pathway, interacting with PINK1 and PRKN, which are central to the pathogenesis of Parkinson's disease. Mutations in SQSTM1 have been associated with familial amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). These mutations can lead to the accumulation of misfolded proteins and impaired autophagy, contributing to neurodegeneration. Thus, the SQSTM1 allele contributes to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in selective autophagy, particularly in the clearance of damaged mitochondria through the process known as mitophagy. In the given pathway, SQSTM1 is downstream of PINK1 and PRKN, which are central to mitophagy. Mutations in SQSTM1 are associated with an inherited neurodegenerative disorder called **Pancost disease** or more specifically, **SQSTM1-related neurodegeneration**. This condition is also linked to a form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), suggesting a role in neuronal dysfunction and degeneration due to impaired autophagy and mitochondrial quality control. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the activation of NRAS and KRAS, which are members of the RAS family of GTPases. These proteins activate PI3K, leading to the production of PIP3, which in turn activates AKT. AKT phosphorylates BAD, promoting cell survival by inhibiting apoptosis. Mutations in NRAS can lead to constitutive activation of this pathway, resulting in uncontrolled cell proliferation and survival. This aberrant signaling is commonly observed in various cancers, particularly melanoma, where NRAS mutations are frequently detected. These mutations contribute to tumor development and progression by overriding normal growth control mechanisms. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS family members (KRAS and NRAS) activating PI3K, leading to the production of PIP3, which in turn activates AKT. AKT then phosphorylates BAD, an anti-apoptotic event. Mutations in NRAS that constitutively activate this pathway can lead to uncontrolled cell proliferation and survival, contributing to various cancers. Specifically, NRAS mutations are commonly associated with melanoma, a type of skin cancer. These mutations are often found in the G12, G60, or Q61 codons of NRAS, leading to constitutive activation of the RAS-MAPK and PI3K-AKT signaling pathways. This dysregulation promotes tumorigenesis and resistance to apoptosis. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves NRAS and KRAS activating PI3K, leading to PIP3 production, which phosphorylates AKT. AKT then inhibits BAD, promoting cell survival and proliferation. Mutations in NRAS can lead to constitutive activation of this pathway, contributing to uncontrolled cell growth. This aberrant signaling is commonly associated with various cancers, particularly melanoma, where NRAS mutations are prevalent. These mutations disrupt normal cell cycle regulation and apoptosis, facilitating tumor development and progression.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the ubiquitin-proteasome system, which regulates protein degradation. In the given pathway, VHL interacts with RBX1, ELOC, ELOB, and CUL2 to form an E3 ubiquitin ligase complex, which targets EPAS1 for degradation. When VHL is mutated or dysfunctional, EPAS1 accumulates and dimerizes with ARNT to activate transcription of downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. This leads to increased angiogenesis and cell proliferation, contributing to the development of clear cell renal cell carcinoma (ccRCC). \n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the regulation of hypoxia-inducible factor (HIF) proteins, which control cellular responses to oxygen levels. When functional, the VHL pathway (VHL*+RBX1+ELOC+ELOB+CUL2) ubiquitylates and degrades HIF-\u03b1 subunits, such as EPAS1, in the presence of oxygen. Under hypoxia, EPAS1 binds with ARNT to activate transcription of genes like VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. Mutations in VHL disrupt this pathway, leading to stabilization of HIF-\u03b1 subunits and constitutive activation of these genes, promoting angiogenesis, cell proliferation, and survival. This dysregulation is a hallmark of von Hippel-Lindau disease, a hereditary cancer syndrome characterized by the development of benign and malignant tumors in multiple organs.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that regulates the degradation of hypoxia-inducible factors (HIFs), such as EPAS1. In the absence of functional VHL, EPAS1 accumulates and forms a complex with ARNT, activating transcription of downstream genes like VEGFA, CXCL8, GLUT1, and EPO. This leads to increased angiogenesis, cell proliferation, and survival. These effects are central to the development of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. The pathway described reflects this mechanism, linking VHL inactivation to oncogenic signaling via the HIF pathway.\n\n\\boxed{Clear cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of damaged proteins. Mutations in PRKN are a common cause of autosomal recessive juvenile Parkinson's disease. The pathway involving PRKN and MFN1/2 is critical for mitochondrial dynamics and quality control. Disruption of this pathway can lead to impaired mitochondrial function and increased susceptibility to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, a protein involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are a common cause of autosomal recessive early-onset Parkinson's disease. The pathway involving PRKN and MFN1/2 is critical for mitochondrial dynamics and function. Impairment of this pathway can lead to mitochondrial dysfunction and neuronal degeneration, which are hallmarks of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are associated with autosomal recessive juvenile Parkinsonism (also known as Parkin-Linked Parkinson's Disease). This disease is a form of early-onset Parkinson's disease characterized by progressive degeneration of dopaminergic neurons in the substantia nigra. The PRKN pathway, which also includes MFN1 and MFN2, is involved in mitochondrial dynamics, including fusion and fission processes. Disruption of this pathway can lead to impaired mitochondrial function, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene encodes cyclin-dependent kinase 4, which, when activated by cyclin D proteins (CCND1, CCND2, CCND3), phosphorylates the tumor suppressor protein RB1. This phosphorylation inactivates RB1, allowing the E2F transcription factors to activate genes necessary for DNA synthesis and cell division. Mutations or overexpression of CDK4 can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation. This aberrant regulation is a key feature in the development of certain cancers, particularly melanoma. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele, when aberrantly activated, contributes to uncontrolled cell proliferation by phosphorylating RB1, leading to the release of E2F transcription factors. This promotes the transition from G1 to S phase in the cell cycle, a hallmark of cancer. The dysregulation of this pathway is strongly associated with various cancers, particularly those involving the cyclin D-CDK4-RB1-E2F axis. This pathway is frequently mutated or overexpressed in cancers such as breast, pancreatic, and melanoma. \n\n\\boxed{(Cancer)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the CDK4 gene, which, when activated (CDK4*), interacts with cyclin D proteins (CCND1, CCND2, CCND3) to phosphorylate the tumor suppressor protein RB1. This phosphorylation inactivates RB1, allowing the E2F transcription factors (E2F1, E2F2, E2F3) to promote the expression of genes required for DNA replication and cell cycle progression. Dysregulation of this pathway, particularly through overexpression or activating mutations of CDK4, can lead to uncontrolled cell proliferation. This is a hallmark of many cancers. Specifically, mutations in CDK4 are notably associated with neurofibromatosis type 1 (NF1) and are also frequently observed in melanoma and other cancers. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS (KRAS and NRAS) proteins activating PI3K, leading to the production of PIP3, which in turn activates AKT. AKT then phosphorylates BAD, inhibiting apoptosis. Mutations in NRAS can constitutively activate this pathway, leading to uncontrolled cell proliferation and survival. This is a known mechanism in several cancers. Such activation is commonly observed in melanoma, where NRAS mutations are a significant cause. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, when mutated, can constitutively activate the RAS signaling pathway by enhancing the GTP-bound state of NRAS. This leads to continuous activation of downstream effectors such as PI3K, which phosphorylates PIP3 to activate AKT. Activated AKT promotes cell survival and proliferation by phosphorylating targets like BAD, preventing apoptosis. Mutations in NRAS are frequently observed in various cancers, including melanoma, myeloma, and some leukemias. These mutations contribute to uncontrolled cell growth and tumor formation by disrupting normal regulatory mechanisms of the pathway.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS/MAPK and PI3K/AKT signaling cascades, which are crucial for cell proliferation, survival, and differentiation. NRAS is a proto-oncogene, and mutations in NRAS can lead to constitutive activation of these pathways, promoting uncontrolled cell growth. This is commonly observed in various cancers, particularly in melanoma, where activating NRAS mutations are known to drive tumorigenesis. The presence of NRAS mutations in this pathway context is strongly associated with melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for lysosomal enzyme activation. The pathway includes PSAP and enzymes such as GBA and GALC, which are involved in lipid metabolism. Mutations in PSAP can lead to impaired saposin function, resulting in the accumulation of sphingolipids. This is associated with a lysosomal storage disorder known as saposin deficiency, which includes types such as Farber disease and certain forms of neuronal ceroid lipofuscinosis. \n\n\\boxed{Farber disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the function of lysosomal enzymes like GBA and GALC. Mutations in PSAP lead to a deficiency in these saposins, impairing the activity of GBA and GALC. This results in the accumulation of their substrates, such as glucosylceramide and galactosylceramide, in lysosomes. This accumulation causes cellular dysfunction, particularly in neurons, leading to the development of a rare genetic disorder known as neuronal ceroid lipofuscinosis (NCL), specifically the type known as saposin B deficiency or CLN13. This disease is characterized by progressive neurological degeneration, vision loss, seizures, and early mortality. \n\n\\boxed{Neuronal Ceroid Lipofuscinosis (CLN13)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to reduced saposin levels, impairing the activity of these enzymes. This contributes to the accumulation of substrates that these enzymes normally break down, leading to the lysosomal storage disorder known as saposin deficiency. This condition is also associated with a specific form of neuronal ceroid lipofuscinosis (NCL), a group of neurodegenerative disorders. Given the involvement of GBA and GALC, the most relevant disease linked to PSAP mutations is **infantile sialic acid storage disease**, though it is also implicated in certain forms of NCL. \n\n\\boxed{Neuronal Ceroid Lipofuscinosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET proto-oncogene encodes a receptor tyrosine kinase involved in cell proliferation, survival, and migration. In this pathway, MET activates GAB1, leading to PI3K, which generates PIP3 and subsequently activates AKT, which phosphorylates and inactivates BAD, promoting cell survival. Mutations or overactivation of MET can drive uncontrolled cell growth and survival, contributing to cancer. MET amplification or activating mutations are commonly observed in various cancers, including lung adenocarcinoma, gastric cancer, and others. This pathway dysregulation is a hallmark of oncogenesis, supporting tumor progression and resistance to therapy. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, through activation of the MET receptor tyrosine kinase, initiates a signaling pathway involving GAB1, PI3K (catalyzed by PIK3CA, PIK3CB, or PIK3CD), PIP3, and AKT, which ultimately influences BAD. This pathway is known to promote cell survival, proliferation, and migration. Aberrant activation of this pathway, often due to MET mutations or amplifications, contributes to uncontrolled cell growth and is implicated in various cancers. Specifically, MET alterations are frequently observed in lung adenocarcinoma, gastric cancer, and other malignancies. The MET-driven pathway is a recognized oncogenic driver in these diseases.\n\n\\boxed{Lung Adenocarcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele is associated with the MET proto-oncogene, a receptor tyrosine kinase that activates downstream signaling pathways such as the PI3K/AKT pathway. In this pathway, MET activates GAB1, which in turn activates PI3K, leading to PIP3 production and subsequent activation of AKT. AKT then regulates BAD, a pro-apoptotic protein, by phosphorylation, promoting cell survival and proliferation. When MET is mutated or overactivated, it can lead to uncontrolled cell growth and tumor formation. This pathway is frequently dysregulated in several cancers, particularly in non-small cell lung cancer (NSCLC) and some gastrointestinal cancers. The activation of the MET pathway promotes tumor growth, invasion, and resistance to therapy. \n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when mutated or constitutively activated (as in the BCR-ABL fusion protein), leads to uncontrolled cell proliferation and survival. This fusion protein is central to the pathogenesis of chronic myeloid leukemia (CML). The pathway involves activation of CRKL, CBL, and CRK, which then activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT inhibits BAD, which promotes apoptosis, thus contributing to the survival and proliferation of leukemic cells. This aberrant signaling is a hallmark of CML and other related leukemias.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when mutated or overactivated (as in the BCR-ABL fusion protein), leads to constitutive activation of downstream signaling pathways such as PI3K/AKT, which promote uncontrolled cell proliferation and survival. This aberrant signaling is a hallmark of chronic myeloid leukemia (CML). The pathway described includes key players like CRKL, CBL, and CRK, which are involved in transmitting signals from BCR-ABL to PI3K and AKT, and ultimately to BAD, a pro-apoptotic protein. This results in evasion of apoptosis and increased cell survival, which are characteristic features of CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that is central to the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML). This fusion results in constitutive activation of the ABL tyrosine kinase, leading to uncontrolled cell proliferation and survival. The pathway involves CRKL, CBL, and CRK as adaptors, activating PI3K, which generates PIP3 and subsequently activates AKT. AKT phosphorylates BAD, inhibiting apoptosis. This dysregulated pathway contributes to the malignant transformation and progression of CML. \n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of damaged proteins. In the provided pathway, PRKN initiates a signaling cascade leading to PLCG1 activation, IP3 production, and ultimately Ca\u00b2\u207a release via ITPRs. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease 1 (PARK1). This disease is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. The biological effect of a dysfunctional PRKN allele is impaired protein quality control and mitochondrial dysfunction, contributing to the progressive loss of dopaminergic neurons in the substantia nigra. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination of proteins, particularly in the process of mitochondrial quality control. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease (EOPD). The pathway described involves PRKN initiating a cascade that leads to PLCG1 activation, IP3 production, and subsequent Ca\u00b2\u207a release via ITPR receptors. This pathway is linked to calcium signaling, which is crucial in various cellular processes, including apoptosis and autophagy. Dysregulation of this pathway due to PRKN mutations can lead to mitochondrial dysfunction and neuronal death, characteristic of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PRKN (parkin), which is an E3 ubiquitin ligase, and is linked to calcium signaling via PLCG1, IP3, and ITPR receptors. Mutations in PRKN are a known cause of early-onset autosomal recessive Parkinson's disease. The function of PRKN in this pathway may involve regulation of calcium homeostasis, and its dysfunction could lead to neurodegeneration seen in Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. These are a group of rare, fatal neurodegenerative disorders caused by the misfolding of the prion protein into a pathogenic form. The NOTCH1 gene is involved in cell signaling and is not directly associated with prion diseases. Therefore, the PRNP allele specifically contributes to prion-related diseases, most notably Creutzfeldt-Jakob disease (CJD), including its genetic variant, Gerstmann-Str\u00e4ussler-Scheinker syndrome. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when mutated, can lead to the development of prion diseases. These are a group of rare, progressive, and often fatal neurodegenerative disorders. The specific PRNP allele in question is associated with the transmission of these diseases, particularly when it leads to the misfolding of the prion protein, resulting in the accumulation of abnormal prion proteins in the brain. This process causes spongiform changes and neuronal loss. The most well-known prion disease linked to PRNP mutations is Creutzfeldt-Jakob disease (CJD). Genetic variants of PRNP are also involved in other prion-related conditions such as Gerstmann-Str\u00e4ussler-Scheinker syndrome and fatal insomnia. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. These are a group of rare, progressive, and usually fatal neurodegenerative disorders. The PRNP allele, particularly with certain mutations, can lead to the misfolding of the prion protein, resulting in the accumulation of pathological prion protein (PrPSc), which causes neuronal damage. The NOTCH1 gene is involved in cell signaling and development, and its interaction with PRNP is part of a broader network. However, the primary disease associated with PRNP is transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease (CJD) in humans. The PRNP allele itself is a key contributor to these conditions.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes a tumor suppressor protein that is part of an E3 ubiquitin ligase complex involved in the degradation of hypoxia-inducible factors (HIFs), such as HIF-1\u03b1 and HIF-2\u03b1 (also known as EPAS1). Under normal oxygen conditions, VHL targets these proteins for ubiquitination and proteasomal degradation. When VHL is mutated or inactivated, HIFs accumulate, leading to the activation of genes involved in angiogenesis, cell proliferation, and survival, such as VEGFA, CXCL8, GLUT1, and EPO. This aberrant activation contributes to the development of clear cell renal cell carcinoma (ccRCC), a common and aggressive form of kidney cancer. The provided pathway highlights how the VHL complex regulates HIF-activity, and its disruption leads to dysregulated expression of downstream genes, promoting tumorigenesis.\n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the regulation of hypoxia-inducible factor (HIF) through the ubiquitination and degradation of HIF-1\u03b1. In the given pathway, VHL interacts with RBX1, ELOC, ELOB, and CUL2 to form an E3 ubiquitin ligase complex that targets EPAS1 (HIF-2\u03b1) for degradation. Under normal oxygen conditions, this complex ensures that EPAS1 is degraded. However, in the absence of functional VHL, EPAS1 accumulates and binds with ARNT to activate downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which are involved in angiogenesis, inflammation, and erythropoiesis. This dysregulation contributes to the development of von Hippel-Lindau disease, a hereditary disorder associated with hemangioblastomas, renal carcinomas, and other tumors.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the VHL (von Hippel-Lindau) tumor suppressor gene and its role in a ubiquitin ligase complex (VHL, RBX1, ELOC, ELOB, CUL2) that targets EPAS1 for degradation. When VHL is mutated or inactivated, EPAS1 is stabilized and forms a complex with ARNT, activating downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. This leads to increased angiogenesis, cellular proliferation, and survival, promoting tumor growth. This pathway is central to the pathogenesis of von Hippel-Lindau disease, a hereditary condition associated with the development of benign and malignant tumors in various organs, including the kidneys, brain, and adrenal glands.\n\n\\boxed{von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway describes a sequence involving HTT (huntingtin), which is central to the pathogenesis of Huntington's disease. The HTT* allele, associated with mutant huntingtin, leads to the dysregulation of calcium signaling through NMDAR, MCU, and subsequent mitochondrial dysfunction, culminating in apoptosis via the intrinsic pathway. This aberrant signaling is implicated in the progressive neuronal degeneration observed in Huntington's disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, encoding the huntingtin protein, is implicated in Huntington's disease. This pathway outlines a mechanism where mutant HTT disrupts the function of NMDAR (N-methyl-D-aspartate receptors), leading to increased intracellular calcium levels. Excess calcium enters the mitochondria via the MCU (mitochondrial calcium uniporter), which can trigger the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c (CYCS). This initiates the apoptotic cascade through APAF1 and caspases (CASP9 and CASP3), contributing to neuronal death. This neurodegenerative process is characteristic of Huntington's disease, a devastating autosomal dominant disorder that leads to progressive motor, cognitive, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, associated with the Huntington's disease gene, leads to the production of mutant huntingtin protein. This protein aggregates and disrupts multiple cellular processes, including mitochondrial function and calcium homeostasis. In the provided pathway, HTT* (mutant huntingtin) initiates a cascade involving NMDAR, Ca\u00b2\u207a influx, mitochondrial Ca\u00b2\u207a overload, and subsequent mitochondrial permeability transition. This leads to cytochrome c release, activation of APAF1, and caspase cascade, ultimately resulting in apoptosis. The pathway reflects the neurodegenerative process characteristic of Huntington's disease, where neuronal death occurs due to these molecular defects.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel, which plays a crucial role in regulating neuronal excitability. Mutations in this gene have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The dysfunction of KCNC3 leads to impaired potassium channel activity, disrupting normal neuronal signaling and contributing to the pathogenesis of SCA13. \n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel protein, which is critical for the regulation of neuronal excitability. Mutations in KCNC3 have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive loss of coordination, gait instability, and speech difficulties. This disease results from the dysfunction of cerebellar and brainstem neurons due to the altered potassium channel activity. The extracellular potassium dynamics, as indicated in the pathway, further suggest a role in maintaining proper neuronal firing thresholds. Dysregulation of these channels can lead to impaired neural signaling and contribute to the ataxic phenotype observed in SCA13.\n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel that plays a critical role in the repolarization phase of action potentials in neurons and cardiac muscle. Mutations in KCNC3 have been implicated in a form of episodic ataxia, specifically episodic ataxia type 6 (EA6). This disorder is characterized by recurrent episodes of ataxia, nystagmus, and sometimes seizures. The dysfunction of the KCNC3-encoded potassium channel likely disrupts normal neuronal excitability, leading to the clinical manifestations observed in EA6. \n\n\\boxed{Episodic Ataxia Type 6}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease (PD). The pathway described includes PRKN, which likely influences intracellular calcium signaling through downstream effectors such as PLCG1, IP3, and ITPR. These molecules are key players in calcium release from the endoplasmic reticulum, which is essential for various cellular processes. Dysregulation of calcium homeostasis can lead to neuronal dysfunction and degeneration. Therefore, mutations in PRKN that disrupt this pathway may contribute to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in the process of mitophagy. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease (PD). The pathway described involves PRKN initiating a cascade that leads to Ca\u00b2\u207a release through IP\u2083 receptors, which can impair mitochondrial function. This dysfunction is implicated in neurodegeneration. Therefore, the biological effect of PRKN alleles with pathogenic mutations is a predisposition to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. Parkin is essential for mitochondrial quality control via mitophagy. Disruption of PRKN function leads to impaired mitochondrial function and accumulation of defective mitochondria, contributing to neuronal degeneration in dopaminergic neurons. This pathway, involving PRKN, PLCG1, IP3, and ITPR, is related to calcium signaling, which is critical for neuronal survival and function. Dysregulation in this pathway may exacerbate neuronal damage in Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the *PRNP* gene, encodes the prion protein, which is central to the pathogenesis of prion diseases. In the given pathway, PRNP interacts with BIP (a chaperone protein), which is involved in the unfolded protein response (UPR). The UPR is a cellular stress response pathway activated by endoplasmic reticulum (ER) stress, and it includes the EIF2AK3 (PERK) kinase, which phosphorylates EIF2S1, leading to the activation of ATF4, a transcription factor that induces DDIT3 (CHOP), a pro-apoptotic protein. Dysregulation of this pathway can contribute to neurodegeneration. In the context of prion disease, misfolded PRNP proteins can trigger aberrant UPR signaling, leading to neuronal dysfunction and death. This contributes to the development of prion-related neurodegenerative diseases such as Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of rare, progressive neurodegenerative disorders. The pathway described involves the PRNP gene, which encodes the prion protein, and several downstream molecular players involved in the unfolded protein response (UPR). The network includes BIP (a chaperone protein), EIF2AK3 (a kinase that activates the UPR), and the transcription factor ATF4, which regulates DDIT3, a gene involved in cellular stress responses. Dysregulation of this pathway due to mutations in PRNP can lead to misfolding and accumulation of the prion protein, resulting in neurotoxicity. This contributes to diseases such as Creutzfeldt-Jakob disease (CJD), including its hereditary form, fatal familial insomnia (FFI), and other prion-related disorders.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of rare, fatal neurodegenerative disorders. These diseases occur due to the misfolding of the prion protein (PrP), leading to accumulation of pathological prion protein (PrP^Sc) and subsequent neurotoxicity. In the provided pathway, the PRNP gene influences the unfolded protein response (UPR) through its interaction with BIP, which is involved in the endoplasmic reticulum (ER) stress response. The pathway leads to the activation of ATF4 and DDIT3, which are transcription factors involved in ER stress and DNA damage responses. Therefore, the PRNP allele contributes to prion-related diseases, such as Creutzfeldt-Jakob disease. \n\n\\boxed{Prion disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with several neurological disorders, including spinocerebellar ataxia type 6 (SCA6), a progressive neurodegenerative disease characterized by loss of coordination and motor control. Additionally, CACNA1A mutations have been implicated in episodic ataxia type 2 and some forms of migraine. These findings underscore the gene's pivotal role in maintaining normal cerebellar function and neuronal signaling. \n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of a voltage-gated calcium channel, which plays a critical role in regulating calcium influx into neurons. Mutations in CACNA1A are associated with various neurological disorders, particularly those involving dysfunctional calcium signaling. This gene is specifically implicated in episodic ataxia type 2, a condition characterized by episodes of uncoordinated movement, and in spinocerebellar ataxia type 6, a progressive neurodegenerative disorder affecting coordination and balance. These diseases result from impaired calcium channel function, leading to abnormal neuronal activity and degeneration in the cerebellum. The extracellular calcium influx mediated by CACNA1A is essential for normal nerve function, and its disruption contributes to the pathophysiology of these ataxias.\n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of a voltage-gated calcium channel, which is critical for calcium ion influx into neurons. Mutations in CACNA1A are associated with several neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired coordination, seizures, and migraine headaches. The dysfunction of this calcium channel disrupts normal neuronal signaling and excitability, leading to the observed clinical manifestations. \n\n\\boxed{Spinocerebellar ataxia type 6}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway involves TBK1, a kinase that phosphorylates LC3-II, which is critical for autophagy. This pathway also includes autophagy receptors like SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1, which recognize ubiquitinated cargo for autophagic degradation. Mutations in TBK1 have been associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). TBK1 is involved in the clearance of misfolded proteins and damaged organelles, and its dysfunction can lead to the accumulation of toxic proteins, contributing to neuronal degeneration. Therefore, this TBK1 allele likely contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 gene plays a critical role in the autophagy pathway by phosphorylating SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1, leading to the recruitment of LC3-II, which is essential for autophagosome formation. Mutations in TBK1 that impair this function can lead to defective autophagy. This disruption is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). TBK1 is a key component in the regulation of autophagy and immune responses, and its dysfunction contributes to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway describes the interaction of TBK1 with several autophagy-related proteins (SQSTM1, OPTN, NDP52, TAX1BP1, NBR1) leading to LC3-II, a key marker of autophagosome formation. TBK1 plays a critical role in the regulation of selective autophagy, particularly in the clearance of damaged organelles and pathogenic proteins. Mutations in TBK1 have been implicated in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). These mutations often result in impaired autophagy function, leading to the accumulation of toxic proteins in neurons. This disruption in cellular homeostasis contributes to neuronal dysfunction and death, hallmark features of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component of Lewy bodies, pathological inclusions found in the brains of individuals with Parkinson's disease. Mutations in SNCA, or increased expression of the gene, are associated with the development of Parkinson's disease and other neurodegenerative disorders, such as multiple system atrophy and dementia with Lewy bodies. The interaction of SNCA with complex I (CxI) of the mitochondrial respiratory chain, as indicated by the pathway definition, may contribute to mitochondrial dysfunction, which is a common feature in these neurodegenerative conditions.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the pathogenesis of Parkinson's disease. Accumulation of misfolded alpha-synuclein leads to the formation of Lewy bodies, a hallmark of Parkinson's disease. The SNCA allele, when mutated or overexpressed, contributes to neurodegeneration and the progression of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the pathogenesis of Parkinson's disease. Mutations in SNCA, including the SNCA* allele, have been associated with an increased risk of Parkinson's disease. This allele may lead to the misfolding and aggregation of alpha-synuclein, forming Lewy bodies that are characteristic of the disease. These protein aggregates are thought to disrupt normal cellular function, leading to neuronal degeneration in brain regions involved in motor control, such as the substantia nigra. This contributes to the progressive loss of motor function and other neurological symptoms typical of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPARK7 encodes the DJ1 protein, which is involved in protecting neurons against oxidative stress and maintaining mitochondrial function. The provided pathway shows DJ1 interacting with DAXX and ASK1 to activate JNK, a key kinase in stress response and apoptosis. Mutations in PARK7 are linked to early-onset Parkinson's disease, contributing to neuronal degeneration through impaired stress response and mitochondrial dysfunction. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves PARK7 (DJ1), which is linked to Parkinson's disease. The network includes DAXX and ASK1 (MAP3K5) leading to JNK (MAPK8, MAPK9, MAPK10), a key signaling node in stress responses. Mutations in PARK7 can disrupt this pathway, leading to mitochondrial dysfunction and oxidative stress, both implicated in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the gene PARK7 (DJ1), which interacts with DAXX and ASK1 (MAP3K5) to influence the JNK signaling pathway. Mutations in PARK7 are associated with early-onset Parkinson's disease. DJ1 plays a role in protecting neurons by maintaining mitochondrial function and reducing oxidative stress. Disruption of this pathway can lead to neurodegeneration, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is a key component of the mitogen-activated protein kinase (MAPK) signaling pathway. In the given pathway, BRAF activates MEK, which in turn activates ERK. Activating mutations in BRAF, such as V600E, lead to constitutive activation of the MAPK pathway, promoting cell proliferation and survival. This aberrant signaling is a common feature in several cancers, particularly melanoma. The persistent activation of ERK downstream of mutant BRAF contributes to tumor initiation and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is part of the MAPK/ERK signaling pathway, which plays a crucial role in cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the pathway, promoting uncontrolled cell proliferation. This aberrant signaling is a well-known driver in several cancers, notably melanoma. The pathway components MEK and ERK are also implicated in the progression of these diseases. Therefore, mutations in BRAF contribute significantly to the development of melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is part of the MAPK/ERK signaling pathway, which is crucial for cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the BRAF kinase, resulting in uncontrolled cell proliferation. This aberrant activation of the BRAF->MEK->ERK pathway is a well-documented driver in several cancers, including melanoma, thyroid carcinoma, and colorectal cancer. The presence of such a mutation in chromosome 7, along with the associated genes (MAP2K1, MAP2K2, MAPK1, MAPK3) implicated in the same pathway, further supports its role in promoting tumorigenesis.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in purine salvage pathway. Mutations in the APRT gene can lead to a deficiency in this enzyme, which impairs the body's ability to recycle adenine into adenosine monophosphate (AMP). This deficiency results in the accumulation of 2,8-dihydroxyadenine, which can form crystals and lead to kidney damage. The condition is known as 2,8-dihydroxyadenine urolithiasis or adenine phosphoribosyltransferase deficiency. This disease is characterized by the formation of kidney stones and may lead to renal failure if left untreated.\n\n\\boxed{Adenine phosphoribosyltransferase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine synthesis. It catalyzes the conversion of adenine to inosine monophosphate (IMP). Mutations in the APRT gene can lead to a deficiency in this enzyme, impairing the body's ability to efficiently recycle adenine. This deficiency can result in the accumulation of adenine and its metabolites, which may contribute to the formation of kidney stones. Specifically, mutations in APRT are associated with 2,8-dihydroxyadenine (DHA) urolithiasis, a rare genetic disorder characterized by the formation of DHA crystals in the kidneys and urinary tract, leading to kidney damage and stones.\n\n\\boxed{2,8-dihydroxyadenine urolithiasis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine nucleotide synthesis. Mutations in the APRT gene can lead to a deficiency in this enzyme, impairing the body's ability to recycle adenine into adenosine monophosphate (AMP). This results in the accumulation of 2,8-dihydroxyadenine, which can form crystals and deposits in various tissues. The condition caused by APRT deficiency is known as 2,8-dihydroxyadenine urolithiasis or adenine phosphoribosyltransferase (APRT) deficiency. It is a rare autosomal recessive disorder characterized by the formation of kidney stones and potential renal failure. \n\n\\boxed{Adenine phosphoribosyltransferase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene is a tumor suppressor gene that plays a critical role in regulating the cell cycle. Mutations in RB1 can lead to uncontrolled cell proliferation, as the gene's function in inhibiting E2F transcription factors is compromised. The provided pathway, involving RB1 and E2F family members, underscores the role of RB1 in repressing E2F-mediated transcription of genes required for cell cycle progression. Loss of RB1 function results in the activation of E2F transcription factors, promoting cell cycle entry and DNA replication. This contributes to the development of retinoblastoma, a childhood cancer of the retina. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes a tumor suppressor protein that plays a critical role in regulating the cell cycle by inhibiting the E2F family of transcription factors. When RB1 is dysfunctional or mutated, it leads to uncontrolled cell proliferation. The E2F proteins, including E2F1, E2F2, and E2F3, are key regulators of the G1/S transition in the cell cycle. In the absence of functional RB1, E2F proteins are no longer effectively inhibited, leading to inappropriate cell cycle progression and DNA replication. This loss of control is a hallmark of many cancers. Mutations in RB1 are strongly associated with retinoblastoma, a childhood eye cancer. Therefore, the biological effect of a nonfunctional RB1 allele is the development of retinoblastoma.\n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes a tumor suppressor protein that is essential in regulating the cell cycle by inhibiting E2F transcription factors, which are critical for the initiation of DNA replication. Mutations or deletions in RB1 lead to uncontrolled cell proliferation. This pathway, defined by the interaction of RB1 with E2F1, E2F2, and E2F3, is central to the regulation of the G1/S phase transition in the cell cycle. Loss of RB1 function results in overactivation of E2F and subsequent unchecked cell division, contributing to tumorigenesis. This genetic disruption is closely associated with retinoblastoma, a childhood cancer of the retina. Thus, the RB1 allele, when inactivated, contributes to the development of retinoblastoma.\n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes a protein involved in the ubiquitin-proteasome system, which is crucial for degrading misfolded or damaged proteins. Mutations in ATXN3, particularly those leading to expanded CAG trinucleotide repeats, are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other neurological symptoms. The biological effect of the ATXN3 allele in the given pathway likely relates to impaired calcium homeostasis and mitochondrial dysfunction, which can contribute to neuronal degeneration. These findings underline the role of ATXN3 in maintaining cellular health and its disruption in disease.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes for ataxin-3, a protein that is involved in the ubiquitin-proteasome system, which is crucial for protein degradation. When mutated, ATXN3 can lead to the accumulation of misfolded proteins, causing neuronal dysfunction and degeneration. Specifically, the ATXN3 allele with a CAG trinucleotide repeat expansion is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This autosomal dominant neurodegenerative disorder is characterized by progressive degeneration of the cerebellum and brainstem, leading to ataxia, dystonia, and other motor deficits. Given its role in the calcium signaling pathway described, ATXN3 dysfunction can disrupt calcium homeostasis and mitochondrial function, further contributing to neuronal death and disease progression.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system. The pathway described involves calcium signaling through the mitochondrial calcium uniporter (MCU) and the mitochondrial permeability transition pore (MPTP), leading to cytochrome c (CYCS) release, which is a key event in apoptosis. Mutations in ATXN3, particularly those leading to expanded CAG repeats, result in spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor coordination, oculomotor abnormalities, and other neurological symptoms due to the toxic accumulation of mutant ataxin-3 in neurons.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway depicted involves the unfolded protein response (UPR) in the endoplasmic reticulum (ER), initiated by the accumulation of misfolded proteins. SOD1 (superoxide dismutase 1) is involved in the regulation of this pathway. When SOD1 is mutated, it can lead to the accumulation of misfolded SOD1, triggering the UPR through the ATF6 and DDIT3 pathways. This dysfunction is strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The specific SOD1 allele mutations are known to cause a familial form of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that neutralizes superoxide radicals. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The provided pathway involves SOD1, which likely influences the endoplasmic reticulum (ER) stress response through its interaction with BIP (BiP, a chaperone protein), ATF6 (a transcription factor activated under ER stress), and DDIT3 (also known as CHOP, a pro-apoptotic gene induced by ER stress). Dysfunctional SOD1 might lead to ER stress and subsequent neurodegeneration, contributing to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the ER stress response, starting with SOD1, which is associated with the production of reactive oxygen species. This can lead to the activation of ER stress pathways, including the IRE1, PERK, and ATF6 cascades. Here, SOD1* (a potentially mutant or altered form of SOD1) may lead to increased oxidative stress and misfolding of proteins, which activates the ATF6 pathway and upregulates DDIT3 (CHOP), a pro-apoptotic protein. This pathway is involved in the unfolded protein response (UPR) and can contribute to cell death under prolonged ER stress. Mutations in SOD1 are strongly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron death. Therefore, the SOD1 allele contributes to the development of $\\boxed{\\text{Amyotrophic Lateral Sclerosis (ALS)}}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, the loss or inactivation of PTEN leads to increased PIP3 levels, which in turn activates AKT kinases (AKT1, AKT2, AKT3). This aberrant activation promotes cell survival, proliferation, and migration, contributing to uncontrolled cell growth. Such genetic alterations are frequently observed in various cancers. The PTEN allele's dysfunction is strongly associated with the development of **Cowden syndrome**, a hereditary condition that predisposes individuals to multiple types of cancer, particularly breast, thyroid, and endometrial cancers.\n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT pathway by dephosphorylating PIP3. Mutations or deletions in PTEN lead to constitutive activation of AKT, promoting cell survival, proliferation, and migration. This dysregulation is implicated in various cancers, most notably in Cowden syndrome, a hereditary condition characterized by an increased risk of benign and malignant tumors, including breast cancer, thyroid cancer, and endometrial cancer. PTEN mutations also contribute to other cancers such as glioblastoma and prostate cancer. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a tumor suppressor phosphatase that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, PTEN* (a mutant or loss-of-function allele) would fail to dephosphorylate PIP3, leading to its accumulation. This results in the persistent activation of AKT1, AKT2, and AKT3, which promotes cell survival, proliferation, and growth. Such dysregulation is a hallmark of cancer. PTEN mutations are frequently observed in various cancers, including breast, endometrial, and prostate cancers. The loss of PTEN function disrupts normal cellular control mechanisms, contributing to tumorigenesis.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, as part of the described genomic pathway, contributes to the biological effect of prion disease. The pathway outlines a sequence from PRNP to NMDAR, leading to calcium influx and subsequent mitochondrial permeability transition, culminating in apoptosis. This pathway is strongly associated with the pathogenesis of prion diseases, such as Creutzfeldt-Jakob disease (CJD). Prion proteins, when misfolded, trigger a cascade of events that include neuronal dysfunction and death, contributing to the progression of these neurodegenerative disorders.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of rare, fatal, neurodegenerative disorders. The provided pathway illustrates the involvement of PRNP in a sequence leading to apoptosis, with the activation of caspase 3, a key executioner of programmed cell death. This pathway includes calcium influx through NMDA receptors, mitochondrial calcium uptake via MCU, and the release of cytochrome c, ultimately triggering caspase-dependent apoptosis. The implication of this cascade in neuronal death is consistent with the pathogenesis of prion diseases such as Creutzfeldt-Jakob disease. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, as part of the described pathway, contributes to neurodegenerative disease through the activation of a cascade leading to apoptosis. PRNP encodes the prion protein, which, when misfolded, can trigger a series of events including NMDA receptor activation, calcium influx, and mitochondrial dysfunction via MCU. This ultimately leads to the opening of the mitochondrial permeability transition pore (MPTP), release of cytochrome c (CYCS), and initiation of the intrinsic apoptotic pathway via APAF1, CASP9, and CASP3. This pathway is implicated in prion diseases such as Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway suggests a link between the SOD1 gene and apoptosis regulation. SOD1 is an antioxidant enzyme that normally detoxifies superoxide radicals. In the context of the provided pathway, SOD1 interacts with BCL2, which is a key anti-apoptotic protein. Disruption of this pathway, possibly due to a defective SOD1 allele, could lead to increased apoptosis through the activation of BAX and BAK1, release of CYCS, and subsequent caspase activation. This type of pathway is commonly implicated in neurodegenerative diseases, particularly those involving oxidative stress and neuronal apoptosis. The most well-known disease associated with SOD1 dysfunction is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the regulation of apoptosis. SOD1, a key antioxidant enzyme, is shown to negatively regulate BCL2, which in turn regulates the pro-apoptotic proteins BAX and BAK1. This leads to the release of cytochrome c (CYCS), activation of APAF1, and subsequent activation of the caspase cascade (CASP9 and CASP3), promoting apoptosis. Mutations in the SOD1 gene are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. These mutations lead to misfolded SOD1 protein, which can cause oxidative stress and mitochondrial dysfunction, triggering neuronal death through mechanisms that may involve the described apoptotic pathway. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided genomic pathway outlines a sequence leading to apoptosis. SOD1 (superoxide dismutase 1) plays a role in mitochondrial function and antioxidant defense. Mutations in SOD1 are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations may lead to protein misfolding and aggregation, contributing to mitochondrial dysfunction and neuronal death. The pathway involves BCL2, BAX, BAK1, and other apoptotic regulators, ultimately leading to activation of caspases, which execute the apoptotic process. In the context of ALS, dysregulation of this pathway contributes to the selective death of motor neurons. \n\n\\boxed{Amyotrophic lateral sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, as part of the described genomic pathway, contributes to the activation of the RAS/RAF/MEK/ERK signaling cascade, leading to increased cell proliferation and survival. Dysregulation of this pathway is commonly observed in various cancers. Specifically, mutations or overactivation of MET can drive tumorigenesis, particularly in cancers such as non-small cell lung cancer, gastric cancer, and some pediatric cancers. The pathway's downstream target, CCND1, is a key regulator of the cell cycle, and its activation supports uncontrolled cell division.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with the MET proto-oncogene, is involved in cell growth, survival, and motility. Activation of MET leads to downstream signaling through GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately increasing the expression of CCND1, which promotes the cell cycle. Dysregulation of this pathway, particularly through mutations or overexpression of MET, can lead to uncontrolled cell proliferation, a hallmark of cancer. This aberrant signaling is implicated in various malignancies, especially those involving the RAS/ERK signaling cascade. The MET-driven pathway is frequently associated with solid tumors, including non-small cell lung cancer, gastric cancer, and glioblastoma. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, as defined, is a key signaling cascade involved in cell growth, survival, and migration. MET is a receptor tyrosine kinase that, when activated, initiates a series of downstream events through GRB2, SOS, and RAS proteins, leading to the activation of RAF, MEK, ERK, and ultimately CCND1. This pathway is essential for normal development but can be dysregulated in disease. Mutations or overexpression of MET, along with other components of the pathway, have been implicated in various cancers. Specifically, aberrant activation of this pathway is frequently observed in non-small cell lung cancer (NSCLC), where it contributes to tumor progression and resistance to therapy. Therefore, the biological effect of a MET allele with activating mutations or alterations in this signaling network is associated with the development of \\boxed{Non-Small Cell Lung Cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in mitochondrial quality control and autophagy. Mutations in PRKN are a common cause of autosomal recessive early-onset parkinsonism. The pathway described includes PRKN and MAO (monoamine oxidases A and B), which are involved in dopamine metabolism. PRKN mutations lead to impaired mitochondrial function and increased susceptibility to neuronal degeneration, particularly in dopaminergic neurons. This contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and subsequent degradation of damaged proteins. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (also known as Parkinson disease 5, or PD5). The pathway described involves PRKN interacting with MAO (monoamine oxidase) to produce DOPAL (3,4-dihydroxyphenylacetaldehyde), a neurotoxic compound. Impaired PRKN function may lead to the accumulation of damaged proteins and increased neurotoxic metabolites, contributing to dopaminergic neuron degeneration, a hallmark of Parkinson's disease. Thus, the PRKN allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of damaged proteins. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson\u2019s disease. The pathway described involves PRKN interacting with MAO (monoamine oxidase) to generate DOPAL (3,4-dihydroxyphenylacetaldehyde), a neurotoxic compound. Impairment in this pathway due to PRKN dysfunction may contribute to dopaminergic neuron degeneration, a hallmark of Parkinson\u2019s disease. Thus, the biological effect of a PRKN allele with loss-of-function mutations is the contribution to the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the p53 tumor protein, a critical regulator of the cell cycle and apoptosis. Mutations in TP53 can disrupt its tumor-suppressive function, leading to uncontrolled cell proliferation and genomic instability. The described pathway includes downstream targets of p53 such as CDKN1A (p21), GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all involved in cell cycle arrest, DNA repair, and apoptotic pathways. Dysfunctional TP53 can contribute to the development of various cancers, including Li-Fraumeni syndrome, a hereditary disorder associated with a high risk of multiple tumor types. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the tumor suppressor protein p53, which plays a critical role in regulating the cell cycle, DNA repair, and apoptosis. The pathway described involves TP53 and its downstream targets such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA damage response, cell cycle arrest, and apoptosis. Mutations in TP53 can lead to loss of these critical functions, promoting uncontrolled cell growth and tumorigenesis. Germline mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary condition that dramatically increases the risk of developing various types of cancer, including breast cancer, leukemia, and sarcomas, at an early age.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. In the defined pathway, TP53 activates downstream genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA damage response, cell cycle arrest, and apoptosis. Mutations or loss of function in TP53 can disrupt these processes, leading to genomic instability and uncontrolled cell proliferation. This contributes to the development of various cancers. Specifically, germline mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome characterized by a high risk of developing multiple types of malignancies, including breast cancer, osteosarcoma, and leukemia.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway begins with the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). This initiates a cascade leading to increased intracellular calcium, mitochondrial calcium overload, and activation of the apoptotic pathway involving cytochrome c, APAF1, and caspases 9 and 3. This sequence of events is strongly associated with neurodegeneration and is a hallmark of Alzheimer's disease. The accumulation of Abeta and subsequent mitochondrial dysfunction are key contributors to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway outlines a series of molecular events initiated by the APP gene, which encodes the amyloid beta precursor protein. The pathway leads through the production of amyloid beta (Abeta), which activates GRM5, a glutamate receptor, and continues through a cascade involving calcium release and mitochondrial dysfunction, culminating in apoptosis via caspase activation. This cascade is closely associated with the pathogenesis of Alzheimer's disease, where accumulation of Abeta and subsequent neurotoxic effects are key features. The involvement of calcium dysregulation and mitochondrial permeability transition also supports the role of this pathway in neuronal damage observed in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway described involves the production of Abeta, which can lead to increased intracellular calcium levels through the activation of GRM5 and subsequent signaling through PLCB, IP3, and ITPR, resulting in Ca2+ release and mitochondrial calcium overload. This contributes to mitochondrial dysfunction and the opening of the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c and activation of the caspase cascade, ultimately promoting apoptosis. This pathway is implicated in neurodegeneration. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the pathogenic variants of the PRNP gene, contributes to the development of prion diseases, such as Creutzfeldt-Jakob disease (CJD). This pathway outlines the involvement of PRNP in initiating a cascade that leads to excessive calcium release from the endoplasmic reticulum and mitochondrial dysfunction, ultimately triggering apoptosis via the intrinsic pathway. The dysregulation of calcium homeostasis through RYR, ITPR, and MCU proteins leads to mitochondrial permeability transition, releasing cytochrome c and activating the caspase cascade. This leads to neuronal death and progressive neurodegeneration.  \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, particularly when harboring pathogenic mutations, is implicated in prion diseases. These are neurodegenerative disorders characterized by the misfolding of the prion protein (PrP^C) into a pathogenic form (PrP^Sc), which leads to progressive brain damage. The provided pathway outlines the molecular cascade initiated by PRNP, involving calcium dysregulation through RYR and ITPR receptors, mitochondrial calcium uptake via MCU, and subsequent activation of the apoptotic pathway via MPTP, CYCS, APAF1, CASP9, and CASP3. This suggests a mechanism where PRNP mutations may trigger excessive calcium influx and mitochondrial dysfunction, leading to neuronal apoptosis. This biological effect is a hallmark of prion-related diseases.\n\n\\boxed{Prion Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the mutant forms of the prion protein (PrP), is associated with prion diseases, a group of fatal, transmissible neurodegenerative disorders. These diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS), and Fatal Familial Insomnia (FFI). The pathway described involves the prion protein initiating a cascade that leads to intracellular calcium dysregulation, mitochondrial permeability transition, and ultimately apoptosis. This mechanism highlights the role of PRNP in triggering neuronal death, a hallmark of prion diseases.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, thereby playing a critical role in protecting cells from oxidative stress. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations can lead to protein misfolding, aggregation, and dysfunction of SOD1, contributing to neuronal degeneration. The pathway described involves SOD1 interacting with DERL1 and the ubiquitin-proteasome system, suggesting a mechanism by which damaged or misfolded SOD1 may be targeted for degradation. Dysregulation of this pathway could exacerbate ALS pathology.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described includes components involved in protein degradation, suggesting that dysfunction in this pathway may contribute to the accumulation of misfolded or damaged proteins, which is a hallmark of ALS. The interaction of SOD1 with DERL1 and the proteasome system implies a role in the quality control of proteins, particularly in the context of oxidative stress. This allele likely contributes to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that plays a critical role in protecting cells from oxidative damage by catalyzing the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in the SOD1 gene are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations often result in the production of a dysfunctional or toxic form of the SOD1 protein, which leads to the progressive degeneration of motor neurons in the brain and spinal cord. The provided pathway suggests a connection between SOD1 and proteasomal degradation pathways, which may be involved in the accumulation of misfolded SOD1 proteins and subsequent neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, in the context of the NRG//ERBB4* pathway, is involved in cellular signaling through the neuregulin (NRG) family of ligands. ERBB4 functions as a receptor tyrosine kinase and is crucial in various developmental and physiological processes, including neurogenesis, cardiac development, and immune responses. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, which may contribute to several diseases. Notably, ERBB4 has been implicated in neurodevelopmental disorders and psychiatric conditions. Specifically, alterations in ERBB4 have been associated with schizophrenia, a complex psychiatric disorder characterized by disturbances in thought, perception, and behavior. ERBB4 signaling is important in brain development and function, and its disruption may underlie some of the pathophysiological mechanisms in schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in cell signaling, and it interacts with neuregulins (NRG1\u2013NRG4) to modulate developmental and physiological processes. Variants in ERBB4 have been associated with several neurological and psychiatric disorders, particularly those involving synaptic dysfunction and altered neurotransmission. Specifically, ERBB4 has been implicated in schizophrenia, with studies showing that genetic variations in this gene may disrupt normal brain development and function, contributing to the disorder's pathogenesis. The interaction between ERBB4 and NRG1 is particularly important in myelination and neuronal migration. Given its role in these processes, the ERBB4 allele contributes to the development of \\boxed{schizophrenia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a crucial role in various cellular processes including cell growth, differentiation, and migration. It is part of the HER family of receptors and interacts with neuregulins (NRG1-4), which are ligands that modulate its activity. ERBB4 is involved in neural development, synaptic function, and placental development. Genetic variations or mutations in ERBB4 have been implicated in several diseases. Specifically, ERBB4 has been associated with schizophrenia, a complex psychiatric disorder characterized by hallucinations, delusions, and cognitive deficits. Studies have identified linkage and association between ERBB4 and schizophrenia, suggesting that it may contribute to the disease through altered neuronal signaling and brain development.\n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, and mutations in this gene lead to Huntington's disease. The provided pathway\u2014HTT* \u2192 MLK2 \u2192 MKK7 \u2192 JNK\u2014suggests a signaling mechanism involving the JNK pathway, which is implicated in apoptosis and stress responses. The HTT allele with a mutation, likely a CAG trinucleotide repeat expansion, results in an abnormal huntingtin protein. This malformed protein causes neurodegeneration, primarily affecting the basal ganglia and cerebral cortex. The disease is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway HTT* -> MLK2 -> MKK7 -> JNK. This pathway is involved in stress response and apoptosis. Mutations in the HTT gene, particularly expansions of CAG trinucleotide repeats, lead to the production of a toxic form of huntingtin. This aberrant protein disrupts normal cellular functions and leads to progressive neurodegeneration. The resulting disease is Huntington's disease, characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway HTT* -> MLK2 -> MKK7 -> JNK. Mutations in the HTT gene, specifically expansions of CAG trinucleotide repeats, lead to the production of a dysfunctional huntingtin protein. This dysfunctional protein disrupts normal cellular processes, including transcription, mitochondrial function, and synaptic plasticity. The JNK pathway is implicated in apoptosis and stress responses, suggesting that HTT mutations may exaggerate these responses, leading to neurodegeneration. This pathway is closely associated with Huntington's disease, a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in signaling pathways crucial for neuronal development and function. Variants in ERBB4 have been implicated in several neurological and psychiatric conditions. Specifically, alterations in this gene have been associated with schizophrenia, a severe mental disorder characterized by disturbances in thought, perception, and behavior. ERBB4 plays a role in the development of the nervous system, and its dysregulation may disrupt normal brain function, contributing to the pathogenesis of schizophrenia. The NRG (neuregulin) ligands, which interact with ERBB4, are also involved in this pathway, suggesting that the interaction between NRG and ERBB4 is critical for proper neural development and that disruptions may lead to the disease. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that belongs to the epidermal growth factor receptor (EGFR) family. It plays a crucial role in cell signaling pathways involved in neuron development, myelination, and synaptic function. The NRG (neuregulin) ligands bind to ERBB4, activating downstream signaling cascades. Mutations or dysregulation of ERBB4 have been implicated in various neurological and psychiatric disorders. Specifically, variants in ERBB4 have been associated with schizophrenia, a severe mental disorder characterized by cognitive, emotional, and behavioral disturbances. These variants may affect the structure or function of ERBB4, leading to impaired neural connectivity and synaptic plasticity. Thus, the biological effect of this ERBB4 allele contributes to the pathogenesis of schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in cell signaling pathways, particularly in the nervous system and during development. Variants or mutations in ERBB4 have been implicated in several neurological and psychiatric disorders. Specifically, certain ERBB4 alleles have been associated with an increased risk of schizophrenia. This association is supported by genetic linkage studies, genome-wide association studies (GWAS), and functional analyses showing that ERBB4 plays a role in synaptic plasticity and neural development\u2014processes that are disrupted in schizophrenia.\n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of misfolded proteins. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease. The pathway described involves PRKN interacting with the MAO enzymes (MAOA and MAOB) through a network that leads to the production of DOPAL, a neurotoxic compound. This suggests a role for parkin in the regulation of monoamine metabolism, potentially influencing dopaminergic neuron survival. Disruption of this pathway may contribute to the neurodegeneration observed in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of misfolded or damaged proteins. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (ARJD), also known as early-onset Parkinson's disease. The pathway described involves PRKN, which may interact with MAO (monoamine oxidase) enzymes, contributing to pathways that regulate neurotransmitter metabolism. Disruption of PRKN function can impair mitochondrial function and increase susceptibility to neuronal degeneration, particularly in dopaminergic neurons, leading to the characteristic motor symptoms of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of damaged proteins. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (ARJP), a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway described connects PRKN with MAO (monoamine oxidase), which catalyzes the breakdown of monoamines like dopamine. DOPAL, a neurotoxic byproduct of dopamine metabolism, is implicated in neuronal damage. Thus, the PRKN allele's biological effect is most directly linked to the pathogenesis of Parkinson's disease.  \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies reactive oxygen species. In the provided pathway, SOD1 is connected to BIP (BiP, a chaperone protein), which is involved in the unfolded protein response (UPR). The pathway proceeds through EIF2AK3 (PERK), which phosphorylates EIF2S1, leading to the activation of ATF4, a transcription factor that upregulates DDIT3 (CHOP), a protein associated with apoptosis and endoplasmic reticulum (ER) stress. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described reflects the UPR and ER stress mechanisms, which are implicated in the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, a gene encoding superoxide dismutase 1, which plays a critical role in detoxifying reactive oxygen species. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway outlined shows a link between SOD1 and the unfolded protein response (UPR) through HSPA5 (BIP), EIF2AK3 (PERK), and downstream factors like ATF4 and DDIT3, which are involved in stress response and apoptosis. Dysfunctional SOD1 can lead to oxidative stress and protein misfolding, initiating the UPR and ultimately contributing to neuronal death. This genetic interaction supports the role of SOD1 in ALS pathogenesis.\n\n\\boxed{Amyotrophic lateral sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nChromosome 21 is implicated in Down syndrome, and the pathway outlined reflects stress response mechanisms involving SOD1, a gene associated with oxidative stress. SOD1 mutations are also linked to amyotrophic lateral sclerosis (ALS). However, in the context of this pathway and the chromosomal location, the focus is on Down syndrome, which results from trisomy 21. The network suggests a pathway involving endoplasmic reticulum (ER) stress, as indicated by HSPA5 (BIP), EIF2AK3 (PERK), and downstream effectors leading to DDIT3 (CHOP). This pathway is critical in ER stress-induced apoptosis, which is observed in neurodegenerative conditions. While SOD1 is more commonly linked to ALS, its role in this context and on chromosome 21 may contribute to neurological effects in Down syndrome. \n\n\\boxed{Down syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, a RBR E3 ubiquitin protein ligase involved in the ubiquitination and degradation of misfolded or damaged proteins. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism (also known as PARK2). This disease is a form of early-onset Parkinson's disease characterized by motor symptoms such as tremor, bradykinesia, and rigidity. The pathway involving PRKN, along with ubiquitin conjugating enzymes like UBE2L3 and UBE2L6, and SNCAIP, suggests a role in the ubiquitin-proteasome system, which is crucial for maintaining cellular protein homeostasis. Disruption of this system can lead to the accumulation of toxic proteins, contributing to neuronal dysfunction and degeneration in Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as parkinsonism with early onset, or PARK2. This disease is a form of Parkinson\u2019s disease that typically presents before the age of 40 and is characterized by motor symptoms such as tremors, rigidity, and bradykinesia. The pathway includes ubiquitin conjugating enzymes (UBCH7/8) and ubiquitin ligase (PRKN), which are crucial for protein degradation and cellular quality control. Dysfunctional parkin may lead to impaired mitochondrial function and abnormal protein aggregation, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson\u2019s disease. Parkin plays a crucial role in mitochondrial quality control through mitophagy. When PRKN is dysfunctional due to allelic mutations, this leads to impaired mitochondrial function and neuronal degeneration, primarily in dopaminergic neurons of the substantia nigra, resulting in Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of autosomal recessive juvenile Parkinson's disease (PD). Parkin is essential for the degradation of damaged mitochondrial proteins and for mitophagy, the selective degradation of damaged mitochondria. Disruption of PRKN function can lead to the accumulation of defective mitochondria and subsequent neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra, a hallmark of Parkinson's disease. The provided pathway, involving ubiquitin conjugating enzymes and PRKN, is central to the regulation of protein quality control and mitochondrial health. Therefore, the biological effect of a pathogenic PRKN allele is $\\boxed{\\text{Parkinson's disease}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and proteasomal degradation of proteins. Mutations in PRKN are a well-known cause of early-onset autosomal recessive Parkinson's disease. This pathway, involving ubiquitination machinery such as UBCH7/8 and PAELR, suggests a role for impaired ubiquitin-proteasome system function in neurodegeneration. The presence of GPR37, a protein implicated in neuronal survival and degradation pathways, further connects this network to Parkinson's disease pathogenesis.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a known cause of early-onset autosomal recessive Parkinson's disease. The pathway includes components like UBCH7/8 (ubiquitin conjugating enzymes), PRKN (E3 ligase), and PAELR (ubiquitin-like modifier), suggesting a role in ubiquitination and protein degradation. The presence of GPR37, a G protein-coupled receptor, may indicate a broader cellular stress response. The PRKN allele, when mutated, disrupts this pathway, leading to impaired mitochondrial function and neuronal degeneration. This contributes to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that plays a central role in the MAPK/ERK signaling pathway, which regulates cell proliferation, differentiation, and survival. The given pathway (BRAF \u2192 MEK \u2192 ERK) illustrates this critical signaling cascade. A mutation in BRAF, particularly the V600E mutation, leads to constitutive activation of the pathway, promoting uncontrolled cell growth. This aberrant activation is a well-documented driver in several cancers, most notably melanoma. The presence of the BRAF allele with such mutations contributes to the development of melanoma by enabling continuous ERK signaling, which supports tumor growth and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase involved in the MAPK/ERK signaling pathway, which regulates cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the pathway, driving uncontrolled cell proliferation. This dysregulation is a key factor in the development of various cancers, most notably melanoma. The pathway components MEK and ERK are downstream effectors of BRAF, and their activation is critical for tumor progression. Thus, BRAF mutations contribute significantly to the pathogenesis of melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the MAPK/ERK signaling pathway, which regulates cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the pathway, promoting uncontrolled cell proliferation. This dysregulation is a major driver in the development of melanoma, a type of skin cancer. The pathway defined (BRAF* -> MEK -> ERK) highlights its role in transmitting signals that, when aberrantly activated, contribute to tumorigenesis. BRAF mutations are also implicated in other cancers, including thyroid, colorectal, and ovarian cancers. Targeted therapies against BRAF have been developed to treat these malignancies.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins that are essential for the activity of lysosomal enzymes such as GBA and GALC. Mutations in PSAP can lead to a loss of saposin function, impairing the activity of these enzymes. This results in the accumulation of undegraded substrates within lysosomes, leading to cellular dysfunction. This pathway is closely related to lysosomal storage diseases, specifically Niemann-Pick disease type C (NPC), which is associated with defects in cholesterol and lipid trafficking. However, the specific network defined here involving PSAP, GBA, and GALC is more indicative of a related disorder, such as Sandhoff disease or Tay-Sachs disease, which involve more generalized deficiencies in lysosomal enzyme function.\n\n\\boxed{Niemann-Pick disease type C}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor for saposins that are essential for the activity of lysosomal enzymes such as GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing the function of GBA and GALC. This results in the accumulation of their substrates, such as glucosylceramide and galactosylceramide, in lysosomes. This condition is associated with a rare autosomal recessive disorder known as neuronal ceroid lipofuscinosis (NCL), specifically the type associated with defects in saposin C, a component derived from prosaposin. This leads to progressive neurodegeneration. \n\n\\boxed{Neuronal Ceroid Lipofuscinosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor protein that is cleaved into saposins, which are essential for the activity of various lysosomal enzymes, including GBA and GALC. Mutations in PSAP lead to a deficiency in these saposins, impairing the function of the associated enzymes. This results in the accumulation of substrates that these enzymes normally break down, leading to the neurodegenerative disease known as **Saposin-D (SAP-D)**, also referred to as **Saposin B deficiency** or **Prosaposin deficiency**. This condition is part of a group of lysosomal storage diseases and is characterized by developmental delay, hypotonia, seizures, and progressive neurological deterioration.\n\n$$\n\\boxed{Saposin-D}\n$$"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is implicated in spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dysphagia, dystonia, and other neurological symptoms. The pathogenic mechanism often involves the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of an abnormally long ataxin-3 protein. This protein can accumulate and form toxic aggregates, contributing to neuronal dysfunction and degeneration. The presence of ATXN3 in the provided pathway suggests its involvement in calcium signaling and mitochondrial function, which are critical for neuronal health. Disruption of these processes by mutant ATXN3 may exacerbate the neurodegenerative phenotype.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system. Expanded CAG repeats in the ATXN3 gene lead to the production of a toxic, unstable protein that accumulates in neurons, causing progressive degeneration of the cerebellum and brainstem. This results in a neurodegenerative disorder characterized by gait ataxia, loss of coordination, and other motor impairments. The pathway described includes calcium signaling and mitochondrial dysfunction, mechanisms implicated in neuronal damage. This genetic abnormality is the molecular basis for spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the ATXN3 allele in this genomic pathway relates to its role in calcium signaling, particularly through the ITPR1-mediated release of Ca\u00b2\u207a. ATXN3 is a polyQ protein, and pathogenic expansions in the ATXN3 gene are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder involves dysfunction in calcium homeostasis, mitochondrial dynamics, and proteostasis, leading to progressive motor and neurological impairments.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. Mutations in TP53 can lead to loss of its tumor-suppressing function, increasing the risk of uncontrolled cell proliferation and tumorigenesis. The pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are involved in cell cycle arrest, DNA repair, and apoptosis\u2014processes that are dysregulated in the absence of functional p53. Loss of TP53 function is strongly associated with various cancers, most notably Li-Fraumeni syndrome, a hereditary disorder characterized by a high predisposition to multiple types of cancer, including breast cancer, sarcomas, brain tumors, and leukemia. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor protein p53, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. In the given pathway, TP53 is upstream of genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA damage response, apoptosis, and cell cycle regulation. Mutations in TP53 that disrupt its function can lead to loss of these protective mechanisms, increasing the risk of uncontrolled cell proliferation and tumor formation. This is directly linked to the development of various cancers, most notably Li\u2013Fraumeni syndrome, a hereditary disorder characterized by a high predisposition to multiple types of cancer, including breast cancer, sarcomas, brain tumors, and leukemias. \n\n\\boxed{Li\u2013Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor that regulates the cell cycle, DNA repair, and apoptosis. Mutations in TP53 can lead to loss of its function, resulting in uncontrolled cell proliferation and increased risk of cancer. The genes in the given pathway (CDKN1A, GADD45 family, BAX, BAK1, DDB2, and POLK) are known to be involved in DNA damage response, cell cycle arrest, and apoptosis\u2014functions that are regulated by p53. Loss of TP53 function disrupts these protective mechanisms, contributing to genomic instability and tumorigenesis. This pathway is often dysregulated in various cancers, particularly those with TP53 mutations. \n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic cleavage of amyloid precursor protein (APP). This process generates beta-amyloid peptides, which are central to the pathogenesis of Alzheimer's disease. Mutations in PSEN1 are associated with early-onset familial Alzheimer's disease (FAD). The pathway described involves PSEN1 activating GSK3B, which in turn phosphorylates tau protein, a hallmark of Alzheimer's pathology. The interaction with KIF5 and KLC proteins suggests a role in intracellular transport, possibly affecting the distribution of amyloid-beta and tau. These molecular events contribute to neurodegeneration and the cognitive decline characteristic of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). The provided pathway outlines a network where PSEN1 influences GSK3B, which in turn regulates the kinesin motor complex (KIF5 + KLC). This interaction is likely involved in intracellular transport and signaling pathways that are dysregulated in AD. Dysfunctional PSEN1 can lead to abnormal processing of APP, resulting in increased production of beta-amyloid peptides, a hallmark of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic cleavage of amyloid precursor protein (APP). The pathway described involves PSEN1 influencing GSK3B, which in turn regulates the expression of KIF5 and KLC proteins, essential for intracellular transport. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. These mutations lead to abnormal processing of APP, resulting in increased production of amyloid-beta peptides, a hallmark of Alzheimer's pathology. This contributes to the formation of amyloid plaques and neurofibrillary tangles, ultimately leading to neuronal dysfunction and cognitive decline.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele is involved in the cAMP signaling pathway, which regulates various cellular processes including hormone secretion and gene expression. Mutations in GNAS can lead to aberrant signaling, contributing to conditions such as pseudohypoparathyroidism and tumorigenesis. Specifically, the GNAS gene encodes the Gs alpha subunit, which is critical for the activation of adenylate cyclase and subsequent cAMP production. Dysfunctions in this pathway have been implicated in multiple endocrine neoplasia type 1 (MEN1), a genetic disorder characterized by the development of tumors in endocrine glands. \n\n\\boxed{Multiple Endocrine Neoplasia Type 1 (MEN1)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the Gs protein, which is crucial in the cAMP signaling pathway. Mutations in GNAS can lead to aberrant activation or inactivation of this pathway, impacting downstream effectors such as ADCY (adenylate cyclase), cAMP, PKA, CREB, and ultimately ACTH. This pathway is involved in various physiological processes including hormone signaling, cell growth, and differentiation. Pathogenic variants in GNAS are known to cause diseases such as pseudohypoparathyroidism, Albright hereditary osteodystrophy, and tumorigenesis in some cases. These conditions are characterized by end-organ resistance to PTH, which is mediated via the cAMP pathway, and other related hormonal dysfunctions. The specific effect depends on the mutation type and location within the GNAS gene.\n\n\\boxed{Pseudohypoparathyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the stimulatory G protein (G\u03b1s), which plays a central role in the cAMP signaling pathway. The provided pathway illustrates the activation of this pathway through GNAS, leading to cAMP production and downstream effects involving PKA and CREB. Mutations in GNAS can lead to aberrant signaling and are associated with pseudohypoparathyroidism type 1a (PHP1a), a disorder characterized by resistance to parathyroid hormone (PTH). This condition results from inactivating mutations in the GNAS gene, affecting PTH signaling and leading to hypocalcemia and hyperphosphatemia.\n\n\\boxed{Pseudohypoparathyroidism type 1a}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP) to produce amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. The pathway defined includes GSK3B, which phosphorylates tau protein, and KIF5 and KLC proteins, which are involved in intracellular transport. The interaction between these components likely influences amyloid-beta production and tau phosphorylation, both of which are central to Alzheimer's pathology. Thus, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). This pathway, defined by PSEN1 \u2192 GSK3B -| (KIF5+KLC), suggests a regulatory interaction involving GSK3B and kinesin complexes, which may influence intracellular trafficking and processing of APP. Dysregulation of PSEN1 function is strongly associated with early-onset Alzheimer\u2019s disease (AD), as mutations in PSEN1 lead to increased production of amyloid-beta peptides, a hallmark of AD pathology. These mutations disrupt normal gamma-secretase activity, contributing to the accumulation of amyloid plaques in the brain. Thus, the PSEN1 allele plays a pivotal role in the pathogenesis of Alzheimer\u2019s disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). The pathway described involves PSEN1 activating GSK3B, which in turn phosphorylates tau protein, a hallmark of neurofibrillary tangles in AD. The interaction with KIF5 and KLC proteins suggests a role in intracellular transport, potentially affecting the distribution of pathological proteins. Collectively, this network contributes to the neurodegenerative processes observed in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits cyclin-dependent kinases, playing a crucial role in cell cycle regulation and tumor suppression. Mutations in CDKN2A are strongly associated with melanoma and certain types of neurocutaneous syndromes, such as familial atypical multiple mole melanoma (FAMMM) syndrome. The given pathway illustrates the tumor suppressor function of CDKN2A, which regulates the p53 pathway and the Rb-E2F pathway\u2014both essential for controlling cell proliferation and apoptosis. Disruption of CDKN2A can lead to uncontrolled cell growth, increasing the risk of melanoma development.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that plays a critical role in regulating the cell cycle. In the provided pathway, CDKN2A inhibits MDM2, which otherwise promotes the degradation of TP53, a key tumor suppressor. TP53 activates CDKN1A, which inhibits cyclin D and CDK4/6, thereby blocking the cell cycle at the G1 phase. This pathway is tightly regulated by RB1 and E2F transcription factors. Mutations or deletions in CDKN2A impair this regulatory mechanism, leading to uncontrolled cell proliferation. This disruption is frequently observed in melanoma and other cancers, contributing to tumor development. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a critical tumor suppressor protein, p16INK4a, which regulates the cell cycle by inhibiting cyclin-dependent kinases CDK4 and CDK6. In the described pathway, CDKN2A inhibits MDM2, which in turn would otherwise target TP53 for degradation. Inactivation or mutation of CDKN2A removes this inhibitory effect, leading to unchecked MDM2 activity, degradation of TP53, and loss of its tumor-suppressive functions. This disruption leads to uncontrolled cell proliferation and genomic instability. CDKN2A mutations are strongly associated with melanoma and neurofibromatosis type 1, among other cancers. The loss of CDKN2A function is a known driver in several malignancies due to its central role in cell cycle regulation.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described represents the Wnt/\u03b2-catenin signaling cascade. CTNNB1 (\u03b2-catenin) is a key component that, when not properly regulated by the destruction complex (GSK3B, AXIN, APC), accumulates in the nucleus and interacts with TCF/LEF transcription factors to activate target genes such as BIRC5, MYC, and CCND1. This activation promotes cell proliferation and survival. Dysregulation of this pathway is commonly observed in various cancers, particularly colorectal cancer, where mutations in APC, CTNNB1, or components of the destruction complex lead to constitutive Wnt signaling. This contributes to uncontrolled cell growth and tumor formation. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is a canonical Wnt/\u03b2-catenin signaling pathway. CTNNB1 (\u03b2-catenin) is a key component that, when stabilized (due to inactivation of GSK3B, AXIN, and APC), accumulates in the nucleus and activates TCF/LEF transcription factors. This leads to the upregulation of target genes such as BIRC5, MYC, and CCND1, which are involved in cell proliferation and survival. Dysregulation of this pathway is commonly observed in colorectal cancer, where mutations in APC or CTNNB1 are frequently found. The stabilization and nuclear accumulation of \u03b2-catenin drive the expression of oncogenic genes, promoting uncontrolled cell growth and tumor formation. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway represents a key component of the Wnt/\u03b2-catenin signaling cascade. CTNNB1 (\u03b2-catenin) is central to this pathway, and its stabilization leads to the transcription of target genes like BIRC5, MYC, and CCND1, which are involved in cell proliferation and survival. Mutations or dysregulation of this pathway, particularly in CTNNB1, can result in uncontrolled cell growth, a hallmark of cancer. This pathway is frequently dysregulated in colorectal cancer due to mutations in APC, AXIN, or CTNNB1, which normally act as negative regulators of \u03b2-catenin. This dysregulation leads to aberrant activation of TCF/LEF targets, promoting tumorigenesis. \n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 allele, as part of the described mitochondrial calcium signaling pathway, is involved in the regulation of intracellular calcium levels, which is crucial for mitochondrial function and apoptosis. Disruption or dysfunction of this pathway can lead to impaired mitochondrial calcium uptake and release, contributing to mitochondrial permeability transition and subsequent cell death. This pathway's dysregulation has been implicated in neurodegenerative diseases, particularly those involving neuronal apoptosis and mitochondrial dysfunction. Specifically, the SIGMAR1 allele has been associated with Alzheimer's disease, where mitochondrial calcium dysregulation and increased apoptosis are key pathological features.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes a protein involved in calcium signaling and mitochondrial function. In the given pathway, SIGMAR1 influences intracellular calcium dynamics through ITPR and MCU, regulating mitochondrial calcium uptake and MPTP activation, which can release cytochrome c and initiate apoptosis. Dysregulation of this pathway may disrupt mitochondrial homeostasis, leading to excessive apoptosis or impaired cellular function. This has been implicated in neurodegenerative diseases, particularly Parkinson\u2019s disease, where mitochondrial dysfunction and abnormal calcium handling are key features. Thus, the SIGMAR1 allele contributes to the pathogenesis of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 allele, as part of the described pathway, is involved in calcium signaling and mitochondrial function. SIGMAR1 influences calcium influx through ITPR, leading to mitochondrial calcium uptake via MCU. This process is crucial for maintaining mitochondrial homeostasis. Dysregulation in this pathway may lead to mitochondrial permeability transition, release of cytochrome c, and apoptosis. Such dysregulation has been linked to neurodegenerative diseases. Specifically, the SIGMAR1 allele is associated with Alzheimer's disease, where mitochondrial dysfunction and calcium imbalance contribute to neuronal damage and cognitive decline.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves PINK1, which is associated with mitochondrial quality control through the regulation of Parkin. When PINK1 is functional, it prevents the accumulation of damaged mitochondria. The pathway shows that PINK1 interacts with HTRA2 and TRAP1, which are involved in stress responses and mitochondrial dynamics. CYCS, APAF1, CASP9, and CASP3 are key players in the intrinsic apoptotic pathway. A malfunctioning PINK1 allele may lead to impaired mitochondrial function and increased apoptosis, which is linked to neurodegenerative diseases, particularly Parkinson's disease. This connection is supported by the role of PINK1 in protecting dopaminergic neurons. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves PINK1, a kinase associated with mitochondrial quality control, and its interaction with proteins involved in apoptosis, such as HTRA2, TRAP1, CYCS, APAF1, CASP9, and CASP3. PINK1's role in this network suggests it is involved in regulating apoptotic signaling. Mutations in PINK1 are linked to early-onset Parkinson's disease, a neurodegenerative disorder characterized by loss of dopaminergic neurons. These mutations may impair mitochondrial function and increase susceptibility to apoptosis, contributing to neuronal death. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves PINK1, which is a serine/threonine kinase associated with mitochondrial quality control. PINK1's role in the pathway includes the activation of HTRA2 and TRAP1, leading to the release of cytochrome c (CYCS), which triggers the apoptotic cascade via APAF1, CASP9, and CASP3. Mutations in PINK1 have been linked to autosomal recessive early-onset Parkinson's disease. This disease is characterized by progressive neurodegeneration, primarily affecting the dopaminergic neurons in the substantia nigra. The loss of PINK1 function impairs mitochondrial function and increases susceptibility to oxidative stress, leading to neuronal death. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of an abnormal ataxin-3 protein. This protein accumulates in neurons, causing progressive degeneration of the cerebellum and other parts of the central nervous system. The pathway described involves autophagy-related proteins, highlighting a potential link between defective autophagy and the pathogenesis of the disease. The dysfunction of this pathway may exacerbate the accumulation of the mutant ATXN3 protein, contributing to the neurodegenerative process.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of a mutant ataxin-3 protein. This mutant protein aggregates in the brain, particularly in the cerebellum and brainstem, resulting in progressive loss of motor control, oculomotor dysfunction, and other neurological symptoms. The pathway involving ATXN3 and its interaction with autophagy-related genes like BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 may be relevant to the cellular processes affected by the disease, such as protein degradation and autophagy dysfunction.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive degeneration of the cerebellum and other brain regions, leading to movement disorders, ophthalmoplegia, and various other neurological symptoms. ATXN3 is part of a pathway involving autophagy-related genes, which suggests its role in cellular stress responses and protein degradation. Mutations in ATXN3 lead to the accumulation of toxic protein aggregates, contributing to neuronal dysfunction and death.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, as defined, involves a cascade from MET to CCND1, influencing cell proliferation and survival. Mutations or overexpression of the MET gene can lead to constitutive activation of this pathway, contributing to uncontrolled cell growth. This aberrant signaling is associated with several cancers, including but not limited to lung, gastric, and glioblastoma. The activation of RAS and subsequent MAPK signaling promotes tumor growth and progression. Given the downstream effect on CCND1, which regulates the cell cycle, the biological effect of this MET allele is primarily linked to oncogenesis.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET proto-oncogene encodes a receptor tyrosine kinase that, when activated, initiates a signaling cascade through GRB2, SOS, RAS, RAF, MEK, ERK, and ultimately CCND1. This pathway is crucial for cell proliferation, survival, and migration. Mutations or overactivation of MET can lead to constitutive activation of this signaling pathway, promoting uncontrolled cell growth and contributing to the development of cancer. This aberrant signaling is frequently observed in various cancers, particularly in nonsmall cell lung cancer (NSCLC), gastric cancer, and some types of sarcomas. The MET-driven pathway is a validated therapeutic target in oncology.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, as part of the described signaling pathway, contributes to the activation of downstream effectors such as RAS, RAF, MEK, and ERK, ultimately leading to the upregulation of CCND1, which promotes cell cycle progression. This pathway is commonly dysregulated in various cancers, especially when MET is overactivated due to mutations or amplification. The MET-driven pathway is implicated in the development and progression of non-small cell lung cancer (NSCLC), gastric cancer, and other solid tumors. The activation of this pathway can lead to uncontrolled cell proliferation and tumorigenesis. \n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits the activity of cyclin-dependent kinases CDK4 and CDK6, which are crucial for the progression of the cell cycle. In the provided pathway, CDKN2A acts as a negative regulator by inhibiting the CDK4/6-cyclin D complex, which in turn prevents the inactivation of RB1. Active RB1 suppresses the E2F transcription factors, which are involved in the expression of genes required for DNA replication. Mutations in CDKN2A that result in loss of function can lead to uncontrolled cell proliferation, as the inhibitory effect on CDK4/6 is lost, leading to RB1 inactivation and E2F activation. This pathway is commonly disrupted in melanoma. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the activity of cyclin-dependent kinases (CDK4/6), which in turn controls the function of the RB1 protein. Inactivation of CDKN2A leads to unchecked activation of CDK4/6, inactivation of RB1, and subsequent activation of E2F transcription factors, promoting cell cycle progression and DNA synthesis. This dysregulation is a hallmark of uncontrolled cell proliferation, contributing to the development of various cancers. Specifically, mutations in CDKN2A are strongly associated with melanoma, a type of skin cancer.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits the activity of cyclin-dependent kinases CDK4 and CDK6, thereby preventing the phosphorylation of RB1. When CDKN2A is inactivated or mutated, it allows the cyclin D-CDK4/6 complex to phosphorylate RB1, leading to the release of E2F transcription factors, which promote cell cycle progression. This pathway is critical for regulating the G1 to S phase transition of the cell cycle. Mutations in CDKN2A are associated with uncontrolled cell proliferation and are implicated in the development of melanoma and neurofibromatosis type 1. These mutations disrupt normal cell cycle regulation, contributing to tumorigenesis. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, when mutated, can constitutively activate the RAS-RAF-MEK-ERK signaling pathway, leading to uncontrolled cell proliferation. This pathway is crucial for regulating cell growth and division. When NRAS is mutated, it acts as an oncogene, promoting tumor development. This aberrant signaling is commonly observed in various cancers, including melanoma, leukemia, and certain solid tumors. The continuous activation of downstream effectors such as ERK results in increased expression of cyclin D1 (CCND1), which drives the cell cycle forward. These mutations in NRAS contribute significantly to the progression of cancer by disrupting normal cellular control mechanisms.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided genomic pathway suggests a signaling cascade initiated by NRAS (and KRAS) activating RAF, leading through MEK and ERK to CCND1. This resembles the RAS-RAF-MEK-ERK pathway, a critical signaling route in cell growth and proliferation. Mutations in NRAS, particularly those leading to constitutive activation, can result in uncontrolled cell proliferation and are commonly observed in several cancers. NRAS mutations are frequently found in melanoma, certain leukemias, and other malignancies, often contributing to tumor development and progression by continually activating downstream effectors such as ERK and cyclin D1, which drive the cell cycle. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway describes a signaling cascade beginning with NRAS, which activates RAF (including ARAF, BRAF, and RAF1), leading through MEK (MAP2K1 and MAP2K2) to ERK (MAPK1 and MAPK3), ultimately influencing CCND1, a gene involved in cell cycle regulation. Mutations in NRAS, particularly activating ones, lead to constitutive activation of this MAPK/ERK pathway, promoting uncontrolled cell proliferation. This aberrant signaling is frequently observed in various cancers, notably melanoma, and is a well-established driver in several malignancies. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when constitutively active due to chromosomal translocation (e.g., Philadelphia chromosome t(9;22)), forms the BCR-ABL fusion protein. This fusion protein is a hallmark of chronic myeloid leukemia (CML), a hematologic malignancy characterized by uncontrolled proliferation of myeloid cells. The BCR-ABL fusion protein activates downstream signaling pathways, including the RAS-RAF-MEK-ERK pathway, promoting cell survival and proliferation. This aberrant signaling contributes to the pathogenesis of CML and, in some cases, leukemias with blast crisis. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when mutated or deregulated, can lead to uncontrolled cell proliferation. In the context of the BCR-ABL fusion protein, which is commonly found in chronic myeloid leukemia (CML), ABL1 contributes to the constitutive activation of downstream signaling pathways like the RAS-RAF-MEK-ERK cascade, as indicated by the provided pathway. This persistent activation promotes cellular growth and survival, hallmark features of cancer. The network definition and involvement of key oncogenes such as RAS, RAF, MEK, and ERK further support the role of ABL1 in leukemogenesis.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when fused with BCR (breakpoint cluster region) in chronic myeloid leukemia (CML), forms the BCR-ABL fusion protein. This fusion protein is constitutively active, leading to uncontrolled cell proliferation by activating the RAS/MAPK signaling pathway through GRB2, SOS, RAS, RAF, MEK, and ERK. This aberrant signaling is a hallmark of CML and contributes to the malignant transformation of hematopoietic cells. Targeted therapies, such as imatinib, inhibit BCR-ABL kinase activity and are used in the treatment of CML.\n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease. Parkin plays a crucial role in mitochondrial quality control by tagging damaged mitochondria for autophagy. When PRKN is dysfunctional, impaired mitochondrial dynamics and increased oxidative stress can lead to neurodegeneration, particularly in dopaminergic neurons of the substantia nigra. This contributes to the characteristic motor symptoms of Parkinson's disease, including tremors, rigidity, and bradykinesia. The MFN1 and MFN2 genes, which encode mitofusins involved in mitochondrial fusion, are also implicated in mitochondrial function and may influence disease progression. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control. Mutations in PRKN are a major cause of early-onset autosomal recessive Parkinson's disease. The pathway involving PRKN and MFN1/2 is crucial for mitochondrial dynamics, including fusion and fission. Dysfunction in this pathway disrupts mitochondrial integrity and function, leading to the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in mitochondrial quality control through mitophagy. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (PD). The pathway involving PRKN and MFN1/2, which are mitochondrial fusion proteins, is crucial for maintaining mitochondrial integrity. Disruption of this pathway can lead to impaired mitochondrial function and increased cell death, particularly in dopaminergic neurons, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, and mutations in this gene are responsible for Huntington's disease. The provided pathway shows HTT interacting with CREB and TAF4 to regulate PPARGC1A, a key coactivator involved in mitochondrial biogenesis and energy metabolism. Altered HTT function due to mutation can disrupt these processes, contributing to cellular dysfunction. This disruption is implicated in the pathogenesis of Huntington's disease, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, and mutations in this gene, particularly the expansion of CAG repeats, lead to the neurodegenerative disease Huntington's disease. In the provided pathway, HTT interacts with CREB family members and TAF4 to influence the expression of PPARGC1A, a coactivator involved in mitochondrial biogenesis and energy metabolism. Dysregulation of this pathway due to mutant HTT may contribute to the cellular and metabolic dysfunction observed in Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele contributes to Huntington's disease. This allele encodes mutant huntingtin, which disrupts the function of the CREB and ATF transcription factor family members, impairing their ability to co-regulate the expression of PPARGC1A, a critical coactivator in mitochondrial biogenesis and energy metabolism. This disruption leads to cellular dysfunction, particularly in neurons, resulting in the neurodegenerative symptoms characteristic of Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is involved in a mitochondrial quality control pathway that protects neurons from apoptosis. When PINK1 is functional, it stabilizes the mitochondrial membrane and prevents the release of cytochrome c, a critical step in the intrinsic apoptotic pathway. A mutation or dysfunction in the PINK1 allele can lead to the activation of this pathway, as seen in the given network: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3. This sequence suggests that loss of PINK1 function leads to apoptosis, contributing to neurodegeneration. This pathway is implicated in Parkinson\u2019s disease, where dopaminergic neurons are selectively vulnerable to apoptosis. Thus, the PINK1 allele contributes to the development of $\\boxed{Parkinson's disease}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene encodes PTEN induced kinase 1, a serine/threonine kinase involved in mitochondrial quality control and cell survival. In the given pathway, PINK1 is upstream of PRKN (parkin), which is part of a signaling cascade leading to mitochondrial fission and the degradation of damaged mitochondria. If PINK1 is dysfunctional, this pathway may be impaired, leading to the accumulation of damaged mitochondria. This can trigger apoptosis via the intrinsic pathway involving BAX, CYCS, APAF1, and caspases 9 and 3. The PINK1-PRKN pathway is crucial for maintaining mitochondrial integrity, and its dysfunction is strongly linked to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Therefore, the biological effect of a defective PINK1 allele is the contribution to $\\boxed{\\text{Parkinson's disease}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is part of a mitochondrial quality control pathway that prevents apoptosis and maintains mitochondrial integrity. Mutations in PINK1 have been implicated in autosomal recessive Parkinson's disease. The pathway includes PINK1, PRKN (parkin), BAX, and a sequence leading to caspase activation, indicating a role in apoptosis regulation. Dysfunction in this pathway may lead to increased susceptibility to neuronal death, contributing to neurodegeneration. The involvement of PINK1 in this apoptotic signaling cascade suggests its critical role in protecting neurons from programmed cell death. Therefore, the PINK1 allele contributes to \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and cellular signaling. In the given pathway (NXN* -| DVL), it appears to interact with DVL proteins (DVL1, DVL2, DVL3), which are key components of the Wnt signaling pathway. Disruption of this pathway can lead to developmental abnormalities and disease. Mutations in NXN have been associated with a rare genetic disorder known as **nucleoredoxin deficiency**, which is implicated in a form of **Wnt signaling dysfunction** and may contribute to **Wnt-related developmental disorders**. However, the direct disease linked specifically to NXN mutations is **nucleoredoxin-related autosomal recessive disorder**, a condition that can result in developmental delay, intellectual disability, and other neurological impairments. \n\n\\boxed{Nucleoredoxin-related autosomal recessive disorder}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox signaling and cellular response to oxidative stress. It interacts with DVL proteins, which are central to the Wnt/planar cell polarity (PCP) signaling pathway. Mutations or dysregulation of NXN may disrupt this pathway, potentially leading to developmental and neurological disorders. Evidence suggests that alterations in NXN function are implicated in schizophrenia, as it affects neuronal development and synaptic plasticity. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and antioxidant defense. In the given pathway (NXN* -| DVL), NXN is associated with dishevelled proteins (DVL1, DVL2, DVL3), which are key components of the Wnt signaling pathway. Dysregulation of this pathway is implicated in various diseases, including cancer. Specifically, alterations in the NXN gene have been linked to cancer progression, particularly in promoting tumor growth and resistance to apoptosis. While NXN itself is not typically classified as a direct oncogene, its dysfunction may contribute to tumorigenesis by affecting cellular redox status and signal transduction. Therefore, the biological effect of an NXN allele may contribute to the development of cancer.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, thus playing a critical role in protecting cells from oxidative stress. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons. The provided pathway involves SOD1 interacting with BIP (a chaperone protein) and ATF6 (a transcription factor), which are components of the unfolded protein response (UPR), and ultimately leading to the activation of DDIT3, which is involved in stress response and apoptosis. Dysfunctional SOD1 can lead to mitochondrial dysfunction and oxidative damage, contributing to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the SOD1 allele in this genomic pathway is associated with amyotrophic lateral sclerosis (ALS). SOD1 encodes a copper-zinc superoxide dismutase that normally detoxifies superoxide radicals. Mutations in SOD1 can lead to misfolding and aggregation of the protein, which is implicated in the pathogenesis of ALS. In this pathway, SOD1 interacts with BIP (a chaperone protein) and ATF6 (a transcription factor involved in the unfolded protein response), which leads to the induction of DDIT3, a gene associated with stress responses and cellular damage. This pathway highlights the role of endoplasmic reticulum stress and protein misfolding in the progression of ALS.\n\n\\boxed{Amyotrophic lateral sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to the production of toxic SOD1 protein variants that aggregate and cause motor neuron degeneration. The given pathway involves SOD1 interacting with other stress response genes like HSPA5 (BIP), ATF6, and DDIT3, suggesting a role in endoplasmic reticulum (ER) stress and unfolded protein response (UPR) pathways. ER stress is implicated in various neurodegenerative diseases, and the SOD1 mutations may exacerbate this stress, contributing to neuronal dysfunction and death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes a protein that plays a role in the regulation of calcium release and mitochondrial function. In the given pathway, ATXN3 is associated with ITPR1, which is involved in calcium signaling through the IP3 pathway. Mutations or aberrant function of ATXN3 can disrupt this pathway, leading to impaired calcium homeostasis and mitochondrial dysfunction. Such disruptions are implicated in neurodegenerative diseases, particularly spinocerebellar ataxias (SCAs). Specifically, ATXN3 is the causative gene for SCA3, also known as Machado-Joseph disease, which is characterized by progressive ataxia, dystonia, and other neurological symptoms. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a sequence starting with glutamate binding to GRM1, activating GNAQ, which then activates PLCB, leading to IP3 production. IP3 triggers Ca\u00b2\u207a release via ITPR1, which is modulated by ATXN2 and ATXN3. Ca\u00b2\u207a enters mitochondria via MCU and is involved in the MPTP complex, influencing CYCS release. ATXN3 is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by expansion of a CAG repeat in the ATXN3 gene, resulting in protein dysfunction and progressive brain degeneration.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that plays a critical role in the ubiquitin-proteasome system, particularly in the degradation of hypoxia-inducible factor (HIF) proteins. Mutations in VHL lead to stabilization of HIF, which activates the transcription of genes involved in angiogenesis and cell proliferation, such as VEGFA, CXCL8, and EPO. This pathway is central to the development of von Hippel-Lindau disease, a hereditary condition associated with the formation of hemangioblastomas, cysts, and clear cell renal cell carcinomas. The provided pathway illustrates the VHL-dependent regulation of these hypoxia-response genes through the CUL2-ELOC-ELOB-RBX1 ubiquitin ligase complex and the HIF pathway. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes the von Hippel-Lindau tumor suppressor protein, which is a key component of an E3 ubiquitin ligase complex that targets the HIF (hypoxia-inducible factor) transcription factors for degradation under normoxic conditions. In the provided pathway, the VHL complex (VHL*+RBX1+ELOC+ELOB+CUL2) is involved in the degradation of EPAS1, a HIF-1\u03b1-like protein. Under hypoxia, EPAS1 binds to ARNT to activate transcription of genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which promote angiogenesis, glycolysis, and erythropoiesis. Loss of functional VHL leads to stabilization of EPAS1, resulting in constitutive activation of these hypoxia-response genes. This dysregulation is a hallmark of clear cell renal cell carcinoma (ccRCC), a common kidney cancer. \n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway, is involved in the regulation of hypoxia-inducible factor (HIF) through a ubiquitination complex (VHL+RBX1+ELOC+ELOB+CUL2) that targets EPAS1 (a HIF-1\u03b1 subunit) for degradation. Under normoxic conditions, this complex ensures the degradation of EPAS1. In the absence of functional VHL, EPAS1 accumulates and dimerizes with ARNT to activate transcription of downstream genes (VEGFA, CXCL8, SLC2A1, EPO) involved in angiogenesis, inflammation, and erythropoiesis. This leads to the pathogenesis of von Hippel-Lindau disease, characterized by the development of hemangioblastomas, cysts, and pheochromocytomas. \n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the RAS (KRAS and NRAS) proteins, which are key components of the PI3K/AKT signaling cascade. Mutations in NRAS can lead to constitutive activation of this pathway, promoting cell survival, proliferation, and resistance to apoptosis. This aberrant signaling is a well-known driver in several cancers. Specifically, mutations in NRAS are commonly associated with melanoma, a type of skin cancer. These mutations can lead to uncontrolled growth and progression of melanoma tumors. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-MAPK and PI3K-AKT signaling cascades, which are central to cell proliferation, survival, and differentiation. Mutations in NRAS, a proto-oncogene, can lead to constitutive activation of these pathways, promoting uncontrolled cell growth. This is commonly observed in various cancers. Specifically, NRAS mutations are associated with melanoma, Noonan syndrome, and certain leukemias. The activation of PI3K by NRAS, leading to PIP3 production and subsequent AKT activation, enhances cell survival and proliferation, contributing to tumorigenesis. Given the context, the biological effect of the NRAS allele is to promote oncogenesis, specifically contributing to the development of melanoma.  \n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-MAPK and PI3K-AKT signaling cascades, which are critical for cell growth, survival, and proliferation. NRAS, along with KRAS, activates PI3K, leading to the production of PIP3, which in turn activates AKT. AKT promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins like BAD. Mutations in NRAS can lead to constitutive activation of this pathway, resulting in uncontrolled cell growth and resistance to apoptosis. Such alterations are frequently observed in various cancers, including melanoma, leukemia, and some solid tumors. The persistent activation of this pathway is a well-known contributor to tumorigenesis.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the APP gene, which encodes the amyloid beta precursor protein, and its downstream effects leading to the release of cytochrome c (CYCS), a key event in apoptosis. This pathway is closely associated with the accumulation of beta-amyloid (Abeta), which is a hallmark of Alzheimer's disease. The involvement of mitochondrial proteins such as VDACs and SLC25 family members suggests a role in mitochondrial dysfunction, which is also a feature of Alzheimer's disease. Therefore, the APP allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway begins with the APP gene, which encodes the amyloid beta precursor protein. Abnormal processing of APP leads to the production of amyloid-beta (Abeta) peptides, a hallmark of Alzheimer's disease. These peptides aggregate and form plaques in the brain, contributing to neurodegeneration. The pathway then progresses through PPID, which may influence the stability or toxicity of Abeta. MPTP (mitochondrial permeability transition pore) activation is involved in mitochondrial dysfunction and cell death, and CYCS (cytochrome c) release is a key step in apoptosis. The presence of VDACs and SLC25 family members indicates involvement of mitochondrial membrane proteins critical for ion transport and mitochondrial function. This network suggests a role in neuronal damage and apoptosis, characteristic of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is located on chromosome 21 and is central to the amyloidogenic pathway. The network defined, APP* -> Abeta -> PPID -> MPTP -> CYCS, outlines a sequence leading to mitochondrial dysfunction and apoptosis, which is a hallmark of Alzheimer's disease. Abeta accumulation is a key factor in the pathogenesis of Alzheimer's. The involvement of PPID, MPTP, and CYCS further supports this pathway's role in neurodegeneration. The presence of APP mutations, along with other genes like VDAC1-3 and SLC25A4-6, emphasizes a mitochondrial and apoptotic mechanism linked to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of misfolded SOD1 proteins, which can accumulate and cause toxic effects in motor neurons, ultimately leading to their death. The pathway described involves the ubiquitin-proteasome system, which is responsible for degrading misfolded or damaged proteins. The involvement of DERL1 and components of the 26S proteasome suggests that the proper degradation of SOD1 is essential for maintaining cellular health, and failure in this process can contribute to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves SOD1, a gene encoding superoxide dismutase 1, which is a key antioxidant enzyme. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The network described outlines the involvement of SOD1 in a pathway that includes the ubiquitin-proteasome system, indicating a possible role in protein degradation and cellular stress response. Disruption of this pathway may lead to the accumulation of misfolded proteins, a hallmark of neurodegenerative diseases like ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a critical role in protecting cells from oxidative stress. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to misfolding and aggregation of SOD1 protein, which is toxic to motor neurons. The pathway described involves the proteasome machinery (26S) responsible for degrading damaged or misfolded proteins, including the SOD1* (mutant) protein, which may accumulate and contribute to neurodegeneration. Thus, the SOD1 allele implicated in this pathway contributes to $\\boxed{Amyotrophic Lateral Sclerosis (ALS)}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, which is a component of the \u03b3-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). This pathway is implicated in the generation of amyloid-\u03b2 peptides, which accumulate in the brain and are a hallmark of Alzheimer's disease. PSEN1 mutations are strongly associated with early-onset familial Alzheimer's disease. These mutations can lead to altered \u03b3-secretase activity, resulting in increased production of toxic amyloid-\u03b242, which promotes amyloid plaque formation and neurodegeneration. The pathway described connects PSEN1 to mitochondrial calcium dysregulation and apoptosis, which are also key features in Alzheimer's disease pathogenesis.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, which is a component of the \u03b3-secretase complex involved in the processing of amyloid precursor protein (APP). This pathway describes a mitochondrial calcium-mediated apoptotic cascade initiated by PSEN1 and PSEN2, leading to the activation of caspases through the intrinsic apoptotic pathway. Dysregulation of this pathway, particularly through mutations in PSEN1, is strongly associated with early-onset Alzheimer's disease. These mutations disrupt normal \u03b3-secretase function, leading to altered APP processing and increased production of amyloid-\u03b2 peptides, a hallmark of Alzheimer's pathology. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, involved in the cleavage of amyloid precursor protein (APP), leading to the production of amyloid-beta (A\u03b2) peptides. Accumulation of A\u03b2 is a hallmark of Alzheimer's disease. The pathway described involves PSEN1 and PSEN2 in the regulation of calcium dynamics through RYR3, MCU, VDACs, and SLC25 family members, which influence mitochondrial function and the opening of the mitochondrial permeability transition pore (MPTP). This can lead to cytochrome c release, activation of APAF1, and subsequent caspase-dependent apoptosis. Dysregulation in this pathway due to PSEN1 mutations is strongly associated with early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 gene encodes a receptor tyrosine kinase crucial in hematopoietic cell signaling. Mutations in FLT3, particularly internal tandem duplications (ITD) in the juxtamembrane domain, lead to constitutive activation of the FLT3 receptor, resulting in uncontrolled cell proliferation. This aberrant signaling activates downstream effectors such as STAT5 and PIM kinases, promoting survival and growth of myeloid progenitor cells. FLT3 mutations are frequently observed in acute myeloid leukemia (AML), contributing to disease progression and poor prognosis. These mutations are associated with increased relapse rates and reduced overall survival in AML patients.  \n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nFLT3 is a receptor tyrosine kinase involved in the JAK-STAT signaling pathway, and its activation leads to the phosphorylation of STAT5, which in turn activates the expression of PIM1 and PIM2 genes. These PIM kinases are known to promote cell survival and proliferation. Mutations in FLT3, especially internal tandem duplications (ITD) in its juxtamembrane domain, result in constitutive activation of the kinase, leading to uncontrolled cell growth. This aberrant signaling is commonly observed in acute myeloid leukemia (AML), contributing to leukemogenesis by enhancing the self-renewal and survival of leukemic blasts. \n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 pathway, involving FLT3, STAT5, and PIM1/2, is crucial in hematopoiesis and cell survival. Mutations in FLT3, especially internal tandem duplications (ITD) in its kinase domain, are frequently observed in acute myeloid leukemia (AML). These mutations lead to constitutive activation of FLT3, promoting uncontrolled cell proliferation and survival, which contributes to leukemogenesis. This aberrant signaling is associated with poor prognosis in AML patients.\n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves LRRK2, a protein associated with the pathogenesis of Parkinson's disease. The cascade described, starting with LRRK2 leading to the activation of the intrinsic apoptotic pathway through cytochrome c release and subsequent caspase activation, suggests a pro-apoptotic effect. Mutations in LRRK2 are known to contribute to the development of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. These mutations may enhance kinase activity, leading to disrupted cellular processes and neuronal death. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves LRRK2 leading to the activation of the caspase cascade through the intrinsic apoptotic pathway, which is a key mechanism of programmed cell death. Mutations in LRRK2 are strongly associated with Parkinson's disease. These mutations may lead to increased kinase activity, which can disrupt normal cellular processes, including mitochondrial function and autophagy, ultimately contributing to neurodegeneration. The activation of CASP3, a key executioner caspase, indicates a progression towards apoptosis, which is observed in the degeneration of dopaminergic neurons in Parkinson's disease. Therefore, the LRRK2 allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves LRRK2, a kinase, which activates the cytochrome c (CYCS) release cascade through APAF1, leading to caspase 9 (CASP9) and caspase 3 (CASP3) activation. This sequence is a key part of the intrinsic apoptotic pathway. Mutations in LRRK2 are primarily associated with Parkinson's disease, where it contributes to the progressive degeneration of dopaminergic neurons. These mutations may disrupt normal kinase activity, leading to faulty regulation of cell death and survival pathways in neurons. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel. Mutations in this gene are associated with a range of neurological disorders, including episodic ataxia, spinocerebellar ataxia type 6 (SCA6), and familial hemiplegic migraine type 1. These conditions are characterized by impaired calcium channel function, leading to abnormal neuronal excitability and function. The biological effect of the CACNA1A allele, particularly when mutated, disrupts normal calcium influx in neurons, contributing to the pathogenesis of these neurodegenerative and neurovascular disorders. \n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of a voltage-gated calcium channel, which plays a critical role in calcium ion influx into cells. Mutations in CACNA1A have been implicated in various neurological disorders due to its involvement in cellular signaling and neuronal excitability. Specifically, this gene is associated with spinocerebellar ataxia type 1 (SCA1), a progressive neurodegenerative disease characterized by impaired coordination and gait abnormalities. It is also linked to episodic ataxia type 2 and hemiplegic migraine. These conditions highlight the gene's significant role in maintaining normal neuronal function and its contribution to pathophysiology when disrupted.\n\n\\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of a voltage-gated calcium channel, which plays a critical role in cellular signaling and neurotransmitter release. Mutations in CACNA1A have been associated with several neurological disorders, including episodic ataxia, spinocerebellar ataxia type 6 (SCA6), and hemiplegic migraine. These conditions are characterized by episodic loss of coordination, progressive ataxia, and migraine with aura, respectively. The biological effect of the CACNA1A allele is the dysregulation of calcium ion influx, which disrupts normal neuronal function. This leads to the pathophysiological features observed in these diseases. \n\n\\boxed{Spinocerebellar Ataxia Type 6}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. In the provided pathway, SNCA interacts with BIP (a chaperone protein) and ERN1, which activates XBP1, indicating involvement in endoplasmic reticulum (ER) stress response. Abnormal accumulation of SNCA can lead to ER stress, contributing to neuronal dysfunction and degeneration. This pathway suggests SNCA's role in ER stress signaling, which is a key mechanism in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA allele, encoding synuclein alpha, is implicated in the pathogenesis of Parkinson's disease. In the given pathway, SNCA interacts with BIP (a chaperone protein) and influences ERN1, which activates XBP1, a transcription factor involved in the unfolded protein response. Dysregulation of this pathway may lead to endoplasmic reticulum stress and contribute to neuronal dysfunction. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is implicated in the formation of Lewy bodies, a hallmark of Parkinson's disease. In this pathway, SNCA interacts with BIP (an ER chaperone) and ERN1 (a sensor of ER stress), leading to the activation of XBP1, which is involved in the unfolded protein response. Mutations or overexpression of SNCA can disrupt ER function, contributing to neuronal degeneration. This pathway is central to the pathogenesis of neurodegenerative disorders. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination of target proteins, playing a critical role in mitochondrial quality control and cellular stress response. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism (also known as PARK2), a form of early-onset Parkinson's disease. This disease is characterized by progressive motor dysfunction, including tremors, rigidity, and bradykinesia. The pathway involving PRKN, along with UBCH7/8 and PAELR, likely contributes to the regulation of protein degradation and cellular homeostasis, and its disruption can lead to neuronal degeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease. This pathway involves ubiquitin conjugating enzymes (UBCH7/8) and the E3 ligase PRKN, which tags proteins for degradation. The presence of PRKN* suggests a pathogenic variant, contributing to impaired protein degradation and mitochondrial dysfunction, key mechanisms in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins for degradation. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism (also known as PARK2). This condition is a form of early-onset Parkinson's disease, typically presenting before the age of 40. The pathway includes components involved in ubiquitin-mediated protein degradation, such as UBCH7/8 (ubiquitin-conjugating enzymes), PRKN (parkin), and PAELR (which interacts with parkin). These elements are crucial for the proper function of the ubiquitin-proteasome system, and defects in this pathway disrupt mitochondrial quality control, leading to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the pathogenesis of Parkinson's disease. The 26S proteasome pathway, as described, is involved in protein degradation. Dysregulation of this pathway, particularly related to SNCA, may lead to the accumulation of misfolded proteins, including alpha-synuclein, contributing to the formation of Lewy bodies. These pathological inclusions are a hallmark of Parkinson's disease and other synucleinopathies. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein that is a key component in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA have been implicated in the formation of Lewy bodies, which are pathological inclusions found in the brains of individuals with Parkinson's disease and other synucleinopathies. The SNCA allele is part of a network involving proteasome subunits, which suggests a role in protein degradation pathways that may be impaired in disease. This disruption could contribute to the accumulation of misfolded proteins and neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a component of Lewy bodies, pathological inclusions found in Parkinson's disease. The 26S proteasome, a multi-subunit complex involved in protein degradation, is implicated in the clearance of misfolded proteins. Dysregulation or dysfunction in proteasome activity, potentially influenced by SNCA, is associated with the accumulation of toxic protein aggregates, contributing to neurodegeneration. Mutations or overexpression of SNCA have been linked to Parkinson's disease and other synucleinopathies. Therefore, the SNCA allele contributes to the development of \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene is part of a genomic pathway involving amyloid precursor protein (APP) processing, calcium ion regulation, and apoptosis. Mutations in PSEN2, along with PSEN1, are known to cause early-onset Alzheimer's disease by affecting the normal function of presenilin proteins, which are essential for the gamma-secretase complex. These mutations can lead to abnormal production of amyloid-beta peptides, contributing to the accumulation of amyloid plaques in the brain, a hallmark of Alzheimer's disease. Additionally, the pathway suggests a role in mitochondrial calcium handling and apoptosis, which may further exacerbate neuronal dysfunction and cell death. Thus, the PSEN2 allele contributes to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway begins with PSEN1 and PSEN2, which are involved in the gamma-secretase complex and are crucial for amyloid precursor protein (APP) processing. Mutations in PSEN1 and PSEN2 are known to cause early-onset Alzheimer's disease by increasing the production of amyloid-beta peptides, a hallmark of the disease. The pathway describes a mitochondrial calcium dysregulation cascade, starting with RYR3, MCU, and other mitochondrial calcium transporters, leading to mitochondrial permeability transition pore (MPTP) activation, cytochrome c release, and subsequent caspase activation, which is central to apoptosis. PSEN2's role in this pathway may contribute not only to Alzheimer's disease but also to mitochondrial dysfunction and neurodegenerative processes. The most direct biological effect of a pathogenic PSEN2 allele is $\\boxed{\\text{Alzheimer's disease}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 allele is involved in a genomic pathway that contributes to Alzheimer's disease. PSEN1 and PSEN2 are presenilin proteins essential for gamma-secretase activity, which processes amyloid precursor protein (APP) into amyloid-beta (A\u03b2) peptides. Mutations in PSEN2 can lead to increased production of toxic A\u03b242, a key component of amyloid plaques observed in Alzheimer's disease. The pathway also includes calcium signaling components such as RYR3, MCU, and MPTP, which are involved in mitochondrial dysfunction and apoptosis, processes closely linked to neurodegeneration. Ultimately, the pathway leads to the activation of caspases, promoting cell death. This combination of A\u03b2 accumulation and mitochondrial dysfunction suggests that PSEN2 mutations contribute to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the protein huntingtin, which is implicated in the pathway leading to calcium dysregulation and subsequent apoptosis. The HTT allele, specifically the mutant form associated with expanded CAG repeats, is responsible for Huntington's disease. This expansion leads to the production of a dysfunctional huntingtin protein, which disrupts calcium homeostasis by interfering with the IP3-mediated calcium release from the endoplasmic reticulum and mitochondrial calcium uptake. This ultimately leads to neuronal dysfunction and degeneration, particularly in the striatum and cortex. The pathway involving ITPR, MCU, MPTP, and the subsequent activation of caspases is a key contributor to the neuronal apoptosis seen in Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is involved in various cellular processes including vesicle trafficking, gene transcription, and mitochondrial function. In the provided pathway, HTT interacts with ITPR to regulate Ca\u00b2\u207a release, which is crucial for mitochondrial Ca\u00b2\u207a uptake via MCU. Mutations in HTT, specifically CAG trinucleotide repeat expansions, lead to the production of a toxic polyglutamine-expanded huntingtin protein. This mutation is responsible for Huntington's disease, a neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The toxic huntingtin protein disrupts multiple pathways, including those involving Ca\u00b2\u207a homeostasis and mitochondrial function, ultimately leading to neuronal death.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the protein huntingtin, which is central to the pathology of Huntington's disease. This pathway highlights the role of HTT in calcium signaling through its interaction with ITPR, which is critical for Ca\u00b2\u207a release from the endoplasmic reticulum. Mutations in HTT, specifically CAG trinucleotide repeat expansions, lead to the production of a dysfunctional huntingtin protein, which disrupts intracellular calcium homeostasis and mitochondrial function. This disruption contributes to neuronal dysfunction and degeneration, particularly in the striatum and cortex. The dysregulation of Ca\u00b2\u207a and mitochondrial integrity through this pathway is a key mechanism in the neurodegenerative process of Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is crucial in the pathogenesis of prion diseases. A specific allele of PRNP, particularly the methionine-to-leucine substitution at codon 177 (PRNP (177M\u2192L)), contributes to the development of Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS), a rare, inherited neurodegenerative disorder. This mutation leads to the misfolding of prion proteins, resulting in the accumulation of pathological prion protein (PrPSc) in the brain. This accumulation causes progressive neurological symptoms, including ataxia, cognitive decline, and ultimately leads to death. The NOTCH1 gene, although involved in cellular signaling, is not directly implicated in prion disease pathology in this context. \n\n\\boxed{Gerstmann-Str\u00e4ussler-Scheinker syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. These are a group of rare, progressive, and fatal neurodegenerative disorders caused by the misfolding of the prion protein into a pathogenic form. The NOTCH1 gene is involved in various cellular processes including cell fate determination and differentiation. However, the specific interaction between PRNP and NOTCH1 in the context of the given pathway is not well-documented in the literature. The primary disease associated with mutations in the PRNP gene is Creutzfeldt-Jakob disease (CJD), which includes both sporadic, genetic, and acquired forms. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to prion diseases. A specific PRNP allele, such as those with mutations like P102L or V126I, is associated with the development of Creutzfeldt-Jakob disease (CJD), a rare, rapidly progressive, and fatal neurodegenerative disorder. These mutations can lead to the misfolding of prion proteins, which in turn cause the accumulation of pathological prion protein (PrPSc) in the brain, resulting in neuronal damage and spongiform changes. The NOTCH1 gene, though not directly involved in prion propagation, may influence cell fate decisions and apoptosis, which could modulate the neurodegenerative process. However, the primary disease linked to PRNP is \\boxed{Creutzfeldt-Jakob disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves components of the ubiquitin system, including ubiquitin (UB) chains, free ubiquitin (UB), and the deubiquitinating enzyme UCHL1 (ubiquitin C-terminal hydrolase L1). UCHL1 is responsible for removing ubiquitin from proteins, playing a key role in regulating protein turnover and maintaining cellular homeostasis. Mutations in the *UCHL1* gene have been linked to alterations in this pathway and are associated with neurodegenerative diseases, particularly Parkinson's disease. These mutations can lead to impaired ubiquitin recycling, which may result in the accumulation of ubiquitinated proteins and subsequent neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in the proteasomal degradation pathway, playing a key role in the ubiquitin-proteasome system. Mutations in UCHL1 have been associated with familial Parkinson's disease. Specifically, the S18Y mutation in UCHL1 is linked to early-onset, autosomal dominant Parkinson's disease. This mutation may lead to reduced enzymatic activity, impairing protein degradation and contributing to the accumulation of misfolded proteins, a hallmark of neurodegenerative disorders such as Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in the deubiquitination of ubiquitin chains. It plays a crucial role in the ubiquitin-proteasome system, which is essential for protein turnover and regulation of various cellular processes. The pathway involves ubiquitin (UB) chains, free ubiquitin (UB), and UCHL1, which can cleave ubiquitin from proteins. Mutations in UCHL1 have been implicated in neurodegenerative diseases, particularly Parkinson's disease. These mutations may lead to impaired function of UCHL1, disrupting ubiquitin homeostasis and contributing to the accumulation of misfolded or dysfunctional proteins, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a crucial role in protecting cells from oxidative damage. Mutations in the SOD1 gene are the most common cause of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons in the brain and spinal cord. The pathway described involves proteins associated with the dynein complex, which is essential for intracellular transport and ciliary function. Dysregulation of this network, potentially influenced by SOD1 dysfunction, may contribute to the pathogenesis of ALS by impairing cellular transport mechanisms and increasing oxidative stress in motor neurons.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that plays a critical role in protecting cells from oxidative damage by catalyzing the conversion of superoxide radicals to hydrogen peroxide and oxygen. The pathway described involves components of the dynein-dynactin complex, essential for intracellular transport and ciliary function. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations often lead to misfolding and aggregation of the SOD1 protein, resulting in toxic effects on motor neurons. Therefore, the biological effect of this SOD1 allele contributes to the development of $\\boxed{\\text{Amyotrophic Lateral Sclerosis (ALS)}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, in the context of the described pathway involving dynein and dynactin components, is primarily associated with amyotrophic lateral sclerosis (ALS). SOD1 (superoxide dismutase 1) is a key gene in the pathogenesis of familial ALS, where mutations in SOD1 lead to the production of toxic protein aggregates that damage motor neurons. The pathway described includes structural and motor components of cilia and flagella, which are essential for cellular transport and function. While the direct link between SOD1 and the dynein/dynactin pathway is not fully established, dysfunction in these pathways can contribute to neurodegenerative processes. Therefore, the biological effect of this SOD1 allele is its contribution to amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nChromosome 21 contains the *SOD1* gene, which encodes superoxide dismutase 1, an enzyme that protects cells from oxidative damage. Mutations in *SOD1* are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive degeneration of motor neurons. The provided pathway involves *SOD1* influencing the unfolded protein response through BIP and ATF6, ultimately leading to DDIT3, which is involved in cellular stress responses. Dysfunctional *SOD1* can lead to mitochondrial dysfunction and oxidative stress, contributing to neuronal death in ALS. \n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nSOD1 (superoxide dismutase 1) is a key enzyme involved in the detoxification of reactive oxygen species. Mutations in the SOD1 gene are the most common cause of familial amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the death of motor neurons. The pathway described involves SOD1, which when dysregulated, may lead to endoplasmic reticulum (ER) stress and subsequent activation of the unfolded protein response, as indicated by the involvement of BIP, ATF6, and DDIT3. This stress response is a hallmark of ALS and other neurodegenerative conditions. Therefore, the SOD1 allele, particularly when mutated, contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a crucial role in protecting cells from oxidative damage. Mutations in the SOD1 gene are implicated in familial amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations often lead to misfolding and aggregation of the SOD1 protein, causing toxic effects on motor neurons. The provided pathway suggests that SOD1 interacts with BIP (a chaperone protein) and ATF6 (an ER stress sensor), which in turn activates DDIT3 (CHOP), a transcription factor associated with apoptosis. This pathway may be involved in the cellular stress response and could contribute to the neurodegenerative process in ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that is part of the BCR-ABL fusion protein, commonly found in chronic myeloid leukemia (CML). This fusion results from a chromosomal translocation, specifically the Philadelphia chromosome (t(9;22)), which leads to the constitutive activation of ABL1, driving uncontrolled cell proliferation. The BCR-ABL pathway activates downstream effectors such as GRB2, SOS, RAS, RAF, MEK, and ERK, promoting cell growth and survival. This aberrant signaling contributes to the pathogenesis of CML and other leukemias. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when constitutively activated through chromosomal translocation (e.g., BCR-ABL fusion), leads to uncontrolled cell proliferation. This aberrant signaling is a hallmark of chronic myeloid leukemia (CML) and some forms of acute lymphoblastic leukemia (ALL). The BCR-ABL fusion protein activates downstream effectors like GRB2, SOS, RAS, RAF, MEK, and ERK, promoting cell survival and division. This pathway's dysregulation is central to the pathogenesis of these leukemias.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when aberrantly activated (e.g., via the BCR-ABL fusion protein), drives uncontrolled cell proliferation. This fusion protein is a hallmark of chronic myeloid leukemia (CML), a type of blood cancer characterized by the presence of the Philadelphia chromosome. The BCR-ABL pathway activates downstream effectors such as GRB2, SOS, RAS, RAF, MEK, and ERK, promoting cellular growth and survival. This dysregulated signaling contributes to the pathogenesis of CML and related diseases.\n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway, as defined, involves a series of sequential activations starting with the KIT receptor tyrosine kinase. Activating mutations in KIT can lead to constitutive (constant) signaling through this pathway, bypassing normal regulatory controls. This uncontrolled activation promotes cell proliferation and survival, contributing to the development of certain cancers. Specifically, mutations in the KIT gene are frequently associated with gastrointestinal stromal tumors (GISTs), a type of soft tissue sarcoma. These mutations are often found in the juxtamembrane domain of KIT and result in enhanced tyrosine kinase activity. Therefore, the biological effect of this KIT allele is the promotion of tumor growth, particularly in GISTs.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, can lead to constitutive activation of the KIT receptor tyrosine kinase, initiating downstream signaling without the need for ligand binding. This continuous activation promotes uncontrolled cell proliferation and survival, contributing to the development of certain cancers. Specifically, mutations in the KIT gene are commonly associated with gastrointestinal stromal tumors (GISTs). These tumors typically arise in the stomach or small intestine and are often driven by activating KIT mutations that result in persistent signaling through the RAS/RAF/MEK/ERK pathway. This pathway is crucial for cell growth and differentiation, and its dysregulation due to KIT mutations can lead to tumor formation. \n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, specifically mutations in the KIT proto-oncogene receptor tyrosine kinase, plays a crucial role in the activation of the RAS-RAF-MEK-ERK signaling pathway. This pathway is involved in cellular proliferation, differentiation, and survival. Mutations in KIT can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This aberrant signaling is frequently observed in gastrointestinal stromal tumors (GISTs), where KIT mutations are prevalent. These mutations result in the continuous activation of downstream effectors, such as ERK, leading to tumorigenesis. Additionally, KIT mutations are also associated with certain leukemias and melanomas. \n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele, when aberrantly activated, contributes to uncontrolled cell cycle progression by phosphorylating RB1, thereby releasing E2F transcription factors. This leads to increased cell proliferation and decreased apoptosis. Such alterations are commonly observed in various cancers, particularly in melanoma, where mutations in CDK4 are frequently found. These mutations often result in the overexpression or activation of CDK4, driving tumorigenesis. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene encodes cyclin-dependent kinase 4, which forms a complex with cyclin D proteins (CCND1, CCND2, CCND3) to phosphorylate the RB1 protein. This phosphorylation inactivates RB1, allowing E2F transcription factors (E2F1, E2F2, E2F3) to activate genes required for DNA replication and cell cycle progression. Aberrant activation of this pathway, such as through CDK4 mutations or overexpression, can lead to uncontrolled cell proliferation. This contributes to the development of various cancers, particularly melanoma and other malignancies where the CDK4/RB1/E2F pathway is dysregulated. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the regulation of the RB1 protein by the CDK4-cyclin D complex, which in turn controls the activity of E2F transcription factors. Dysregulation of this pathway can lead to uncontrolled cell proliferation. Mutations in CDK4 or its cyclin D partners can result in loss of RB1 function, thereby allowing E2F to activate genes involved in DNA synthesis and cell division. This contributes to the development of various cancers. Specifically, mutations in CDK4 are most commonly associated with melanoma. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and the ubiquitin-proteasome system. In the given pathway, SQSTM1 is connected to PINK1 and PRKN, which are key components of the mitochondrial quality control pathway. Mutations in SQSTM1 have been associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). These mutations may disrupt the normal function of SQSTM1, impairing the clearance of damaged mitochondria, which contributes to neuronal degeneration.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in the ubiquitin-proteasome system and autophagy. In the context of the provided pathway, SQSTM1 interacts with the PINK1-PRKN complex and LC3, which are critical components of the mitophagy pathway. Mutations in SQSTM1 have been associated with neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can lead to altered protein function, affecting mitochondrial quality control and contributing to neuronal dysfunction. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and mitochondrial quality control. In the given pathway, SQSTM1 is positioned downstream of PRKN and upstream of LC3, underscoring its role in the PINK1-PRKN-driven mitophagy pathway. Mutations in SQSTM1 are associated with neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can impair autophagic clearance of damaged mitochondria, leading to the accumulation of toxic proteins and subsequent neuronal degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway describes a sequence of events in the intrinsic apoptotic pathway, initiated by the amyloid beta precursor protein (APP). The cleavage of APP leads to the production of amyloid-beta (Abeta), which is a key player in the pathogenesis of Alzheimer's disease. Accumulation of Abeta leads to the activation of the FAS receptor, triggering a cascade that involves FADD, caspase 8, and downstream apoptotic effectors, ultimately leading to caspase 3 activation and apoptosis. This pathway is implicated in neuronal death, a hallmark of Alzheimer's disease. Thus, mutations or overexpression of the APP gene can contribute to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described begins with the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). Accumulation of Abeta is a hallmark of Alzheimer's disease. The cascade proceeds through FAS and FADD, leading to activation of CASP8, which triggers BID, and subsequently BAX and BAK1, promoting mitochondrial outer membrane permeabilization. This releases cytochrome c (CYCS), which activates APAF1 and CASP9, leading to the activation of CASP3, a key executioner caspase in apoptosis. This pathway is central to the neurodegenerative processes in Alzheimer's disease. The APP gene is directly implicated in the production of Abeta, which contributes to the formation of amyloid plaques, a major pathological feature of the disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is associated with the intrinsic apoptotic pathway, initiated by the amyloid beta precursor protein (APP). APP is processed to generate amyloid beta (Abeta), which is implicated in the pathogenesis of Alzheimer's disease. Accumulation of Abeta leads to the activation of the FAS death receptor pathway, triggering a cascade of caspase activation, including CASP8, BID, BAX, BAK1, and eventually CASP3, leading to apoptosis. This pathway is closely linked to neurodegenerative processes observed in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT gene encodes a receptor tyrosine kinase involved in cell growth and survival. Mutations in KIT can lead to constitutive activation of the PI3K/AKT signaling pathway, as seen in the provided network. This persistent activation promotes uncontrolled cell proliferation and inhibits apoptosis, particularly affecting cells that depend on this pathway for survival. Such mutations are commonly associated with gastrointestinal stromal tumors (GISTs), a type of cancer that originates in the gastrointestinal tract. These tumors often harbor activating KIT mutations that drive their growth and progression. \n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele is involved in the activation of the PI3K/AKT/BAD signaling pathway, which is critical for cell survival, growth, and proliferation. Mutations in the KIT gene can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This aberrant signaling is commonly observed in gastrointestinal stromal tumors (GISTs), a type of cancer that originates in the gastrointestinal tract. These mutations frequently occur in the juxtamembrane domain of KIT, leading to ligand-independent activation of the receptor tyrosine kinase. This pathway dysregulation contributes to tumor initiation and progression in GISTs.  \n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway, involving KIT, PI3K, PIP3, AKT, and BAD, plays a crucial role in cell survival, proliferation, and differentiation. Mutations in the KIT gene can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This pathway's dysregulation is commonly observed in certain cancers. Specifically, activating mutations in KIT are well-documented in gastrointestinal stromal tumors (GISTs), a type of soft tissue sarcoma. These mutations lead to continuous signaling through the PI3K/AKT pathway, which promotes tumor growth and survival. Thus, the KIT allele contributes to the development of gastrointestinal stromal tumors.\n\n\\boxed{Gastrointestinal Stromal Tumor}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described begins with SOD1, which is involved in the regulation of apoptosis. When SOD1 is mutant or dysregulated, it can lead to increased oxidative stress and disrupt the balance between pro-apoptotic and anti-apoptotic signals. This results in the activation of BAX and BAK1, leading to cytochrome c release, APAF1 activation, and subsequent caspase activation, ultimately promoting apoptosis. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The disruption of this apoptotic pathway due to mutant SOD1 contributes to neurodegeneration.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the regulation of apoptosis, specifically mitochondrial-mediated apoptosis. SOD1, a key component in this network, is an antioxidant enzyme that normally reduces superoxide radicals. However, in certain mutant forms, SOD1 can become toxic and contribute to the formation of protein aggregates. These aggregates can lead to mitochondrial dysfunction and activation of the apoptotic cascade through the BCL2 family members (BAX, BAK1), release of cytochrome c (CYCS), and subsequent activation of caspases (CASP9 and CASP3). This dysregulation of apoptosis is implicated in neurodegenerative diseases. The specific SOD1 mutations associated with this pathway are linked to Amyotrophic Lateral Sclerosis (ALS). \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described outlines a sequence of events in the intrinsic apoptotic pathway, starting with SOD1, which is normally involved in antioxidant defense. A disruption in SOD1 function, such as that caused by a specific allele, can lead to increased oxidative stress. This may impair the regulation of BCL2, allowing BAX and BAK1 to activate, leading to cytochrome c release and subsequent caspase activation. This cascade promotes apoptosis. Mutations in the SOD1 gene are known to cause familial amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive loss of motor neurons. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the MEN1 gene, which encodes menin 1, a protein involved in regulating cell proliferation and tumorigenesis. The pathway also includes KMT2A, a histone methyltransferase, and CDKN1B and CDKN2C, which are cyclin-dependent kinase inhibitors that function in cell cycle control. Mutations in the MEN1 gene are associated with the loss of menin 1 function, leading to uncontrolled cell growth and tumor development. This genetic alteration is a hallmark of Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary disorder characterized by the development of tumors in endocrine glands such as the parathyroid, pituitary, and pancreas. The interaction of MEN1 with other pathway components underscores its role in tumor suppression. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the MEN1 gene, which encodes menin 1, a protein that functions as a tumor suppressor. MEN1 is part of a regulatory network that includes KMT2A, CDKN1B, and CDKN2C, all of which are involved in controlling cell proliferation and DNA methylation. Mutations in the MEN1 gene are associated with Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary disorder characterized by the development of tumors in multiple endocrine glands, such as the parathyroid, pituitary, and enterochromaffin pancreatic cells. The loss of function of the MEN1 allele disrupts normal growth control, leading to uncontrolled cell division and tumor formation. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the MEN1 gene, which encodes menin 1, and is part of a network that includes KMT2A, CDKN1B, and CDKN2C. These genes are involved in cell cycle regulation and chromatin remodeling. Mutations in the MEN1 gene are associated with a tumor suppressor function. Loss of function in MEN1 leads to uncontrolled cell proliferation and is a primary cause of Multiple Endocrine Neoplasia type 1 (MEN1). This hereditary syndrome is characterized by the development of tumors in endocrine glands, including the parathyroid, pituitary, and pancreatic islets. The interaction with CDKN1B and CDKN2C, which are cyclin-dependent kinase inhibitors, suggests a role in controlling cell cycle progression. Therefore, the biological effect of a MEN1 allele with loss-of-function mutations contributes to the development of Multiple Endocrine Neoplasia type 1.\n\n\\boxed{Multiple Endocrine Neoplasia type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway outlines the Wnt/\u03b2-catenin signaling cascade. The APC gene is a negative regulator of this pathway. When APC is mutated or inactivated (APC*), it leads to the stabilization and nuclear translocation of \u03b2-catenin (CTNNB1). This results in the activation of TCF/LEF transcription factors, which in turn upregulate the expression of downstream target genes such as BIRC5, MYC, and CCND1, promoting cell proliferation and survival. Mutations in APC are hallmark features in colorectal cancer, leading to uncontrolled cell growth and tumorigenesis.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway is a core component of the Wnt/\u03b2-catenin signaling cascade. In this pathway, APC (adenomatous polyposis coli) acts as a negative regulator by promoting the degradation of \u03b2-catenin (CTNNB1). When APC is mutated or inactivated, \u03b2-catenin accumulates, translocates to the nucleus, and activates transcription of target genes (e.g., BIRC5, MYC, CCND1) through TCF/LEF transcription factors. This leads to uncontrolled cell proliferation and is a hallmark of colorectal cancer. Germline mutations in APC are associated with familial adenomatous polyposis (FAP), and somatic mutations in APC are frequently observed in sporadic colorectal carcinomas. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes the Wnt/\u03b2-catenin signaling cascade. The APC gene is a negative regulator of this pathway. A mutant or loss-of-function APC allele leads to stabilization of \u03b2-catenin (CTNNB1), which accumulates in the nucleus and, together with TCF/LEF transcription factors, activates target genes such as BIRC5, MYC, and CCND1. This promotes cell proliferation and can lead to colorectal cancer. Therefore, the biological effect of a defective APC allele is the development of colorectal cancer.\n\n\\boxed{Colorectal cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in the regulation of the proteasome system through its interaction with DERL1, which modulates the ubiquitination and degradation of proteins via the 26S proteasome. This pathway involves several genes encoding proteasome subunits and ubiquitin-related proteins, suggesting a role in protein quality control. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. The dysfunction of SOD1 may lead to oxidative stress and impaired proteostasis, contributing to neuronal degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described involves SOD1 interacting with DERL1, which connects to the ubiquitin-proteasome system, suggesting a role in protein degradation and quality control. Dysfunctional SOD1 can lead to the accumulation of misfolded proteins and oxidative stress, contributing to neuronal death. This pathway highlights the interplay between oxidative stress and proteostasis in ALS pathogenesis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of dysfunctional SOD1 protein, which can accumulate and cause oxidative stress, mitochondrial dysfunction, and motor neuron degeneration. The provided pathway includes components involved in ubiquitination and proteasomal degradation, suggesting that the misfolded or dysfunctional SOD1 may be targeted for degradation by the proteasome, a process that is impaired in ALS. Thus, the SOD1 allele contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons in the brain and spinal cord. This pathway, involving SOD1 and related dynein and dynactin complexes, may suggest a role in axonal transport or mitochondrial function, which are crucial for neuronal health. Dysfunctional SOD1 can lead to misfolding, protein aggregation, and subsequent toxicity, contributing to the pathogenesis of ALS. Therefore, the biological effect of this SOD1 allele is its contribution to the development of $\\boxed{Amyotrophic Lateral Sclerosis}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that helps neutralize free radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons in the brain and spinal cord. The provided pathway highlights interactions between SOD1 and other genes involved in the dynein and dynactin complexes, which are essential for intracellular transport and ciliary function. While the specific alleles or mutations in SOD1 are not identified, the presence of SOD1 in this network suggests its role in a broader cellular process that, when disrupted, contributes to neurodegeneration. Therefore, this SOD1 allele is implicated in $\\boxed{\\text{Amyotrophic Lateral Sclerosis (ALS)}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes copper-zinc superoxide dismutase, an enzyme that detoxifies the superoxide radical. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons. The provided network involves genes related to the dynein complex, which is essential for intracellular transport, and the DCTN family, which are components of the dynactin complex that interacts with dynein. The inclusion of SOD1 in this network suggests a possible interaction or interplay between oxidative stress pathways and dynein/dynactin-mediated transport, both of which may be impaired in ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The network pathway SNCA* -| VMAT2 suggests a regulatory or interaction relationship between SNCA (alpha-synuclein) and VMAT2 (vesicular monoamine transporter 2), which is encoded by the SLC18A2 gene. Abnormal accumulation of alpha-synuclein is a hallmark of Parkinson's disease, contributing to the formation of Lewy bodies and neuronal degeneration. This pathway may be involved in the dysregulation of monoamine neurotransmitter systems, which is implicated in Parkinson's disease. Thus, the SNCA allele contributes to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. In the provided pathway, SNCA interacts with VMAT2 (encoded by SLC18A2), which is responsible for transporting neurotransmitters like dopamine into synaptic vesicles. Dysregulation of this interaction may contribute to impaired dopamine packaging and neuronal dysfunction. Accumulation of misfolded alpha-synuclein is a hallmark of Parkinson\u2019s disease, where it forms Lewy bodies, leading to progressive neurodegeneration. This allele may increase the risk of developing Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is involved in synaptic function and is a key component of Lewy bodies, pathological inclusions found in neurodegenerative diseases. The interaction with VMAT2 (encoded by SLC18A2) suggests a role in dopamine neurotransmission. Mutations or overexpression of SNCA are strongly associated with Parkinson's disease. This allele may contribute to the accumulation of misfolded alpha-synuclein, leading to neuronal dysfunction and degeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. Its product, N-acetylglutamate, is a crucial allosteric activator of carbamoyl-phosphate synthase 1 (CPS1), another key enzyme in the urea cycle. A deficiency in NAGS leads to a lack of N-acetylglutamate, which in turn impairs CPS1 activity, disrupting the urea cycle. This results in the accumulation of ammonia in the blood, a condition known as hyperammonemia. The disease associated with NAGS deficiency is **N-Acetylglutamate Synthase Deficiency**, a rare inherited metabolic disorder that can cause neurological damage if left untreated.\n\n\\boxed{N-Acetylglutamate Synthase Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. The urea cycle is responsible for detoxifying ammonia by converting it into urea. NAGS catalyzes the synthesis of N-acetylglutamate, which is a required activator for carbamoyl-phosphate synthase 1 (CPS1), another key enzyme in the urea cycle. Mutations in the NAGS gene result in a deficiency of this enzyme, leading to impaired urea cycle function. This condition is known as NAGS deficiency, a rare autosomal recessive disorder. The inability to properly activate CPS1 results in the accumulation of ammonia in the blood, causing hyperammonemia, which can lead to neurological damage and, in severe cases, death if untreated. \n\n\\boxed{NAGS deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, a necessary activator of carbamoyl-phosphate synthase 1 (CPS1), which is the first committed step in the urea cycle. A deficiency in NAGS leads to a block in the urea cycle, preventing the body from effectively removing ammonia from the blood. This results in hyperammonemia, a life-threatening condition that can cause neurological damage. The disease associated with NAGS deficiency is **N-acetylglutamate synthase deficiency**, also known as **L-arginine:ornithine amidino transferase deficiency**. \n\n\\boxed{N-acetylglutamate synthase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that reduces toxic reactive oxygen species. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described involves endoplasmic reticulum (ER) stress response components such as BIP (HSPA5), ERN1, and XBP1, which are activated in response to ER stress. Dysfunctional SOD1 can lead to oxidative stress and ER stress, contributing to neuronal death. Therefore, the biological effect of this SOD1 allele is the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that neutralizes superoxide radicals. Mutations in SOD1 are linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The provided pathway indicates SOD1 interacts with ER stress-related genes (BIP, ERN1, XBP1), which are involved in the unfolded protein response. Dysfunctional SOD1 may lead to increased oxidative stress and ER stress, exacerbating neuronal damage. This supports the role of SOD1 mutations in contributing to ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given genomic pathway involves the SOD1 gene, which encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen. The pathway includes BIP (a chaperone protein) and ERN1 (also known as IRE1), which activates XBP1, a transcription factor involved in the unfolded protein response. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations lead to misfolding and aggregation of SOD1, causing toxicity and neuronal death. The pathway reflects the endoplasmic reticulum stress response triggered by misfolded proteins, which is a hallmark of ALS pathogenesis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves the RAS-PI3K-AKT signaling cascade, a critical pathway in cell survival and proliferation. The presence of an NRAS mutation (*NRAS*) can lead to constitutive activation of this pathway, promoting uncontrolled cell growth and contributing to tumorigenesis. The pathway includes multiple PI3K catalytic subunits (PIK3CA, PIK3CB, PIK3CD) and AKT isoforms (AKT1, AKT2, AKT3), which are downstream effectors of PI3K. Phosphorylation of BAD by AKT inhibits its pro-apoptotic function, promoting cell survival. Mutations in NRAS are frequently observed in melanoma, leading to aberrant signaling and tumor progression. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-PI3K-AKT signaling cascade, a critical pathway in cell survival, growth, and proliferation. NRAS, along with KRAS, activates PI3K, leading to the production of PIP3, which in turn activates AKT. AKT then phosphorylates and inactivates BAD, a pro-apoptotic protein, thus promoting cell survival. Mutations in NRAS can lead to constitutive activation of this pathway, resulting in uncontrolled cell growth and division. Such mutations are commonly associated with various cancers. Specifically, NRAS mutations are frequently found in melanoma, where they contribute to tumor progression and resistance to therapy.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS gene is part of the RAS family of proto-oncogenes, which play a critical role in signal transduction pathways regulating cell growth and survival. In the provided pathway, both KRAS and NRAS activate PI3K, leading to the production of PIP3, which in turn activates AKT, a key protein kinase. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS, especially in its codon 61, 12, or 13, can lead to constitutive activation of the RAS-PI3K-AKT signaling pathway, which promotes uncontrolled cell proliferation and resistance to apoptosis. This aberrant signaling is commonly observed in various cancers. NRAS mutations are particularly associated with melanoma, T-cell acute lymphoblastic leukemia (T-ALL), and myelodysplastic syndromes.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. The pathway defined here includes genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are downstream targets of p53 and are involved in responses to DNA damage and apoptosis. Mutations in TP53 can lead to loss of its tumor-suppressive functions, resulting in uncontrolled cell proliferation and genomic instability. This contributes to the development of a variety of cancers, particularly Li-Fraumeni syndrome, which is characterized by a high predisposition to multiple types of malignancies, including sarcomas, breast cancer, and brain tumors. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor suppressor protein p53, which plays a crucial role in regulating the cell cycle, DNA repair, and apoptosis. Mutations in TP53 can lead to the loss of its tumor-suppressing function, resulting in uncontrolled cell division and genomic instability. The pathway described involves key downstream targets of p53, such as CDKN1A (p21), GADD45 family members, BAX, BAK1, DDB2, and POLK, all of which are involved in responses to DNA damage, cell cycle arrest, and apoptosis. Loss of functional TP53 disrupts these critical processes, predisposing cells to malignant transformation. This is strongly associated with a variety of cancers, particularly Li-Fraumeni syndrome, a hereditary cancer predisposition disorder. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the p53 protein, a critical tumor suppressor involved in DNA repair, cell cycle regulation, and apoptosis. The pathway described includes genes like CDKN1A, GADD45 family members, BAX, BAK1, DDB2, and POLK, all of which are downstream targets or effectors of p53 in response to DNA damage. A mutated or inactivated TP53 allele disrupts these processes, leading to genomic instability and uncontrolled cell proliferation. This dysfunction is a hallmark of many cancers, especially those with Li-Fraumeni syndrome, and is implicated in a wide range of malignancies, including breast, ovarian, and leukemia. \n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene encodes the DJ1 protein, which is involved in protecting cells from oxidative stress and maintaining mitochondrial function. The given pathway shows that DJ1 interacts with TP53, which then leads to the activation of DUSP1. This pathway suggests a role for DJ1 in cellular stress response and regulation of signaling pathways. Mutations in PARK7 have been associated with early-onset Parkinson's disease. The biological effect of this PARK7 allele, particularly when impaired, is the contribution to the development of Parkinson's disease due to loss of DJ1 function, leading to neuronal degeneration and dysfunction.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves PARK7 (DJ1), TP53, and DUSP1. PARK7 is associated with Parkinson's disease, as mutations in this gene can lead to early-onset Parkinsonism. The pathway suggests that PARK7 may influence TP53 activity, which is a key tumor suppressor. DUSP1, a downstream target, is involved in stress response and cell signaling. Given that PARK7 mutations can disrupt this network, the biological effect of a defective PARK7 allele is likely to contribute to neurodegenerative disease, specifically Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene encodes the DJ1 protein, which is involved in protecting cells from oxidative stress and maintaining mitochondrial function. In the described pathway, DJ1 (PARK7) activates TP53, which in turn upregulates DUSP1, a phosphatase that modulates MAPK signaling. Mutations in PARK7 can disrupt this pathway, impairing the cell's ability to respond to stress, leading to neuronal degeneration. This contributes to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway, as defined, involves a series of signal transduction events starting with FGFR3 activation, leading to the activation of RAS and subsequent ERK signaling, which culminates in the activation of MYC. This pathway is critical in cell proliferation and survival. Gain-of-function mutations in FGFR3 are well-documented in causing achondroplasia, the most common form of short-limbed dwarfism. These mutations lead to constitutive activation of FGFR3, resulting in excessive signaling that disrupts normal bone growth. \n\n\\boxed{Achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described involves a signaling cascade starting with FGFR3 and culminating in the activation of MYC, a key transcription factor involved in cell proliferation and survival. Mutations in FGFR3 are commonly associated with skeletal dysplasias, particularly achondroplasia, the most common form of short-limbed dwarfism. These mutations typically lead to constitutive activation of FGFR3, which disrupts normal chondrocyte proliferation and differentiation, resulting in impaired skeletal development. The persistent activation of downstream effectors like RAS, RAF, MEK, ERK, and MSK1 contributes to the pathogenesis of the disease by altering cellular signaling necessary for normal growth and development.\n\n\\boxed{Achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway, as defined, leads from FGFR3 to activation of the RAS-RAF-MEK-ERK cascade, culminating in the phosphorylation of MYC, a key transcription factor involved in cell proliferation and survival. Mutations in FGFR3 are well-documented in causing achondroplasia, the most common form of short-limbed dwarfism. These mutations lead to constitutive activation of FGFR3, which disrupts normal skeletal development. This aberrant signaling is also implicated in other skeletal disorders and, in some cases, certain cancers. \n\n\\boxed{Achondroplasia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase involved in the RET/PI3K/AKT/MTOR signaling pathway. Mutations in RET can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation and survival. This aberrant signaling is implicated in several diseases, most notably multiple endocrine neoplasia type 2 (MEN2), which includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid carcinoma. RET mutations are also associated with sporadic medullary thyroid carcinoma and some forms of hereditary cancer syndromes. The PI3K, AKT, and MTOR components further amplify the oncogenic signals, contributing to tumor progression. \n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase involved in the RET/PI3K/AKT/MTOR signaling pathway. Mutations in RET can lead to constitutive activation of this pathway, promoting cell proliferation and survival. This dysregulation is implicated in multiple endocrine neoplasia type 2 (MEN2), a hereditary cancer syndrome that includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. RET mutations are also associated with familial medullary thyroid cancer (FMTC) and some sporadic cases of medullary thyroid cancer.\n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase that, when mutated, can lead to constitutive activation of downstream signaling pathways, including the PI3K/AKT/MTOR pathway. This unregulated signaling promotes cellular proliferation, survival, and migration, contributing to the development of tumors. Germline mutations in RET are strongly associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome that includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. Somatic RET mutations have also been implicated in other cancers, such as papillary thyroid carcinoma. \n\n\\boxed{Multiple Endocrine Neoplasia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is a key regulator of actin dynamics, playing a critical role in the nucleation and elongation of actin filaments. Mutations in the PFN1 gene have been associated with a rare neurodegenerative disorder known as **Actin-Related Dystonia-Deafness Syndrome** or **PFN1-related neurodegeneration**. This condition is characterized by dystonia, sensorineural hearing loss, and sometimes intellectual disability. The pathogenic mechanism involves the dysregulation of actin cytoskeleton dynamics, leading to neuronal dysfunction and degeneration. The allele in question, if pathogenic, contributes to this disease by impairing normal profilin 1 function, thereby disrupting essential cellular processes in neurons.\n\n\\boxed{Actin-Related Dystonia-Deafness Syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) plays a critical role in actin dynamics by binding to monomeric actin and facilitating the assembly of filamentous actin. Mutations in PFN1 have been implicated in neurodegenerative diseases, particularly in a condition known as **frontotemporal dementia with parkinsonism-17 (FTDP-17)**, also referred to as **tauopathies**. This disease is characterized by the abnormal accumulation of tau protein, leading to progressive cognitive decline and motor dysfunction. The PFN1 gene is located on chromosome 17, and specific allelic variants are associated with increased susceptibility to this disorder. \n\n\\boxed{Frontotemporal dementia with parkinsonism-17}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PFN1 gene encodes profilin 1, a protein that plays a critical role in actin dynamics by binding to monomeric actin and facilitating its incorporation into filamentous actin. Mutations in PFN1 have been linked to a rare neurodegenerative disorder known as **Amyotrophic Lateral Sclerosis (ALS)**, specifically a subset of familial ALS cases. These mutations can disrupt normal actin regulation, leading to neuronal dysfunction and degeneration. The biological effect of the PFN1 allele, therefore, is its contribution to the pathogenesis of ALS through impaired actin polymerization and cytoskeletal integrity in motor neurons.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the proteolytic processing of amyloid precursor protein (APP), generating beta-amyloid (A\u03b2) peptides. Accumulation of A\u03b2 peptides is a hallmark of Alzheimer's disease. The pathway described connects PSEN1 and PSEN2 to the mitochondrial calcium pathway, which can lead to mitochondrial dysfunction and apoptosis. This involvement in both amyloidogenesis and mitochondrial dysfunction underscores PSEN1's role in Alzheimer's disease. Mutations in PSEN1 are linked to early-onset familial Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key player in the amyloid precursor protein (APP) processing pathway, contributing to the production of \u03b2-amyloid peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer\u2019s disease (AD). In the provided pathway, PSEN1 and PSEN2 are upstream regulators of RYR3, which affects Ca\u00b2\u207a signaling, leading to mitochondrial dysfunction and apoptosis via the intrinsic pathway. This contributes to neurodegeneration, a hallmark of AD. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the proteolytic cleavage of amyloid precursor protein (APP), producing beta-amyloid peptides. Accumulation of these peptides is a hallmark of Alzheimer's disease. The provided pathway illustrates a link between PSEN1 and Ca\u00b2\u207a dysregulation, culminating in apoptosis. PSEN1 mutations are strongly associated with early-onset familial Alzheimer's disease (FAD), leading to neurodegeneration and cognitive decline. This pathway supports the role of PSEN1 in disrupting calcium homeostasis, contributing to neuronal apoptosis and disease progression.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of damaged proteins, particularly in the context of mitochondrial quality control. Mutations in PRKN are strongly associated with autosomal recessive early-onset Parkinson's disease (PD). The pathway described begins with PRKN, which likely influences intracellular signaling events through its interaction with PLCG1, leading to IP3 production, calcium release via ITPR receptors, and subsequent changes in intracellular calcium levels. Dysregulation of calcium homeostasis is implicated in neurodegeneration. Therefore, pathogenic variants in PRKN contribute to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of autosomal recessive early-onset Parkinson's disease. Parkin plays a critical role in mitochondrial quality control by tagging damaged mitochondria for degradation via mitophagy. Disruption of this pathway leads to the accumulation of damaged mitochondria, oxidative stress, and neuronal degeneration, particularly in dopaminergic neurons. This genetic defect contributes to the progressive loss of motor function characteristic of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are a major cause of autosomal recessive early-onset Parkinson's disease (PD). The pathway described involves PRKN initiating a signaling cascade that leads to calcium release via IP3 and ITPR receptors, potentially through modulation of PLCG1. Dysregulation of this pathway might affect calcium homeostasis and neuronal survival, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is involved in the pathway affecting mitochondrial function, as suggested by its interaction with components of the cytochrome c reductase complex (Complex III) in the electron transport chain. Mutations in the HTT gene, specifically expansions of CAG trinucleotide repeats, cause Huntington's disease. This neurodegenerative disorder is characterized by motor dysfunction, cognitive decline, and psychiatric disturbances. The mutant huntingtin protein leads to toxicity, mitochondrial dysfunction, and impaired energy production, contributing to neuronal death, particularly in the striatum and cerebral cortex. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway involving cytochrome c release and apoptosis. Mutations in the HTT gene, particularly expansion of CAG repeats, lead to the production of a dysfunctional huntingtin protein. This results in the accumulation of the mutant protein, which disrupts mitochondrial function and promotes neurodegeneration. The disruption of the electron transport chain, especially complex III, as indicated by the network definition and the involvement of UQCR genes, contributes to neuronal dysfunction and death. This genetic defect is the primary cause of Huntington's disease, an autosomal dominant neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the disease mechanism of Huntington's disease. This neurodegenerative disorder is caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to the production of a mutant huntingtin protein. This protein forms aggregates in neurons, particularly in the brain, which disrupts cellular function and leads to progressive motor, cognitive, and psychiatric symptoms. The provided pathway highlights the interaction of HTT with components of the electron transport chain, specifically complex III (CxIII), which is involved in mitochondrial respiration. The disruption of this pathway may contribute to mitochondrial dysfunction, a hallmark of Huntington's disease. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase that, when mutated, can lead to constitutive activation of the RET-RAS-RAF-MEK-ERK signaling pathway. This uncontrolled activation drives cell proliferation and survival, contributing to the development of certain cancers. Specifically, germline mutations in RET are strongly associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome that includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. Somatic RET mutations are also implicated in other malignancies, including papillary thyroid carcinoma. \n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a key component of the RET-RAS-RAF-MEK-ERK signaling pathway, which is involved in regulating cell growth and differentiation. Mutations in RET can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation. This aberrant signaling is implicated in several cancers, most notably medullary thyroid carcinoma (MTC), a neuroendocrine tumor of the thyroid gland. RET mutations are also associated with multiple endocrine neoplasia type 2 (MEN2), which includes MTC along with adrenal and parathyroid tumors. Additionally, RET alterations have been linked to other cancers such as papillary thyroid carcinoma and certain gastrointestinal stromal tumors. The RET pathway's dysregulation contributes to tumor initiation and progression by enhancing cell survival and proliferation.\n\n\\boxed{Medullary thyroid carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele in the given pathway is involved in a signaling cascade that begins with RET activation, leading to RAS activation (via HRAS, KRAS, or NRAS), followed by RAF (ARA F, BRAF, or RAF1), MEK (MAP2K1 or MAP2K2), and finally ERK (MAPK1 or MAPK3). This pathway is a key component of the MAPK/ERK signaling pathway, which regulates cellular proliferation, differentiation, and survival. Mutations in RET, especially in the context of this pathway, are strongly associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary cancer syndrome that includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. RET mutations can also be implicated in other cancers, such as papillary thyroid carcinoma.\n\n\\boxed{Multiple Endocrine Neoplasia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe presence of a PIK3CA allele with activating mutations can lead to constitutive activation of the PI3K/AKT/mTOR pathway, promoting cell proliferation, survival, and metabolism. This dysregulated pathway is commonly implicated in various cancers. PIK3CA mutations are frequently observed in several tumor types, including breast, colorectal, and endometrial cancers. These mutations contribute to uncontrolled cell growth by enhancing downstream signaling through AKT and MTOR, which in turn activate S6K and other effectors involved in protein synthesis and cell cycle progression. As a result, PIK3CA mutations are a significant driver in oncogenesis.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is central to the PI3K/AKT pathway. Mutations in PIK3CA, especially those that result in constitutive activation of the PI3K enzyme, lead to increased production of PIP3, which in turn activates AKT, MTOR, and S6K. This persistent activation promotes cell proliferation, survival, and growth, contributing to tumorigenesis. PIK3CA mutations are frequently observed in various cancers, including breast, colorectal, and endometrial cancers. These mutations are associated with resistance to targeted therapies, such as those against EGFR. The oncogenic activity of PIK3CA is a key driver in the development and progression of these malignancies.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), a key enzyme in the PI3K/AKT/mTOR signaling pathway. Mutations in PIK3CA, such as those leading to constitutive activation of PI3K, can result in uncontrolled signaling through the pathway. This persistent activation promotes cell proliferation, survival, and metabolic reprogramming, contributing to tumorigenesis. These mutations have been frequently identified in several cancers including breast, colorectal, and endometrial cancers. Therefore, the biological effect of this PIK3CA allele is oncogenic, and it contributes to the development of cancer.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in the process of mitochondrial quality control. Mutations in PRKN are a major cause of early-onset autosomal recessive Parkinson's disease. Specifically, the PRKN allele in question, in the context of the provided pathway involving ubiquitin conjugating enzymes and alpha-synuclein, is strongly associated with parkinsonism. This pathway suggests a role in protein degradation and mitochondrial function, which are critical in neuronal health. Dysfunctional parkin can lead to the accumulation of damaged mitochondria and misfolded proteins, particularly alpha-synuclein, contributing to the neurodegenerative processes in Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of misfolded or damaged proteins. Mutations in PRKN are a major cause of early-onset Parkinson's disease (PD), specifically the recessive form known as PARK2. The pathway described includes ubiquitin conjugating enzymes (UBCH7/8) and ubiquitin ligases (PRKN), which together participate in the ubiquitin-proteasome system essential for protein quality control. The presence of PRKN in this network, along with SNCA (a gene associated with alpha-synuclein), suggests a role in the degradation of alpha-synuclein, a protein implicated in PD pathology. Dysfunction of this pathway may lead to accumulation of toxic proteins and subsequent neuronal degeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a leading cause of autosomal recessive juvenile Parkinson's disease (PD), also known as PARK2. This pathway, involving ubiquitin conjugating enzymes UBCH7/8, PRKN, and other components, is critical for protein degradation and cellular quality control. Disruption of PRKN function impairs the clearance of damaged proteins, leading to the accumulation of toxic proteins such as alpha-synuclein (SNCA), which is a hallmark of Parkinson's disease. Thus, the PRKN allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway, involving PINK1, PRKN (parkin), and MFN1/2, is crucial for mitochondrial quality control through processes like mitophagy. Mutations in PINK1, a serine/threonine kinase, disrupt this pathway, leading to impaired mitochondrial function and accumulation of damaged mitochondria. This dysfunction contributes to neurodegeneration, particularly in dopaminergic neurons. The PINK1 gene is strongly associated with autosomal recessive early-onset Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene encodes a serine/threonine kinase involved in the regulation of mitochondrial function and quality control. Mutations in PINK1 are associated with autosomal recessive early-onset parkinsonism, a neurodegenerative disorder characterized by motor symptoms similar to those of Parkinson's disease, including bradykinesia, rigidity, and resting tremor. This pathway, involving PINK1, PRKN (parkin), and MFN1/2 (mitofusins), plays a crucial role in mitochondrial dynamics and stress responses. Dysfunction in this pathway impairs mitochondrial integrity, leading to dopaminergic neuron degeneration in the substantia nigra. This contributes to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene encodes a serine/threonine kinase involved in mitochondrial quality control. Mutations in PINK1 are associated with early-onset Parkinson's disease. PINK1 works in a pathway with PRKN (parkin) and MFN1/2 (mitofusins), which are involved in mitophagy\u2014the selective degradation of damaged mitochondria. When PINK1 function is impaired, damaged mitochondria are not efficiently cleared, leading to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal degeneration. This contributes to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is central to the amyloid precursor protein (APP) processing pathway, which is crucial in the development of Alzheimer's disease. In this genomic pathway, PSEN1 activates GSK3B, which in turn regulates the activity of KIF5 and KLC proteins involved in intracellular transport. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. These mutations disrupt normal APP processing, leading to the accumulation of \u03b2-amyloid peptides, a hallmark of Alzheimer's pathology. Thus, this PSEN1 allele contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic processing of the amyloid precursor protein (APP). This processing generates amyloid-beta (A\u03b2) peptides, which accumulate in the brain and are a hallmark of Alzheimer's disease. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). The pathway described involves PSEN1 activating GSK3B, which phosphorylates tau protein, contributing to neurofibrillary tangle formation. Additionally, the interaction with KIF5 and KLC proteins suggests a role in intracellular transport, potentially affecting the clearance of A\u03b2 and tau. These disruptions in amyloid processing and tau phosphorylation are central to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in amyloid precursor protein (APP) cleavage. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). In this pathway, PSEN1 activates GSK3B, which in turn regulates the activity of the kinesin motor complex (KIF5+KLC), important for intracellular transport. Dysregulation of this pathway due to PSEN1 mutations may contribute to disrupted neuronal function and amyloid accumulation, hallmarks of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). This pathway, PSEN1* -> GSK3B -| (KIF5+KLC), implicates PSEN1 in modulating GSK3B activity, which in turn affects the microtubule-associated kinesin motor complexes. Dysregulation in this pathway could disrupt axonal transport and neuronal function. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease, contributing to the accumulation of amyloid-beta plaques and neurofibrillary tangles. These pathogenic changes lead to progressive cognitive decline and neurodegeneration.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the amyloid processing pathway. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. In this pathway, PSEN1 influences GSK3B, which in turn regulates the activity of KIF5 and KLC proteins, which are involved in intracellular transport. Dysregulation of this pathway may contribute to the abnormal accumulation of amyloid-beta peptides, a hallmark of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset, autosomal dominant Alzheimer's disease. The pathway described involves PSEN1 activating GSK3B, which in turn regulates the KIF5+KLC complex, potentially affecting intracellular transport and neuronal function. Disruption of this pathway due to PSEN1 mutations may lead to the accumulation of amyloid-beta peptides, a hallmark of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system, which is critical for protein degradation and cellular quality control. Mutations in PRKN are a major cause of autosomal recessive juvenile Parkinson's disease (PD). This pathway involves components like UBCH7/8 (ubiquitin conjugating enzymes) and PAELR, which interact with PRKN to facilitate the ubiquitination and subsequent degradation of proteins, particularly in the context of mitochondrial quality control. Pathogenic variants in PRKN can impair this process, leading to the accumulation of damaged proteins and dysfunctional mitochondria, particularly in dopaminergic neurons, resulting in neurodegeneration and the clinical features of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in the process of mitophagy. Mutations in PRKN are a major cause of autosomal recessive juvenile parkinsonism (also known as Parkinson disease type 2). These mutations can lead to loss of function of parkin, disrupting mitochondrial quality control and leading to the accumulation of damaged mitochondria, which contributes to neuronal degeneration in the substantia nigra. The presence of PRKN in the described pathway, interacting with ubiquitin conjugating enzymes and other components, highlights its role in protein degradation and cellular stress response. Therefore, the biological effect of this PRKN allele is associated with the development of Parkinson disease.\n\n\\boxed{Parkinson disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile Parkinsonism (also known as PARK2). This condition is a form of early-onset Parkinson\u2019s disease, characterized by progressive motor dysfunction, including tremor, rigidity, and bradykinesia. The pathway described involves ubiquitin conjugating enzymes (UBCH7/8 and UBE2L3/6) and PAELR, which are implicated in the ubiquitination and degradation of proteins, a process parkin regulates. Disruption of this pathway can lead to the accumulation of damaged proteins and mitochondrial dysfunction, contributing to neuronal degeneration in Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) allele is central to the amyloid pathway, which is implicated in Alzheimer's disease. APP is proteolytically cleaved to produce Abeta peptides, which aggregate into amyloid plaques. These plaques, along with neurofibrillary tangles, are hallmark features of Alzheimer's disease. The pathway described involves calcium dysregulation through NMDAR, MCU, and MPTP leading to the release of cytochrome c, a key event in apoptosis. This series of events contributes to neuronal dysfunction and death, central to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP allele is central to the amyloidogenic pathway, leading to the generation of amyloid-beta (Abeta) peptides. Accumulation of Abeta is a hallmark of Alzheimer's disease (AD), contributing to the formation of senile plaques. Activation of NMDA receptors (NMDAR) by Abeta can lead to excessive calcium influx, mitochondrial dysfunction via the MCU channel, and ultimately the opening of the mitochondrial permeability transition pore (MPTP), which releases cytochrome c (CYCS), initiating apoptosis. This cascade is implicated in neuronal damage and death in AD. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the amyloid precursor protein (APP), which undergoes cleavage to produce amyloid beta (A\u03b2), leading to the activation of NMDA receptors (NMDAR), increased intracellular calcium, and subsequent mitochondrial calcium overload via MCU. This results in mitochondrial permeability transition pore (MPTP) opening, release of cytochrome c (CYCS), and ultimately apoptosis. These processes are central to the pathogenesis of Alzheimer's disease, particularly linked to the accumulation of A\u03b2 plaques and neurodegeneration. The APP allele is a key contributor to this disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO gene encodes thyroid peroxidase, a critical enzyme in thyroid hormone synthesis. It catalyzes the oxidation of iodide and the coupling of iodinated tyrosine residues on thyroglobulin (TG) to form thyroid hormones (T3 and T4). Mutations in TPO can lead to congenital hypothyroidism, a condition characterized by insufficient thyroid hormone production. This results in impaired metabolic function, growth, and development. The biological effect of a defective TPO allele is thus a failure in thyroid hormone biosynthesis, contributing to congenital hypothyroidism.\n\n\\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) gene is essential in the biosynthesis of thyroid hormones. It catalyzes the oxidation of iodide and the coupling of iodotyrosines to form T3 and T4 within thyroglobulin (TG). A dysfunctional TPO allele would impair this process, leading to reduced synthesis of thyroid hormones. This can result in congenital hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones, which is critical for normal growth and development. If left untreated, it can cause intellectual disability and growth delays. \n\n\\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) gene is critical in the synthesis of thyroid hormones, as it catalyzes the oxidation and coupling of iodotyrosines to form triiodothyronine (T3) and thyroxine (T4) within thyroglobulin (TG). Mutations in the TPO gene can impair this enzymatic activity, leading to congenital hypothyroidism. This condition results in insufficient thyroid hormone production, which can cause growth and developmental delays if untreated. The pathway described reflects the biochemical role of TPO in thyroid hormone biosynthesis, emphasizing its importance in iodide and tyrosine metabolism. A defective TPO allele therefore contributes to a failure in this process, ultimately leading to a deficiency in thyroid hormones.\n\n\\boxed{Congenital Hypothyroidism}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, which is essential for the production of N-acetylglutamate, a required activator of carbamoyl-phosphate synthetase 1 (CPS1) in the urea cycle. Mutations in NAGS lead to a deficiency in N-acetylglutamate, impairing CPS1 activity and disrupting the urea cycle. This results in the accumulation of ammonia in the blood, a condition known as hyperammonemia. The disease caused by NAGS mutations is termed N-acetylglutamate synthase deficiency, also known as NAGS deficiency, which is a rare inherited metabolic disorder affecting the urea cycle.  \n\\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. This enzyme catalyzes the synthesis of N-acetylglutamate, a required activator of carbamoyl-phosphate synthase 1 (CPS1), another key urea cycle enzyme. A defective NAGS allele leads to the inability to produce N-acetylglutamate, thereby inhibiting CPS1 activity and disrupting the urea cycle. This results in the accumulation of ammonia in the blood, a condition known as hyperammonemia. The disease associated with this genetic defect is N-acetylglutamate synthase deficiency, also known as NAGS deficiency. This rare inherited disorder is a cause of neonatal-onset hyperammonemia and is often lethal if not treated promptly. \n\n\\boxed{N-Acetylglutamate Synthase Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the synthesis of N-acetylglutamate (NAG), a critical activator of carbamoyl-phosphate synthase 1 (CPS1), which is essential for the first step in the urea cycle. NAGS encodes N-acetylglutamate synthase, the enzyme responsible for producing NAG. A deficiency or malfunction of the NAGS allele leads to reduced NAG levels, which in turn inhibits CPS1 activity. This results in impaired urea cycle function, leading to the accumulation of ammonia in the blood (hyperammonemia). This condition is known as NAGS deficiency, a rare inherited metabolic disorder that causes severe neurological damage if untreated.  \n\\boxed{N-Acetylglutamate Synthase Deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 allele is implicated in the pathogenesis of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and other neurological symptoms. ATXN3 is a key component of the autophagy pathway, and its dysfunction may disrupt autophagic processes, leading to the accumulation of toxic proteins and neuronal degeneration. The network defined includes several autophagy-related genes, suggesting that ATXN3's role in this pathway may be central to the disease mechanism. Thus, the ATXN3 allele contributes to the development of $\\boxed{\\text{Spinocerebellar Ataxia Type 3}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a gene that encodes ataxin-3, a protein involved in the ubiquitin-proteasome system and autophagy. The provided pathway includes genes like BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are all key components of the autophagy machinery. Mutations in ATXN3, particularly those leading to expansion of a polyglutamine tract, are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor coordination, ophthalmoplegia, and other neurological symptoms. The autophagy pathway is critical for clearing misfolded or aggregated proteins, and dysfunction in this pathway may contribute to the pathogenesis of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes the protein ataxin-3, which is involved in the ubiquitin-proteasome system and autophagy. The pathway defined includes autophagy-related genes such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1\u2014key components of the autophagy machinery. Mutations or dysregulation of ATXN3 can impair autophagy, leading to the accumulation of damaged proteins and organelles. This dysfunction is implicated in neurodegenerative diseases. Specifically, mutations in ATXN3 are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, which is characterized by progressive loss of motor control and other neurological symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that plays a crucial role in the MAPK/ERK signaling pathway, which is involved in cell proliferation and differentiation. Mutations in BRAF, such as the V600E mutation, result in constitutive activation of the kinase, leading to uncontrolled cell growth. This aberrant activation contributes to the development of various cancers, most notably melanoma. The pathway defined\u2014BRAF \u2192 MEK \u2192 ERK\u2014is central to this oncogenic process. The presence of mutated BRAF in this pathway results in continuous signaling through MEK and ERK, promoting tumorigenesis. This mutation is also associated with other malignancies, including thyroid cancer, colorectal cancer, and certain leukemias.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the RAS-RAF-MEK-ERK signaling pathway, which regulates cell growth and proliferation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the kinase, resulting in uncontrolled cell signaling. This aberrant activation contributes to the development of various cancers by promoting cell proliferation and survival. Specifically, BRAF V600E mutations are frequently observed in melanoma, thyroid cancer, and colorectal cancer. These mutations enhance the transformation of normal cells into tumor cells by disrupting normal regulatory mechanisms. Therefore, the biological effect of the BRAF allele in this context is primarily associated with oncogenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that plays a key role in the MAPK/ERK signaling pathway, which is critical for cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, result in constitutive activation of the kinase, leading to uncontrolled cell proliferation. This aberrant signaling is a hallmark of several cancers, most notably melanoma. The pathway defined includes BRAF, MEK (MAP2K1/MAP2K2), and ERK (MAPK1/MAPK3), which are all frequently dysregulated in human cancers. The presence of a mutant BRAF allele in this context is strongly associated with the development of melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is a key component of the Hedgehog (Hh) signaling pathway. When mutated or dysregulated, it can lead to constitutive activation of the pathway, which is implicated in various cancers. This pathway is critical for embryonic development and tissue homeostasis, and its aberrant activation is associated with basal cell carcinoma (BCC), a common skin cancer. Additionally, SMO mutations have been linked to Gorlin syndrome (also known as nevoid basal cell carcinoma syndrome), a hereditary condition characterized by multiple BCCs, jaw keratocysts, and other developmental abnormalities. The provided network indicates interactions with genes like SUFU, KIF7, GLI, and others, all of which are integral to the Hh pathway. Thus, the SMO allele's dysregulation contributes to the development of basal cell carcinoma and Gorlin syndrome.\n\n\\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele, as part of the Hedgehog (Hh) signaling pathway, plays a critical role in regulating cell proliferation, differentiation, and tissue patterning. Gain-of-function mutations in *SMO* can lead to constitutive activation of the Hh pathway, resulting in uncontrolled cell growth. This aberrant activation is implicated in various cancers, particularly basal cell carcinoma (BCC), and other malignancies such as medulloblastoma. These mutations are often found in disorders associated with dysregulated Hh signaling, such as Gorlin syndrome. Therefore, the biological effect of this *SMO* allele contributes to the development of cancer.\n\n\\boxed{Basal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is part of the Sonic Hedgehog (Shh) signaling pathway, which is crucial for embryonic development and tissue maintenance. Mutations in the SMO gene, particularly those that enhance its activity, can lead to uncontrolled cell proliferation and tumorigenesis. This pathway is dysregulated in basal cell carcinoma, a common skin cancer. The provided network highlights SMO's role in influencing GLI proteins and other downstream effectors. Overactivation of this pathway contributes to the development of basal cell carcinoma. \n\n\\boxed{Basal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway described involves the production of Abeta, which accumulates and forms plaques, a hallmark of Alzheimer's. This accumulation is associated with neuronal dysfunction and cognitive decline. The presence of the APP allele and its associated pathway components, particularly those involved in mitochondrial function (e.g., COX genes), highlights a link between mitochondrial dysfunction and amyloid pathology in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is located on chromosome 21 and plays a central role in the amyloidogenic pathway. The pathway described, involving the proteolytic processing of APP into Abeta, is a key feature of Alzheimer's disease. The accumulation of Abeta peptides, particularly in the form of amyloid plaques, is a hallmark of the disease and contributes to neurodegeneration. The downstream effectors listed, such as CxIV and H2O, may represent mitochondrial or oxidative stress-related components, which are also implicated in Alzheimer's pathology. Thus, mutations or overexpression of APP that enhance Abeta production are strongly associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid-beta precursor protein, which is central to the pathogenesis of Alzheimer's disease. The pathway described involves the cleavage of APP to produce Abeta, which is known to aggregate and form plaques in the brain, a hallmark of Alzheimer's disease. The network also includes COX genes, which are components of the mitochondrial electron transport chain. Dysfunction in this pathway may lead to mitochondrial impairment and oxidative stress, further contributing to neurodegeneration. Thus, the APP allele is primarily implicated in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that is involved in various cellular processes, including growth, survival, and differentiation. When activated, it can influence signaling pathways such as the PI3K/AKT and MAPK pathways. In the context of the NRG (neuregulin) signaling pathway, ERBB4 interacts with neuregulin ligands to modulate neural development and function. Dysregulation of ERBB4 signaling has been implicated in several diseases. Specifically, mutations or alterations in ERBB4 have been associated with schizophrenia, a complex psychiatric disorder characterized by impaired cognition, hallucinations, and social dysfunction. These findings suggest that ERBB4 plays a crucial role in brain development and function, and its disruption can lead to neurodevelopmental and psychiatric disorders.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in cell signaling pathways, particularly in response to neuregulins (NRG1-NRG4). Mutations or aberrant activation of ERBB4 can disrupt normal cellular communication, potentially leading to diseases. Specifically, mutations in ERBB4 have been associated with schizophrenia, a complex neuropsychiatric disorder characterized by cognitive and behavioral impairments. ERBB4 is critical for neurodevelopment and synaptic function, and its dysregulation may contribute to the pathophysiology of schizophrenia. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in various cellular processes, including proliferation, differentiation, and survival. It is a key component of the ERBB signaling pathway, which is often dysregulated in several diseases. The NRG (neuregulin) ligands, including NRG1 through NRG4, bind to ERBB4, modulating its activity. Alterations in ERBB4, such as missense mutations or copy number variations, have been implicated in neurodevelopmental and psychiatric disorders. Specifically, ERBB4 has been associated with autism spectrum disorder (ASD). Functional studies suggest that ERBB4 haploinsufficiency may disrupt normal brain development and connectivity, contributing to the diverse phenotypes observed in ASD. \n\n\\boxed{Autism Spectrum Disorder}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis genomic pathway suggests that ATXN1 interacts with RORA and KAT5 to regulate ITPR1, SLC1A6, and GRM1. ATXN1 is known to be involved in transcriptional regulation and is associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway may be involved in neuronal signaling and calcium homeostasis, which are disrupted in SCA1. Therefore, the biological effect of this ATXN1 allele is most likely related to the development of spinocerebellar ataxia type 1.\n\n\\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given genomic pathway involves ATXN1, a gene known to be associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination and movement control. ATXN1 encodes the ataxin-1 protein, which, when mutated, leads to the accumulation of toxic, expanded polyglutamine repeats. This causes neuronal dysfunction and death, primarily in the cerebellum and brainstem. The network includes RORA and KAT5, which may be involved in epigenetic regulation, and downstream targets like ITPR1, SLC1A6, and GRM1, which are implicated in calcium signaling, neurotransmitter transport, and glutamate receptor activity\u2014key processes in neuronal function. Thus, the ATXN1 allele in this pathway contributes to the pathogenesis of $\\boxed{Spinocerebellar Ataxia Type 1}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the gene *ATXN1* (ataxin 1), which is known to be associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder. ATXN1 is involved in various signaling pathways, including those related to calcium release and neurotransmitter signaling, as indicated by downstream genes like *ITPR1* and *GRM1*. This allele's effect may involve dysregulation of these pathways, leading to neuronal dysfunction. The interaction with *RORA* and *KAT5* may suggest epigenetic or transcriptional regulation affecting the expression of these genes. Given the role of ATXN1 in neurodegeneration and its involvement in pathways critical for neuronal function, this allele is most likely to contribute to $\\boxed{Spinocerebellar Ataxia Type 1}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the activity of cyclin-dependent kinases, thereby regulating the cell cycle. In the provided pathway, CDKN2A appears to inhibit MDM2, which in turn regulates TP53. Activation of TP53 leads to the upregulation of CDKN1A, which inhibits cyclin D and CDK4/6, thus preventing the activation of RB1. Inhibition of RB1 releases E2F, which promotes cell cycle progression. A mutation or loss of CDKN2A function would disrupt this tumor suppressive pathway, leading to uncontrolled cell proliferation. This disruption is a well-known contributor to the development of melanoma. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that regulates the cell cycle by inhibiting cyclin-dependent kinases. In the provided pathway, CDKN2A is part of a network involving TP53 and other key cell cycle regulators. Mutations in CDKN2A can lead to loss of its tumor suppressive function, contributing to uncontrolled cell proliferation. This pathway is central to the regulation of the G1/S checkpoint. Disruption of CDKN2A function is strongly associated with melanoma and certain types of neuroendocrine tumors. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a critical cell cycle inhibitor, p16INK4a, which normally suppresses the activity of cyclin-dependent kinases CDK4 and CDK6, thereby preventing the phosphorylation of RB1 and blocking the G1 to S phase transition of the cell cycle. A mutation or deletion in CDKN2A can lead to loss of this inhibitory function, resulting in unchecked cell proliferation. This pathway is frequently disrupted in various cancers, particularly melanoma, where CDKN2A mutations are well-documented. The loss of CDKN2A function contributes to uncontrolled cell division by inactivating the RB1-E2F pathway, a key regulatory mechanism in cell cycle control. \n\n\\boxed{Melanoma}"]]